---
document_datetime: 2023-09-21 18:46:44
document_pages: 81
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/yervoy-h-c-002213-ii-0044-epar-assessment-report-variation_en.pdf
document_name: yervoy-h-c-002213-ii-0044-epar-assessment-report-variation_en.pdf
version: success
processing_time: 98.1574703
conversion_datetime: 2025-12-29 22:41:41.978644
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

14 December 2017 EMA/6592/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Yervoy

International non-proprietary name: ipilimumab

Procedure No. EMEA/H/C/002213/II/0044

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

+44 (0)20 3660 6000

Facsimile

+44 (0)20 3660 5555

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................6                |                                                                                                         |
| 2. Scientific discussion ................................................................................8                  |                                                                                                         |
| 2.1. Introduction.........................................................................................................8 |                                                                                                         |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11          |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................11                                             |
| 2.2.2. Discussion and conclusion on non-clinical aspects................................................12                  |                                                                                                         |
| 2.2.3. Conclusion on the non-clinical aspects................................................................12             |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................12    |
| 2.3.1. Pharmacokinetics.............................................................................................13      |                                                                                                         |
| 2.3.2. Discussion on clinical pharmacology...................................................................26             |                                                                                                         |
| 2.3.3. Conclusions on clinical pharmacology.................................................................27              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................27    |
| 2.4.1. Main study(ies)                                                                                                      | ...............................................................................................27       |
| 2.4.2. Discussion on clinical efficacy............................................................................48        |                                                                                                         |
| 2.4.3. Conclusions on the clinical efficacy.....................................................................51          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................51  |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................69                        |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................71                          |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................71 |
| 2.6. Risk management plan........................................................................................71         |                                                                                                         |
| 2.7. Update of the Product information                                                                                      | ........................................................................74                              |
| 2.7.1. User consultation.............................................................................................74     |                                                                                                         |
| 3. Benefit-Risk Balance..............................................................................74                     |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................74           |
| 3.1.1. Disease or condition.........................................................................................74      |                                                                                                         |
| 3.1.2. Available therapies and unmet medical need.......................................................74                  |                                                                                                         |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................75             |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................75        |
| 3.3. Uncertainties and limitations about favourable effects.............................................75                  |                                                                                                         |
| 3.4. Unfavourable effects...........................................................................................76      |                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................76                                                             |
| 3.6. Effects Table......................................................................................................77  |                                                                                                         |
| 3.7. Benefit-risk assessment and discussion.................................................................78              |                                                                                                         |
| 3.7.1. Importance of favourable and unfavourable effects..............................................78                    |                                                                                                         |
| 3.7.2. Balance of benefits and risks.............................................................................79         |                                                                                                         |
| 3.7.3. Additional considerations on the benefit-risk balance                                                                | ...........................................80                                                           |

3.8. Conclusions .......................................................................................................  80

<div style=\"page-break-after: always\"></div>

## 4. Recommendations .................................................................................  80

5. EPAR changes  ........................................................................................  81

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

Anti-Drug Antibody

AE

Adverse Event

ALC

Absolute Lymphocyte Count

ALP

Alkaline Phosphatase

ALT

Alanine Transaminase

ANC

Absolute Neutrophil Count

AST

Aspartate Transaminase

AUC

Area Under the Curve

BOR

Best Overall Response

CI

Confidence Interval

Cminss

Minimum concentration at steady state

CR

Complete Response

CSR

Clinical Study Report

CTCAE

Common Terminology Criteria for Adverse Events

CTLA-4

Cytotoxic T-Lymphocyte Antigen 4

DC

Discontinuation

DCR

Disease Control Rate

DILI

Drug-induced liver toxicity

DLT

Dose Limiting Toxicity

DMC

Data Monitoring Committee

DOR

Duration of Response

ECOG

Eastern Cooperative Oncology Group

FPFV

First Patient First Visit

GCP

Good Clinical Practice

H

Hour

HLA

Human Leukocyte Antigen

ICF

Informed Consent Form

ICH

International Council on Harmonization

IEC

Independent Ethics Committee

imAR

Immune-mediated Adverse Events

irAE

Immune-related Adverse Events

IRB

Independent Review Board

irRC

Immune-related response criteria

IV

Intravenous

GI

Gastrointestinal

LFT

Liver Function Tests

LLN

Lower Limit of Normal

min

Minute

mL

Milliliter

MTD

Maximum Tolerated Dose

mWHO

Modified World Health Organization Criteria

NA

Not Applicable

NCI-CTCAE

National Cancer Institute Common Terminology Criteria for Adverse events

OR

Overall Response

OS

Overall Survival

PD

Pharmacodynamics

PD

Progressive Disease

PD-1

Programmed Death-1

PDCO

Paediatric Committee

PFS

Progression-Free Survival

PIP

Paediatric Investigation Plan

PK

Pharmacokinetics

PPK

Population Pharmacokinetics

PR

Partial Response

PS

Performance Status

PT

Preferred Term

PY

Person-year

RECIST

Response Evaluation Criteria in Solid Tumors

<div style=\"page-break-after: always\"></div>

SAE Serious Adverse Event SD Stable Disease SOC System Organ Class TBL Total Bilirubin ULN Upper Limit of Normal WBC White Blood Cell

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 8 March 2017 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the treatment of advanced (unresectable or metastatic) melanoma in children and adolescents 12 years of age and older for Yervoy. As a consequence sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and the RMP (version 15) are updated in accordance.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/0003/2017 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP (P/0003/2017) was completed.

The PDCO issued an opinion on compliance for the PIP P/0003/2017.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000,  the  applicant  did  not  submit  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Paula Boudewina van Hennik

Co-Rapporteur:

N/A

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Planned dates     | Actual dates      |
|------------------------------------------------------|-------------------|-------------------|
| Start of procedure:                                  | 25 March 2017     | 25 March 2017     |
| CHMP Rapporteur Assessment Report                    | 19 May 2017       | 19 May 2017       |
| PRAC Rapporteur Assessment Report                    | 26 May 2017       | 01 June 2017      |
| PRAC members comments                                | 31 May 2017       | N/A               |
| Updated PRAC Rapporteur Assessment Report            | 1 June 2017       | 6 June 2017       |
| PRAC Outcome                                         | 9 June 2017       | 9 June 2017       |
| CHMP members comments                                | 12 June 2017      | 12 June 2017      |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 15 June 2017      | 15 June 2017      |
| Request for Supplementary Information                | 22 June 2017      | 22 June 2017      |
| MAH's submission deadline                            | 14 July 2017      | 12 July 2017      |
| Re-start                                             | 17 July 2017      | 17 July 2017      |
| CHMP Rapporteur Assessment Report                    | 15 Aug 2017       | 15 August 2017    |
| PRAC Rapporteur Assessment Report                    | 18 August 2017    | 15 August 2017    |
| PRAC members comments                                | 23 August 2017    | N/A               |
| Updated PRAC Rapporteur Assessment Report            | 24 August 2017    | N/A               |
| PRAC Outcome                                         | 1 September 2017  | 1 September 2017  |
| CHMP members comments                                | 4 September 2017  | 4 September 2017  |
| Updated CHMP Rapporteur Assessment Report            | 7 September 2017  | N/A               |
| Request for Supplementary Information                | 14 September 2014 | 14 September 2017 |
| MAH's submission deadline                            | 13 October 2017   | 12 October 2017   |
| Re-start                                             | 16 October 2017   | 16 October 2017   |
| CHMP Rapporteur Assessment Report                    | 14 November 2017  | 14 November 2017  |
| PRAC Rapporteur Assessment Report                    | 17 November 2017  | 14 November 2017  |
| PRAC members comments                                | 22 November 2017  | 22 November 2017  |
| Updated PRAC Rapporteur Assessment Report            | 23 November 2017  | N/A               |
| PRAC Outcome                                         | 30 November 2017  | 30 November 2017  |
| CHMP members comments                                | 4 December 2017   | 4 December 2017   |
| Updated CHMP Rapporteur Assessment Report            | 7 December 2017   | 7 December 2017   |
| Opinion/Request for supplementary information        | 14 December 2017  | 14 December 2017  |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## Ipilimumab

Ipilimumab (BMS-734016, MDX-010, YERVOY) is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4). The proposed mechanism of action for ipilimumab is blocking the interaction of CTLA-4 with the ligand B7-1 and B7-2 (CD80/CD86). This results in T-cell activation, proliferation, and lymphocyte infiltration into tumours which leads to tumour cell death.

Ipilimumab is approved as monotherapy in the European Union (July 2011), and other countries for the treatment of advanced (unresectable or metastatic) melanoma in adults at a dose of 3 mg/kg administered intravenously (IV) once every 3 weeks for a total of 4 doses.

## Melanoma in paediatric population

Melanoma is predominantly diagnosed in the adult population, however the incidence of paediatric melanoma is rising. Only 0.7-2% of all melanoma cases occur in patients below the age of 20 years, but melanoma is the most common form of skin cancer in the paediatric population. The incidence of cutaneous melanoma in the United States is 5.4 per 1 million paediatric patients and 20.2 per 1 million adult patients. Melanomas in adolescent patients, usually defined as patients from 11 to 19 years, behave similarly to melanoma in adults, but in the preadolescent population the presentation and prognosis differs 1 . Regarding presentation, melanomas in adults and adolescents are usually pigmented and have a diversity in colours and morphology. In preadolescents the melanomas are usually amelanotic, present as a papule or nodule, with regular and well-circumscribed borders and a diameter of less then 6 mm. Paediatric melanomas are therefore more difficult to distinguish from benign lesions. Moreover, preadolescent melanomas locate predominantly on the head and neck, while adolescents and adult patients present more often with truncal lesion. Risk factors between adult and paediatric melanomas are similar with increased risk with a family history of melanomas, history of frequent sunburns, numerous acquired melanocytic naevi or large congenital melanocytic naevi, immunosuppression, and pre-existing skin conditions 1 .

Histologically, paediatric melanomas are often thicker than adults melanomas (Breslow thickness), although this not necessarily correlates with worse prognosis. Morphology in preadolescents is more commonly nodular and unclassified, spitzoid or atypical. Molecularly, the incidence of mutations in BRAF or CDKN2A overlap, but for example c-kit mutations are more specific for paediatric patients 1 .

1 LaChance, Avery et al. 2016. Melanoma: Kids are not just little people, Clinics in Dermatology , Volume 34 , Issue 6 , 742 - 748

<div style=\"page-break-after: always\"></div>

Current treatment regimens in children are based on the treatments used in adults. Advanced melanoma in the paediatric population is challenging to treat with very limited licensed therapeutic options and therefore an unmet medical need exists. Children more often present with thicker lesions, and regional lymph node and distant metastases 2 . Whether the prognosis of preadolescents with melanoma differs from adolescents or adults is under debate. Some reports in literature describe better prognosis in younger children, others conclude that there is no difference or even a worse prognosis 1 . According to the SEER database, 5-year disease-specific survival for paediatric patients below the age of 20 years is 100% for in situ disease, 96% for localised disease, 77% for regional disease, and 57% for distant disease 2 .

Therefore, while preadolescent melanoma patients are not comparable to adults patients, disease, prognosis and treatment of adolescents is considered similar to melanoma in adults. The current extension of the indication involves only adolescents and not pre-adolescents patients.

## Immunotherapy in advanced melanoma

In clinical practice, ipilimumab is no longer used in the first-line setting for melanoma in most countries with the development of anti-PD1 therapies such as nivolumab and pembrolizumab that show efficacy in melanoma and have improved tolerability compared to ipilimumab. Moreover, in BRAF-mutated patients, BRAF and MEK inhibitor combinations can also be used.

Compared to ipilimumab, the anti-PD-1 antibody pembrolizumab leads to prolonged progression-free survival and overall survival and had less high-grade toxicity than ipilimumab in patients with advanced melanoma. Estimated 12-month survival rates were 74.1% for pembrolizumab every 2 weeks, 68.4% for pembrolizumab every 3 weeks, and 58.2% for ipilimumab. The hazard ratio for death upon pembrolizumab every 2 weeks was 0.63 (CI95% 0.47-0.83; p=0.0005) and pembrolizumab every 3 weeks 0.69 (CI95% 0.52- 0.90; p=0.0036) 3 . Also the combination therapy of nivolumab and ipilimumab versus ipilumumab monotherapy in the first line might lead to improved outcomes with 2-year overall survival of 63.8% (CI95% 53.3-72.6) for nivolumab plus ipilimumab and 53.6% (CI95% 38.1-66.8) for ipilimumab alone. Median overall survival has not been reached in either group (HR 0.74, CI95% 0.43-1.26; p=0.26), but follow-up is ongoing 4 . After progression on anti-PD1 inhibitor there is still a need for alternative options and ipilimumab (also in combination with a checkpoint inhibitor) could then be a viable treatment option. Available retrospective efficacy data for ipilimumab monotherapy as second line treatment after nivolumab or pembrolizumab indicate that some of the patients still respond to ipilimumab monotherapy after failure to prior anti PD-therapy. 47 patients were treated with ipilimumab monotherapy and 37 patients with nivolumab and ipilimumab combination therapy after treatment failure to anti-PD-1 therapy. Overall response rates for the monoand combination therapy were 16% and 21%, respectively. Disease control rate was 42% for the mono- and 33% for the combination therapy and 1-year overall survival rates 54% and 55%, respectively 5 . The ESMO guideline states that the recommendations for first-line treatment of

2 Tracy ET, Aldrink JH. Pediatric melanoma. Semin Pediatr Surg. 2016 Oct;25(5):290-298

3 Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino  MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006  investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32

4 Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette  GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1558-1568

5 Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal  JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1  therapy in advanced melanoma. Eur J Cancer. 2017 Apr;75:47-55

<div style=\"page-break-after: always\"></div>

metastatic disease are indeed under debate and that reasonable approaches include anti-PD1 therapies and, for BRAF -mutated melanomas, combinations of BRAF inhibitors with MEK inhibitors 6  .

## Paediatric investigation plan

Based on the activity of ipilimumab against melanoma in adults, similar activity was anticipated in the paediatric population as for the adult population.

An initial Paediatric Investigation Plan (PIP) for all conditions in the category of malignant neoplasms except melanoma, nervous system, haematopoietic and lymphoid tissue (EMEA-000117-PIP01-07), and one for the condition of melanoma (EMEA-000117-PIP02-10) was provided to the European Medicines Agency's (EMA) Paediatric Committee (PDCO) in 2007 and 2010, respectively. Following review by the PDCO, decisions on the PIPs were rendered by the EMA in November 2007 and June 2011, respectively. Subsequent Requests for Modification (RfM) for the PIP in the category of malignant neoplasms (except melanoma, nervous system, haematopoietic and lymphoid tissue) and for the PIP for melanoma were submitted. According to the MAH, the PIP for malignant neoplasms has been completed and all study reports have been checked for compliance. Clinical study NCI7458/CA184070, which was included in both PIPs, was submitted under Article 46 in December 2014 and a decision reached in February 2015. Clinical study CA184178 is currently submitted under Article 46 for the condition of melanoma.

The most recent Request for Modification (EMEA-000117-PIP02-10-M07) for the condition of melanoma was submitted to the PDCO in September 2016 and reached a positive opinion in December 2016, in which the MAH explained the difficulties encountered with recruitment into the phase 2 study CA184178 due to the rarity of the target population and the rapidly evolving therapeutic landscape. This has resulted in new clinical studies competing for patients. In the request, the PDCO agreed to the following modifications:

- Removal of the PIP-targeted indication of 'treatment of patients with melanoma (surgically resected) in the adjuvant setting study' and study CA184116/E1609
- Reduction of the number of treated patients in study CA184178, a study in children ages 12 to &lt;18 years with untreated or previously treated advanced/metastatic melanoma, from 30 to 12
- Removal of the Key Binding Element of lymphocyte phenotyping and circulating levels of selected cytokines assessments for study CA184178
- Addition of PPK modelling and simulation and extrapolation studies to inform physicians in the safe and effective use of ipilimumab in younger advanced/metastatic melanoma patients.

In melanoma patients, two paediatric studies in advanced metastatic melanoma have been completed: NCI7458/CA184070 and CA184178 (Table 1). A third paediatric study, E1609 (also known as CA184116), a phase 3 randomised study of adjuvant ipilimumab anti-CTLA-4 therapy vs high-dose interferon alfa-2b for resected high-risk melanoma, is being conducted with the cooperation of the Eastern Cooperative Oncology Group (ECOG), primarily in high-risk surgically-resected melanoma in the adjuvant setting. The amendment to add a paediatric/adolescent cohort to study CA184116/E1609 was activated on 23-Sep-2014. The primary endpoint for adolescents is safety. Of the originally planned 45 adolescent patients, 3 were enrolled over 15 months up to November 2016 and 2 patients were treated. As of December 2016 enrolment of adolescents in this study was stopped, which was agreed by the PDCO (see above). Safety data from the two patients is provided by the MAH in this submission.

6  Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v126-32

<div style=\"page-break-after: always\"></div>

With the current application, the MAH proposes to extent the indication for treatment of advanced melanoma in adults to adolescents &gt; 12 years of age. The posology is similar in adults and adolescents: Ipilimumab is to be administered intravenously (IV) at doses of 3 mg/kg over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.

Two clinical trials have been conducted to study ipilimumab in children and adolescents: NCI7458/CA184070 and CA184178.

Study NCI7458 (or CA1840701) was a phase 1, multi-center, open-label, dose-escalation (doses of 1, 3, 5 and 10 mg/kg) study conducted with ipilimumab in children, adolescents, and young adults, ranging in age from 1 to 21 year with untreatable, relapsed or refractory solid malignant tumors (including melanoma) without a curative option with standard therapy. A primary objective of this study was to assess the PK of ipilimumab administered IV in subjects ≤ 21 years of age with solid tumors, including advanced melanoma, refractory to standard therapy.

Study CA184178 was a non-randomised, multicenter, open-label, phase 2 study of ipilimumab for children and adolescents 12 to &lt;18 years with previously treated or untreated, unresectable stage III or stage IV malignant melanoma. Children and adolescents were treated with 4 infusions of 3 or 10 mg/kg at weeks 1, 4, 7, and 10. A total of 12 children or adolescents were treated with either 3 (n=4) or 10 (n=8) mg/kg ipilimumab.

Results from study NCI7458/CA184070 have been submitted previously as an Article 46 of regulation (EC) N0 1901/2006 post-authorisation measure EMEA/H/C/002213-EU/1/11/698/001-002. Results from study CA184178 have been discussed and reported previously as part of art 46 procedure. The pharmacokinetic data from study NCI7458/CA184070 and study CA184178 were included in a population pharmacokinetic (PPK) analysis to support this application.

The applicant applied for the following indication:

- YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults, and children and adolescents 12 years of age and older.

The final agreed indication is as follows:

- YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults, and adolescents 12 years of age and older (see section 4.4).

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Ipilimumab is a protein, which is expected to biodegrade in the environment and therefore is considered to not pose a significant risk to the environment. Thus, as ipilumumab and excipients do not pose a significant risk to the environment, it is exempt from an Environmental Risk Assessment, as per the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00).

<div style=\"page-break-after: always\"></div>

## 2.2.2. Discussion and conclusion on non-clinical aspects

The applicant submitted a justification for not submitting ERA studies. As proteins are expected to biodegrade and not be a significant risk to the environment, the lack of ERA studies is acceptable. No changes to the SmPC are considered necessary.

## 2.2.3. Conclusion on the non-clinical aspects

The CHMP considered that the non-clinical aspects have been satisfactorily addressed and that the lack of ERA studies is considered justified. Ipilimumab is not expected to pose a risk to the environment. The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of ipilimumab.

## 2.3. Clinical aspects

## GCP

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 1. Ipilimumab paediatric clinical development program in advanced melanoma

| Study identifier Sponsor/Collaborator            | Type of study/ design features                                                                                                                                             | Study population/ Planned/Enrolled                                                                                                                                                                                                                          | Dosage,regimen                                                                                                                                                                                                                                                                                                                      | Primary Objectives                                                                                                                                                                                                                                                                                                                                                                                          |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NCI7458/CA184070 National Cancer Institute (NCI) | Phase 1, open-label, dose-escalationclinicalstudy of IV ipilimumab in subjects with untreatable, refractory or relapsed solid malignant tumors to evaluate PK and safety.  | Children and adolescents 1 to<18y(+ young adults up to 21 years) with advanced and/or refractory solid malignant tumors. Actual age range: 2.4 to 21.8 years Planned: 30 total Actual: 33 total; 3 at 1 mg/kg; 3 at 3 mg/kg; 14 at 5 mg/kg: 13 at 10 mg/kg. | 4 planned dose levels (1, 3, 5, and 10 mg/kg. Ipilimumab IV Treatment Phase: Day 1 of q21-day cycle for 4 cycles. Maintenance Phase: From Cycle5onward,~q12wks                                                                                                                                                                      | Todeterminethetoleranceand toxicity profile of ipilimumab at a range of doses up to,but not exceeding,the highest dose tolerated in adults in subjects≤ 21 years of age with untreatable, refractory relapsed solid malignant tumors. To assess the pharmacokinetics (PK) ipilimumab administered intravenously (IV) in subjects ≤21 years of age with solid tumors refractory to standard therapy.         |
| CA184178 Bristol-Myers Squibb (BMS)              | Phase 2, open-label, multi- center,single-arm efficacy and safety clinical study of ipilimumabin subjects with untreated or previously treated advanced/metastaticmelanoma | Children age 12 to < 18 y with untreated or previously treated advanced/metastatic melanoma. Actual age range: 12 to 16 years Planned: 30 total; up to 10 at 10 mg/kg; at least 20 at 3 mg/kg Actual: 12 total 8 at 10 mg/kg; 4 at 3 mg/kg                  | Ipilimumab 3 or 10 mg/kg IV Treatment Phase: ipilimumab q3wks (Week 1. 4, 7, 10). Eligible subjects with a PR or CR or SDof≥3months (beginning at Week 12 with SD at Week 24)with subsequent confirmed PD are eligiblefor one course of retreatment therapy consisting of 4 infusions (each dose of ipilimumab 3or 10 mg/kg q3wks). | To estimate the survivalrate at 1 year inadolescent subjects(12to<18 years) with previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma at the 3 mg/kg dose level. To assess safety and tolerability, specifically the frequency of severe (Grade 3 - 5) immune-mediated adverse reactions of ipilimumab in adolescent subjects (12 to<18 years) at the 3 mg/kg dose level. |

<div style=\"page-break-after: always\"></div>

## 2.3.1. Pharmacokinetics

The pharmacokinetic data from two paediatric clinical trials NCI7458/CA184070 and CA184178, which have already been evaluated in previous procedures have been included in a population pharmacokinetic (PPK) analysis to support this application.

## Methods

## Bioanalytical methods

Quantification of ipilimumab in human serum was performed using a validated enzyme linked immunosorbent assay (ELISA). The assay provides a quantitative measurement of ipilimumab in human serum using CTLA4/Fc chimera as the capture reagent and an alkaline phosphatase-labeled goat anti-human IgG F(ab')2 for detection. The validated range for this method in human serum is from 0.800 to 25.6 μg/ml.

Pharmacokinetics of ipilimumab were derived from serum concentration versus time data. Individual participant PK parameter values were calculated by noncompartmental methods by a validated PK analysis program, Phoenix ®  WinNonlin ® Version 6.2.1 (Pharsight Corporation, St Louis, MO).

Antibodies against ipilimumab were analysed by a drug-tolerant electrochemiluminescent (ECL) immunoassay, ICDIM 14 V 2.02. A 3-tiered approach was used: screening, confirmation and quantification of the anti-ipilimumab antibodies.

## popPK analysis

The popPK analysis dataset included 521 adults and 44 pediatric subjects. These studies were selected for inclusion in the popPK analysis on the basis of the available PK data, with ipilimumab monotherapy in the relevant subject populations. The 2 pediatric studies (NCI7458/CA184070 and CA184178) included in this analysis are the only clinical studies in pediatric subjects with advanced or unresectable melanoma. The 4 adult studies (CA184004, CA184007, CA184008, CA184022) are Phase 2 studies in subjects with advanced melanoma treated with ipilimumab at doses of 3 or 10 mg/kg.

The popPK model development consisted of 1) Base Model to re-estimate the PK parameters using a previously determined final model for adults and 2) Full Model to assess the additional age effect on ipilimumab CL. The base mode was a linear 2-compartment model with zero-order IV infusion and first-order elimination, parameterized in terms of CL, volume of central compartment (VC), intercompartmental clearance (Q), and volume of peripheral compartment (VP). The inter-individual variability model was specified by log-normal distributions in the following model parameters among individuals: CL and VC. A combined residual error model (additive and proportional error) was used to describe the random differences between observed values and the corresponding model predictions.

The full model was identical to the base model, with the addition of a covariate effect of age on ipilimumab CL. The covariates tested in the full model described in the following equations and the covariate-parameter effects assessed in the full model are provided below in Table 2. Full model with the addition of covariate effect of age.

<div style=\"page-break-after: always\"></div>

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

Equation - 2

Where CLREF and VCREF are typical values of CL and VC at the reference values of baseline body weight (BW), baseline LDH (BLDH) and Age , BWREF = 78 kg, BLDHREF = 210 U/L, AGEREF = 57 years of age and CLBW, CLLDH, CLAGE and VCBW are model parameters.

The effects of the other demographic and clinical covariates tested in the base model were not statistically significant or the magnitude of the effect was considered to be of minimal clinical relevance (less than ± 20% effect on the typical value of a model parameter relative to the reference value). Parameter estimates from the full model are presented in Table 2. Inferences regarding the effect of covariates were based upon the full model parameter estimates

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

Table 2: Ipilimumab parameter estimates of the full popPK model

| Nane (Units)a,b        | Symbol   | Estinatec      | Standard Error (RSE%)°   | 95% Confidence Intervalé   |
|------------------------|----------|----------------|--------------------------|----------------------------|
| Fixed Effects          |          |                |                          |                            |
| CL (L/h)               | 01       | 0.0141         | 2.45E-04 (1.74)          | 0.0136-0.0146              |
| VC (L)                 | θ2       | 4.12           | 0.0417 (1.01)            | 4.03 - 4.19                |
| Q (L/h)                | 03       | 0.0234         | 0.00257 (11.0)           | 0.0196 - 0.0292            |
| VP (L)                 | 04       | 2.10           | 0.152 (7.24)             | 1.86 - 2.44                |
| CL~WT                  | 07       | 0.954          | 0.0756 (7.92)            | 0.787 - 1.09               |
| CL~LDH                 | 08       | 1.08           | 0.173 (16.0)             | 0.747 - 1.44               |
| VC~WT                  | 012      | 0.891          | 0.0305 (3.42)            | 0.830 - 0.946              |
| CL~AGE                 | 014      | 0.0529         | 0.0416 (78.6)            | -0.0286 -0.136             |
| Random Effectsf        |          |                |                          |                            |
| IIV CL                 | 01,1     | 0.131 (0.362)  | 0.0120 (9.16)            | 0.107 -0.154               |
| COV CL~VC              | 02,2     | 0.0248 (0.157) | 0.00354 (14.3)           | 0.0208 -0.0415             |
| AOO:TO AI CL~VC        | 01,2     | 0.0309 (0.542) | 0.00494 (16.0)           | 0.0178 - 0.0318            |
| Residual Error         |          |                |                          |                            |
| Proportional Error'    | 05       | 0.175          | 0.00688 (3.93)           | 0.159 - 0.187              |
| Additive Error (μg/mL) | 06       | 0.211          | 0.130 (61.6)             | 4.48E-05 - 0.763           |

Analysis Directory: /global/pkms/data/CA/184/C07/prd/ppk-ped-may2016/final

Program Source: Analysis Directory/nm/basemodel\\_OLExcluded\\_ageCL.ctl

Source: Analysis Directory/nm/basemodel\\_OLExcluded\\_ageCL.shenj24.rtf

Abbreviations: CL = clearance; COV = covariance; IIV = inter-individual variability; LDH = lactate dehydrogenase; PPK = population pharmacokinetic; Q = inter-compartmental clearance; RSE = relative standard error; VC = volume of central compartment; VP = volume of the peripheral compartment; WT = weight

a Parameters with fixed values (not estimated) are denoted with a superscript 'f' after the names, with the fixed value given in the Estimate column

Random Effects and Residual Error parameter names containing a colon () denote correlated parameters

Random Effects and Residual Error parameter estimates are shown as Variance (Standard Deviation) for diagonal elements (oi,i or oi,i) and Covariance (Correlation) for off-diagonal elements (oij or oi.j)

RSE% is the relative standard error (Standard Error as a percentage of Estimate)

The confidence interval values are taken from the percentile confidence intervals of 2000 bootstrap runs (1479 minimization successful runs) executed through PsN bootstrap procedure (including the minimization terminated runs due to rounding errors)

Eta shrinkage: ETA\\_CL: 10.0%, ETA\\_VC: 23.9%

Inter-individual variability

## Model evaluation

The popPK model parameters were estimated with good precision. When evaluating all peak and trough concentrations after the first dose, approximately 3.8% and 4.1% of the peak-concentration data fell below and above the 90% prediction interval, respectively, which compared well with the expected 5% of data above and below. For the trough concentration, approximately 7.4% and 9.8% of data fell below and above the 90% prediction interval, respectively. No consistent over- or under-prediction of the model was observed.

<div style=\"page-break-after: always\"></div>

VPC analysis was also stratified by study, and the results from all concentrations of the two pediatric studies NCI7458/CA184070 and CA184178 versus time after the first dose are presented in Figure 1 and Figure 2.

<!-- image -->

Note: Blue circles are observed data. The red lines represent the 5th, 50th and 95th percentiles of observed data, respectively. The shaded areas represent the simulation-based 95% confidence intervals for the 5th, 50th, and 95th percentiles of the predicted data.

Figure 1: Visual Predictive Check of All Ipilimumab Concentration versus Actual Time after First Dose in pediatric patients from Study NCI7458/CA184070 (Full PPK Model)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note: Blue circles are observed data. The red lines represent the 5th, 50th and 95th percentiles of observed data, respectively. The shaded areas represent the simulation-based 95% confidence intervals for the 5th, 50th, and 95th percentiles of the predicted data.

Figure 2: Visual  Predictive  Check  of  All  Ipilimumab  Concentration  versus  Actual  Time after First Dose in pediatric patients from Study CA184178 (Full PPK Model)

## Results

## Study CA184070

In study CA184070, a total of 32 children and adolescents, and young adults were treated with ipilimumab intravenously at 1, 3, 5 and 10 mg/kg. PK samples were collected predose and 2 hours post infusion, Days 2, 4, 8, and 15 during Cycle 1 and 3, and then prior to each dose thereafter.

Pharmacokinetic results study CA184070 as reported in the previous procedures is summarized in

Table 3 . There was no apparent difference in Cmax, AUC0-21, Ctrough between children ( ≥ 2 and &lt;12 years), adolescents ( ≥1 2 and &lt;18 years), and adults. The elimination half-life seemed somewhat longer in paediatric patients&lt;12 years (t1/2=14.1-14.3 days) compared to older patients 9.8-12.7 days.

## Table 3 : Ipilimumab PK Parameters by Age during Cycle 1 (patients &lt;12 and ≥ 12 &lt; 21 years study CA184070, adults studies CA184007 and CA184008 (application dossier))

<div style=\"page-break-after: always\"></div>

|                            | Age < 12 years Study CA184070   | Age < 12 years Study CA184070   | Age ≥ 12 < 21 years Study CA184070   | Age ≥ 12 < 21 years Study CA184070   | Adults $ Study CA184007 & CA184008   |
|----------------------------|---------------------------------|---------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Dose (number) PK parameter | 5 mg/kg N=5                     | 10 mg/kg N=3-4*                 | 5 mg/kg N=5-7*                       | 10 mg/kg N=8                         | 10 mg/kg N=15                        |
| Cmax (µg/ml)               | 93 (13%)                        | 193* (17%)                      | 91* (25%)                            | 203 (22%)                            | 205 (19%)                            |
| AUC 0-21 (µg.h/ml)         | 16318 (20%)                     | 37053 (18%)                     | 12681* (73%)                         | 36751 (14%)                          | 34176 (19%)                          |
| Cl (ml/h/kg)^              | 0.20 (39%)                      | 0.18 (27%)                      | 0.22 (53%)                           | 0.19 (24%)                           | 0.24                                 |
| Vss (L/kg)                 | 0.095 (5%)                      | 0.085 (6%)                      | 0.065 (17%)                          | 0.079 (24%)                          | 0.077                                |
| T1/2 (days)                | 14.3 (5%)                       | 14.1 (3%)                       | 9.8 (5%)                             | 12.7 (5%)                            | 9.5                                  |
| Ctrough (µg/ml)#           | 19                              | 45                              | 28                                   | 33                                   | 57                                   |

## Study CA184178

In study CA184178, ipilimumab was administered intravenously (IV) at doses of 3 or 10 mg/kg over 90 minutes on Day 1 of each 21-day cycle for 4 cycles. Pharmacokinetics of ipilimumab was evaluated following the 3rd administration. By that time 3 out of 8 participants receiving 10 mg/kg and 1 out of 4 participants receiving 3 mg/kg ipilimumab had discontinued treatment due to AEs. Hence, pharmacokinetic data were available from 4 subjects receiving 10 mg/kg and 3 subjects receiving 3 mg/kg. The individual pharmacokinetic parameters are listed in Table 4. Based on the results of this study, the paediatric data suggest that the exposure of ipilimumab (e.g., AUC, Cmax, and Cmin) increased approximately in proportion with doses ranging from 3 to 10 mg/kg, although the data are limited.

Table 4 : Individual  Pharmacokinetic  Parameters  of  Ipilimumab  after  the  Third  Dose, All Pharmacokinetic Eligible Subjects (CA184178)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## popPK analysis

The effect of categorical and continuous covariates on the typical value of the structural model parameters of CL and VC and the estimated covariate effects (and 95% confidence intervals) are presented in Figure 3.

The magnitude of the effect of body weight, LDH on CL, and the effect of body weight on central volume of distribution in this pooled population were comparable to what was previously reported in the adult population only. The effect of age on CL was not clinically relevant (with ± 20% of the reference value) as shown in Figure 3, and the 95% CI of the estimated effect included zero. Accounting for uncertainty, the effect of age on CL in this population is within the ± 20% boundaries.

<div style=\"page-break-after: always\"></div>

Covariate

<!-- image -->

Analysis-Directory:/global/pkms/data/CA/184/C07/prd/ppk-ped-may2016/final/

Program Source: Analysis-Directory/R/scripts/cov-eff-plot-ageCL.r

Abbreviations:  CI  =  confidence  interval;  CL  =  clearance;  LDH  =  lactate  dehydrogenase;  PPK  =  population pharmacokinetic; VC = volume of central compartment

Figure 3: Ipilimumab Covariate Effects on PPK Model Parameters (Full PPK Model)

Comparisons of the dose-normalized ipilimumab exposure and PK parameters by age groups are provided in Table 5 and Table 6. Cl (L/h) was lower in pediatric patients than in adults. The allometric exponent of body weight on CL was estimated to be ~0.95, suggesting the CL increases only slightly less than proportional to body weight. Therefore, a body weight based dosing regimen will result in a similar exposure in different body-weight groups. Although a prolonged beta phase half-life was observed in the paediatric group &lt; 12 years of age, this trend was largely diminished in the age group of 12 to 18 years of age. Overall, the pediatric subjects achieved a slightly greater exposure (geometric mean, normalized by mg/kg dose) than those of adults (Table 6).

Table 5: Comparison of the PK Parameters by Age Groups

|                      | Age Group 1 2 to < 12 years (N=9)   | Age Group 1 2 to < 12 years (N=9)   | Age Group 2 ≥ 12 to < 18 years (N=26)   | Age Group 2 ≥ 12 to < 18 years (N=26)   | Age Group 3 ≥ 18 to ≤ 87 years (N=530)   | Age Group 3 ≥ 18 to ≤ 87 years (N=530)   |
|----------------------|-------------------------------------|-------------------------------------|-----------------------------------------|-----------------------------------------|------------------------------------------|------------------------------------------|
| Parameter            | Geo.Mean                            | (%CV)                               | Geo.Mean                                | (%CV)                                   | Geo.Mean                                 | (%CV)                                    |
| CL (L/h)             | 0.00236                             | (53.6)                              | 0.00872                                 | (66.6)                                  | 0.0147                                   | (38)                                     |
| VSS (L)              | 3.21                                | (15)                                | 4.99                                    | (28.8)                                  | 6.25                                     | (13.3)                                   |
| Alpha Half-life (h)  | 19.5                                | (27.2)                              | 32.7                                    | (13.6)                                  | 37.8                                     | (7.42)                                   |
| Beta Half-life (day) | 41.2                                | (49.7)                              | 17.8                                    | (37.2)                                  | 13.4                                     | (27.9)                                   |

<div style=\"page-break-after: always\"></div>

Table 6: Comparison of the Dose-Normalized Ipilimumab Exposure by Age Groups

|                     | Age Group 1   | Age Group 1   | Age Group 2 ≥ 12 to < 18   | Age Group 2 ≥ 12 to < 18   | Age Group 3 ≥ 18 to ≤ 87   | Age Group 3 ≥ 18 to ≤ 87   |
|---------------------|---------------|---------------|----------------------------|----------------------------|----------------------------|----------------------------|
| [( µ g/mL)/(mg/kg)] | Geo.Mean      | (%CV)         | Geo.Mean                   | (%CV)                      | Geo.Mean                   | (%CV)                      |
| Cmin1               | 3.92          | (14)          | 4.03                       | (40.3)                     | 3.38                       | (36.2)                     |
| Cmax1               | 18.8          | (7.05)        | 19.6                       | (18.9)                     | 18.7                       | (12.1)                     |
| Cavg1               | 5.51          | (20.9)        | 7.39                       | (27.4)                     | 7.19                       | (20.6)                     |
| Cmin4               | 9.75          | (10.5)        | 6.95                       | (53)                       | 5.05                       | (50.1)                     |
| Cmax4               | 27.3          | (7.21)        | 26.7                       | (26)                       | 24                         | (17.7)                     |
| Cavg4               | 12.6          | (9.55)        | 12.1                       | (39.1)                     | 10.3                       | (31.9)                     |

The MAH was asked to discuss the degree of precision (% CV) in the estimation of PK parameters in adolescents in order to conclude that the PK was similar between children/adolescents and adults. In the popPK analysis, the differences in geometric mean (GM) exposure metrics Cmin, Cmax and Cavg were less than 15% (see Figure 4, Figure 5 and Figure 6).

<!-- image -->

Analysis Directory: /global/pkms/data/CA/184/C07/prd/ppk-ped-may2016/final Program Source: Analysis Directory/R/scripts/process-sim-results.r Source: Analysis Directory/R/plots/Simulated-Cmin4-FourthDose.png

Note: The boxes show the median, 25th and 75th percentile per group. The whiskers extend to 1.5 times the interquartile range or the most extreme value (whichever is closer to the median value), and the values outside this range are represented by symbols. The age group ranges are denoted by square brackets (closed interval, inclusive of value), and parentheses (open interval, excludes value).

Figure 4: Simulated Cmin4 after the fourth dose of 3 mg/kg Q3W ipilimumab

<div style=\"page-break-after: always\"></div>

<!-- image -->

Analysis Directory: /global/pkms/data/CA/184/C07/prd/ppk-ped-may2016/final Program Source: Analysis Directory/R/scripts/process-sim-results.1 Source: Analysis Directory/R/plots/Simulated-Cmax4-FourthDose.png

Note: The boxes show the median, 25th and 75th percentile per group. The whiskers extend to 1.5 times the interquartile range or the most extreme value (whichever is closer to the median value), and the values outside this range are represented by symbols. The age group ranges are denoted by square brackets (closed interval, inclusive of value),and parentheses (open interval, excludes value).

Note: The model covariate of age ranged from 2 to 80 years in the databases of National Health and Nutrition Examination Survey (NHANES).

Figure 5: Simulated Cmax4 after the fourth dose of 3 mg/kg Q3W ipilimumab

<div style=\"page-break-after: always\"></div>

Figure 6: Simulated Cavg4 after the fourth dose of 3mg/kg Q3W ipilimumab

<!-- image -->

With reference to literature, key ipilimumab PK parameters (clearance and volume of distribution) in paediatric patients within 60-140% of the typical value, were considered acceptable. Simulated 95% CI of the clearance in percentages for a typical 12, 8 and 4 year-old subject were even within 75%-133%, with a RSE% of less than 15%. Simulated 95% CI of the volume of distribution in percentages for a typical 12, 8 and 4 year-old subject were even within 90%-109%, with a RSE% of less than 5%.

## Exposure-Response Relationship

The exploratory E-R analysis was performed with the available clinical data in paediatric melanoma subjects from CA184070 and CA184178. The similarity in BOR was assessed with respect to a previously developed E-R model of BOR in adults 3 , and the similarity in OS was assessed by comparing OS of adult melanoma subjects at 3 and 10 mg/kg (N=494, CA184004, CA184007, CA184008 and CA184022) with the corresponding OS in paediatric subjects.

The available paediatric BOR data from CA184-070 and CA184-178 (N=38, age ranging from 2 to 22 years) were overlaid on the probability of BOR predicted by the previously developed E-R of BOR in adult subjects (Figure 1). The locally weighted (loess) regression of the paediatric BOR data suggests that the E-R of BOR in paediatric subjects is similar to the E-R in adult subjects.

<div style=\"page-break-after: always\"></div>

Figure 7: Model predictability of BOR for adults and observed BOR for paediatrics versus ipilimumab steady-state trough concentration

<!-- image -->

Note: the black line (95% CI) )represents the model predicted probability of BOR from the logistic regression model developed from adult data; the blue line (95% CI) ) represents the locally weighted (loess) )regression line from the observed BOR data from pediatrics

Paediatric survival data is only available from study CA184178 (N=12, age ranging from 12 to 16 years). The OS of paediatric and adult subjects receiving 3 mg/kg and 10 mg/kg ipilimumab were compared by nonparametric Kaplan-Meier analysis, and are presented in Figure 8 and Figure 9, respectively. Although there is a high degree of uncertainty in the K-M of OS of paediatric patients, the survival probability of paediatric subjects was higher than adult subjects in both the 3 and 10 mg/kg dose groups.

Although the paediatric data are limited, the results of the exploratory analyses of efficacy in paediatric subjects are consistent with the expectation that the E-R of efficacy in paediatric subjects is similar to that of adult subjects.

<div style=\"page-break-after: always\"></div>

Figure 8: Kaplan-Meier estimates with ipilimumab at 3 mg/kg Q3W

<!-- image -->

Figure 9: Kaplan-Meier estimates with ipilimumab at 10 mg/kg Q3W

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Immunogenicity

Among available data for 45 pediatric subjects, 1 subject in the 10 mg/kg group had a HAHA positive result at baseline and 1 subject in the 5 mg/kg group had a HAHA positive results on Day 1 (sample collected 15 minutes into the infusion).

No subjects were considered to be positive up to 26 weeks after ipilimumab treatment. Based on these results, no summaries for neutralizing antibodies were presented.

## 2.3.2. Discussion on clinical pharmacology

The bioanalytical methods for ipilimumab and anti-ipilimumab antibodies have been described in earlier applications and were considered adequate.

The popPK model parameters were estimated with good precision, shrinkage was &lt;25% and based on Cmax and Cmin data in the total population, there is no indication for consistent over- or under prediction of the model. Paediatric patients were ~9% of the total population, and the VPC plots indicated that the popPK model somewhat underestimated the ipilimumab concentrations in paediatric patients by &lt;25% following the first dose. The impact of this seemingly underestimation is low and no further optimization of the model is requested. Based on a population PK analysis using available pooled data from 565 patients from 4 phase 2 adult studies (N=521) and 2 paediatric studies (N=44), clearance of ipilimumab increased with increasing baseline body weight. Age (2-87 years) had no clinically important effect on the clearance of ipilimumab. The estimated geometric mean clearance (CL) is 8.72 mL/h in adolescent patients aged ≥ 12 to &lt;18 years. Exposures in adolescents are comparable with those in adults receiving the same mg/kg dose. Based on the simulation in adults and paediatrics, comparable exposure is achieved in adults and paediatrics at the recommended dose of 3 mg/kg every 3 weeks.

Results from paediatric studies CA184070 and CA184178 confirm that in paediatric patients clearance of ipilimumab is body weight dependent as was previously shown for adults. This supports the dosing based on body weight. Further, the results indicated that ipilimumab exposure in paediatric patients is slightly higher than in adults when dosed by mg/kg. There is however, a great overlap in all exposure parameters. The elimination half-life seemed somewhat longer in paediatric patients&lt;12 years compared to older patients. The results in paediatric patients&lt;12 years of age should be considered with caution since only 6 children had PK data following repeated dosing. Overall, the results from these studies show that adolescents treated with 3 mg/kg ipilimumab will have a similar exposure to ipilimumab as in adults with the approved 3 mg/kg dose.

With regard to the model predicted probability of BOR for adults and observed BOR for paediatrics versus ipilimumab steady-state trough concentration, the applicant indicated that the locally weighted (loess) regression of the paediatric BOR data suggests that the E-R of BOR in pediatric subjects is similar to the E-R in adult subjects, although this seems only be due to 2 data points at the 10 mg/kg dose.

The Kaplan-Meier plots for OS are based on a very limited number of paediatric patients (n=4 and n=8 for 3 and 10 mg/kg, respectively) and therefore these data are only indicative but not conclusive of the potential similarity in OS exposure-response relationship between adolescents and adults.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Conclusions on clinical pharmacology

Results from paediatric studies CA184070 and CA184178 showed that ipilimumab exposure in paediatric patients seemed to overlap with the ipilimumab exposures in adults when dosed by mg/kg. Therefore, exposures in adolescents are comparable with those in adults receiving the same mg/kg dose and hence, the same level of efficacy is expected for this paediatric population. None of the paediatric subjects were found to be positive for anti-drug antibodies. This is in line with the low incidence of anti-drug antibodies in adults. The SmPC section 5.2 has been updated with the popPK analysis.

## 2.4. Clinical efficacy

## 2.4.1. Main study(ies)

Title of Study: Study CA184178: A phase 2 study of ipilimumab in children and adolescents (12 to &lt;18 years) with previously treated or untreated, unresectable stage III of stage IV malignant melanoma

## Methods

## Study participants

## Key inclusion criteria:

The  study  enrolled  male  and  female  adolescent  patients  (12  to  &lt;18  years  of  age)  who  met  the following key target disease criteria:

- -Histologically or cytologically confirmed malignant melanoma.
- -Previously treated or untreated, unresectable stage III or stage IV malignant melanoma.
- -Measurable and/or evaluable disease within 28 days prior to first dose of study treatment.
- -Karnofsky or Lansky Score ≥50.
- -Adequate hematologic, renal and hepatic function.

Key exclusion criteria:

- -Patients with primary ocular melanoma.
- -Active  brain  metastases.  Patients  with  brain  metastases  who  were  free  of  neurologic  symptoms and  who  did  not  require  or  receive  systemic  corticosteroid  therapy  in  the  10  days  prior  to beginning ipilimumab therapy were eligible.
- -History of or current active autoimmune disease.
- -Prior therapy with a CTLA-4, PD-1, PD-L1, or CD137 targeted agents.
- -Prior therapy with systemic immunosuppressive doses of agents such as cyclosporine or high dose steroid treatment within 4 weeks.

<div style=\"page-break-after: always\"></div>

## Treatments

Ipilimumab was administered intravenously (IV) at doses of 3 or 10 mg/kg over 90 minutes on day 1 of each 21-day cycle for 4 cycles unless there was confirmed disease progression (per irRC), unacceptable toxicity, or patient request to stop study treatment. Patients eligible for retreatment could receive up to 4 additional doses of ipilimumab during retreatment: one dose every 3 weeks as was done during the initial treatment phase. Alternative therapy such as both anti-PD1 and ipilimumab were to be offered to the patient if their disease were to progress outside of the study.

Patients who started at 10 mg/kg stayed on 10 mg/kg and no dose reduction was allowed.

<!-- image -->

Corticosteroids (oral or intravenous) were permitted to be used for treatment of irAEs. Alternative immunosuppressive therapies were also permitted to treat irAEs that did not respond to initial steroid therapy.

## Objectives

## Primary Objectives:

- To estimate the survival rate at 1 year in adolescent patients (12 to &lt; 18 years) with previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma at the 3 mg/kg dose level
- To assess safety and tolerability, specifically the frequency of severe (Grade 3-5) immunemediated adverse reactions of ipilimumab in adolescent patients (12 to &lt; 18 years) at the 3 mg/kg dose level

## Secondary Objectives:

<div style=\"page-break-after: always\"></div>

- Estimate the disease control rate (DCR) by mWHO criteria at the 3 mg/kg dose level.
- Estimate progression free survival (PFS) by mWHO criteria at the 3 mg/kg dose level.
- Estimate best overall response rate (BORR) by mWHO criteria at the 3 mg/kg dose level.
- Assess overall survival (OS) at the 3 mg/kg dose level.

## Outcomes/endpoints

In Table 7, the study objectives and a description of corresponding endpoints are presented.

Table 7: Study objectives and endpoints CA184178

| Objective                                                                                                                                                                                                    | Endpoint                                                                                   | EndpointDescription                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PRIMARY                                                                                                                                                                                                      | PRIMARY                                                                                    | PRIMARY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| To estimate the overall survival rate at 1 year in adolescent patients (12 to < 18 years) with previously treated or untreated,unresectable Stage III or Stage IV malignantmelanomaat the 3 mg/kg dose level | OSR                                                                                        | The overall survival rate was estimated in two ways: Kaplan-Meier (KM) estimate at 1-year Proportion of treated subjects that were alive for 1-year or longer. The survival rate at one year was defined as the probability that a participant was alive at one year following start of treatment. .                                                                                                                                                                                                                                                      |
| To assess safety and tolerability, specifically the frequency of severe (grade 3 - 5) immune-mediated adverse reactions of ipilimumab in adolescent patients (12 to < 18 years) at the 3 mg/kg dose level    | Deaths, AEs, SAEs, AEs leading to DC & dose delay, vital signs, specific lab abnormalities | The assessment of safety was based on AEs, SAEs, irAEs, imARs, deaths and the results of vital sign measurements, physical measurements, clinical laboratory tests and exposure to study therapy for participants who received at least 1 dose of study treatment and within 90 days of last dose of ipilimumab administration. AEs were coded using the MedDRA Version 19.0. AEs and laboratory values were graded for severity according to the NCI CTCAE version 3.0.                                                                                  |
| SECONDARY                                                                                                                                                                                                    | SECONDARY                                                                                  | SECONDARY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| To estimate the disease control rate by mWHO criteria at the 3 mg/kg dose level.                                                                                                                             | DCR                                                                                        | The primary definition of DCR was the total number of treated subjects with a best overall response of CR, PR, or SD, divided by the total number of treated subjects. Any participant who was unevaluable for disease control, eg, on account of missing or “not evaluable” assessments, was included in the denominator of the calculation, ie, was considered a non-responder with respect to the DCR endpoint. The time frame for this endpoint was from Day 1 of first participant first treatment to Day 365 from the last participant first visit. |
| To estimate progression free survival (PFS) by mWHO criteria at the 3 mg/kg dose level.                                                                                                                      | PFS                                                                                        | PFS was defined as the time from the start of ipilimumab treatment to progression or death, whichever occurs first. A participant who died without reported progression were considered to have progressed on their date of death. For subjects who remained alive and had not progressed, PFS was censored on the date of the last tumor assessment.                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| ·To estimate best overall response rate (BORR) by mWHO criteria at the 3 mg/kg dose level.                                                                                                | BORR                      | BORRwasdefinedasthetotalnumberoftreatedsubjectswiththebestoverall response of CR or PR, divided by the total number of treated subjects. The time frame for this endpoint was from Day 1 of first participant treatment to Day 365 from the last participant first treatment.                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ·To assess overall survival at the 3 mg/kg dose level                                                                                                                                     | OS                        | OS was defined as the time from the start of ipilimumab treatment date to death. If a participant had not died, the participant was censored at the time of last contact (last known alive date.)                                                                                                      |
| EXPLORATORY                                                                                                                                                                               | EXPLORATORY               | EXPLORATORY                                                                                                                                                                                                                                                                                            |
| To characterize pharmacokinetics of ipilimumab, the immunogenic potential, and to explore exposure- response relationship with selected exposure measure, safety, and efficacy endpoints* | Pharmacokinetics          | Minimum serum concentration-Cmin Maximumseiumconcentration-Cmax Total body clearance- CLT Area under the serum concentration time curve from time zero to time of the last quantifiable concentration - AUC (0-T)b Area under the serum concentration time curve from time zero to 21 day- AUC (o- 21) |
| To explore serum soluble factors and peripheral T cell activation as predictive or pharmacodynamic biomarkers of ipilimumab's clinical activity or safety in this patient populationc     | Immunomodulating activity | Theimmunomodulating activity was to be derived from ALC and the T cell subsets, activated CD4 and CD8 T cells.                                                                                                                                                                                         |

As part of the safety analyses, the MAH evaluated the incidence of immune-related adverse events (irAEs) and immune-mediated adverse events (imARs):

- -irAEs are AEs of unknown aetiology, which are consistent with an immune phenomenon and identified by the investigator as related to study treatment. The irAEs were programmatically determined from a predefined list of MedDRA high-level group terms, high-level terms and preferred terms; changes may be made to this list with each new version of MedDRA. Six subcategories of irAEs were reported: gastrointestinal, liver, skin, endocrine, neurological, and other irAE summaries were also produced on diarrhoea as a separate grouped term.
- -imARs are AEs determined by the investigator to have an immune-mediate aetiology. imARs were likely to be inflammatory events associated with ipilimumab treatment.

<div style=\"page-break-after: always\"></div>

## Sample size

The sample size for this study was not based upon a comparative objective. Initially, the study was designed to enrol approximately 30 patients, from age 12 to &lt;18 years of age, with previously treated or untreated unresectable stage III or IV metastatic melanoma to be treated with 10 mg/kg or 3 mg/kg of ipilimumab. In case not more than 10 patients were treated with 10 mg/kg, this sample size of approximately 30 patients ensured that at least 20 patients would have been treated with 3 mg/kg. If, however, more than 10 patients were treated with 10 mg/kg, the total sample size would have been increased to ensure that at least 20 patients would be treated with 3 mg/kg. With 20 patients treated at the 3 mg/kg dose, the lower boundary of the two-sided exact 95% confidence interval (CI) for the 1-year survival rate would have been at least 27.2% if 10 or more patients are alive after 1 year. The maximum width of the CI would have been 46%. Assuming that the incidence of high-grade imARs was at least 15%, a sample size of 20 patients treated at 3 mg/kg would have provided a two-sided exact 95% CI of 3.2% to 37.9.

## Randomisation

This was a non-randomised study.

## Blinding (masking)

This was an open-label study.

## Statistical methods

Discrete variables were summarised with the number and proportion of patients falling into each category, grouped by treatment group (3 mg/kg or 10 mg/kg total, unless otherwise noted). Unless otherwise indicated, percentages in the tables were column percentages, using all observations that belong in the column as the denominator. Percentages were rounded to the first decimal place and therefore may not always add up to 100. Continuous variables were summarised using descriptive statistics (mean, standard deviation, median, minimum and maximum values). Patient listings were produced to accompany the tabulations. Summary statistics were presented for each treatment group (ipilimumab 3 mg/kg or 10 mg/kg) and for all treated patients unless otherwise noted. No formal statistical testing was performed, only summary statistics are provided.

## Exposure analyses

Ipilimumab dose in mg/kg was calculated as the dose in mg divided by the most recent weight prior to infusion. Cumulative dose was defined as the sum of all calculated doses (mg). Cumulative dose of ipilimumab in mg/kg was defined as the sum of all doses (in mg/kg) received by the patient.

<div style=\"page-break-after: always\"></div>

## Efficacy analyses

Due to the limited number of patients enrolled in this study, only key analyses were performed for each treatment group (3 mg/kg or 10 mg/kg of ipilimumab [primary objective analyses descriptive by dose level]). The 1-year OS rate was based on a Kaplan-Meier estimate along with their corresponding log-log transformed 95% confidence interval. The OS probabilities were estimated using the KaplanMeier product-limit method. The estimates of the median and corresponding two-sided 95% confidence intervals were calculated using the Brookmeyer and Crowley method. In addition, the 1-year survival rate was calculated as the proportion of patients alive at one year divided by the total number of treated patients along with the Clopper-Pearson exact two-sided 95% confidence interval.

The PFS probabilities were estimated using the Kaplan-Meier product-limit method. The estimates of the median and corresponding two-sided 95% confidence intervals were calculated using the Brookmeyer and Crowley method. For both the DCR and BORR, each rate was presented together with its Clopper-Pearson exact two-sided 95% confidence interval. Patients were considered evaluable for tumour response if they completed at least one cycle of therapy, or if they experienced progressive disease prior to that time.

## Safety analyses

All analyses are presented by dose cohort (3 mg/kg and 10 mg/kg). No formal comparisons are made between dose cohorts with the exception of the primary endpoint of imARs. Otherwise, no formal statistical testing was performed, only summary statistics are provided.

The on-study reporting period for safety data was from the first dose of study medication to 90 days (&gt; 5 half-lives) after the last dose was received.

The primary assessment of safety was severe imARs. The rate of severe imAR was calculated as a proportion of patients having a grade 3 or worse immune mediated adverse reaction divided by the total number of treated patients along with its Clopper-Pearson exact two-sided 95% confidence interval to support the primary safety endpoint.

Descriptive statistics of safety were presented for treated patients in each treatment group (3 or 10 mg/kg ipilimumab). All on-study AEs, drug-related AEs, immune-related AEs, SAEs, drug-related SAEs, irAEs, and imARs were tabulated using worst grade per NCI CTCAE by MedDRA version 19.0 system organ class (SOC) and by preferred term (PT).

Summary tables of multiple occurrences of AEs were presented for each treatment group showing the total number and rate (exposure adjusted) of occurrences for all on-study AEs as well as the number of patients experiencing an irAE once or multiple times during on-study period.

irAEs were programmatically determined from a predefined list of MedDRA PTs representing AEs potentially associated with inflammation and based on program-wide experience with ipilimumab (identified by the safety and medical representatives from) that were considered as causally related to study drug exposure by the investigator. These terms were grouped into the following organ-specific subcategories: gastrointestinal, skin, liver, endocrine, neurological, and other. Formal exclusion of a non-inflammatory aetiology was not required for identifying irAEs.

On-study laboratory parameters, including haematology, serum chemistry, liver function, and renal function were summarised using worst CTC grade.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Table 8: Subject disposition all enrolled subjects

|                                                                                                                                          | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|
|                                                                                                                                          | 3 mg/kg Ipilimumab       | 10 mg/kg Ipilimmab       | Total                    |
| NUMBEROFENROLLEDSUBJECTS                                                                                                                 | 5                        | 9                        | 14                       |
| NUMBERTREATED                                                                                                                            | 4 ( 80.0)                | 8 (88.9)                 | 12 ( 85.7)               |
| NUMBERNOTTREATED REASONNOTTREATED                                                                                                        | 1 ( 20.0)                | 1 (11.1)                 | (14.3)                   |
| SUBJECTNOIONGERMEETSSTUDYCRITERIA AIMINISTRATIVEREASONBYSFONSOR ADVERSEEVENT DEATH LOST TO FOLLOW-UP OTHER POOR/NON-COMPLIANCE PREGNANCY | 1 (20.0) 0:0 00 000      | 1 (11.1) 0 0             | 20000000 (14.3)          |
|                                                                                                                                          |                          | 0                        |                          |
| SUBJECTWITHDREWCONSENT                                                                                                                   | 0                        | 0                        | 0                        |

Re-enrollment was permitted for subjects who ciscontinued study as a pretreatment failure.Subjects re-enrolled and subsequently treatedare only countedl once as \"treated\".

## Recruitment

In this study, 40 participants were planned to be enrolled in order to treat approximately 30 participants at the 10mg/kg dose level, but was subsequently amended with the expectation that at least 20 participants would be treated at the 3 mg/kg dose level. Because the rarity of the patient population was greater than anticipated and the availability of competing therapies (eg, anti-PD-L1), the majority of sites was unable to enroll a participant over the 3.5 year period, and study closure was recommended by the data monitoring committee. At the time of study closure, 14 participants were enrolled in US centres and 12 were treated in the study: 4 received 3 mg/kg ipilimumab and 8 received 10 mg/kg ipilimumab.

## Conduct of the study

Ipilimumab at 10 mg/kg was initially chosen for the CA184178 study based on the observations that 10 mg/kg was tolerated in adolescent patients in the study NCI7458 (CA184070) and 10 mg/kg was potentially more active in a randomised phase 2 study (CA184022) of ipilimumab in adult melanoma, with a tolerable safety profile. Given that ipilimumab 3 mg/kg was broadly approved across treatment lines in Europe, the United States, and other countries throughout the world, the MAH amended the protocol in 2014 (amendment 04) to change the dose of ipilimumab from 10 to 3 mg/kg to ensure consistency with the approved adult dose. Inclusion of the 3 mg/kg dose in this study was further supported by similarities between adults and adolescents with advanced melanoma, based upon comparable general clinical characteristics as well as maturation of the immune system for the two populations.

Patients who discontinued study treatment due to toxicity or PD prior to completing the treatment phase were to have an end of treatment assessment. A strict stopping rule based upon the occurrence of drug-related, life threatening toxicities, irAEs (immune-related adverse events) which occur beyond first dose of study drug was employed. In addition, stopping rules were in place for any AE, laboratory abnormality or intercurrent illness which, in the judgment of the investigator, presented a substantial clinical risk to the patient.

<div style=\"page-break-after: always\"></div>

Follow-up for progression/toxicity started after the last dose of study treatment and continued every 12 weeks (±14 days) until documented and confirmed disease progression or AE resolution. Patients were followed for related AEs for a minimum of 90 days following the last dose of study treatment. Adverse events collection was to resume if the patient started retreatment and continue for a minimum of 90 days following the last dose of study treatment. Patients who completed the toxicity follow-up period and had PD per irRC during the treatment or retreatment phase then entered the overall survival follow-up phase. Adverse event assessments continued until all related AEs were resolved, returned to baseline, or were deemed irreversible.

For patients who did not experience PD per irRC, tumour assessments were performed at week 12, 24 and every 12 weeks for the first 2 years and then every 6 months until confirmed and documented irPD.

Patients were followed for long-term survival information until study closure. The survival follow-up phase began after progression per irRC for patients who did not enter the retreatment phase.

Patients with an initial partial response (PR) or complete response (CR) or stable disease of ≥3 months (beginning at week 12 with SD at week 24) who subsequently experienced confirmed PD per irRC were eligible to enter the retreatment phase. Eligible patients could receive up to 4 doses of ipilimumab during retreatment (one dose every 3 weeks as was done during the initial treatment phase). Retreatment had to begin within 14 days of the confirmed PD and the phase ended with discontinuation of ipilimumab at study closure or when the patient entered the toxicity/progression follow-up phase.

Patients who discontinued study treatment due to toxicity or PD prior to completing the treatment phase were to have an end of treatment assessment. A strict stopping rule based upon the occurrence of drug-related, life threatening toxicities, irAEs (immune-related adverse events) which occur beyond first dose of study drug was employed. In addition, stopping rules were in place for any AE, laboratory abnormality or intercurrent illness which, in the judgment of the investigator, presented a substantial clinical risk to the patient.

Follow-up for progression/toxicity started after the last dose of study treatment and continued every 12 weeks (±14 days) until documented and confirmed disease progression or AE resolution. Patients were followed for related AEs for a minimum of 90 days following the last dose of study treatment. Adverse events collection was to resume if the patient started retreatment and continue for a minimum of 90 days following the last dose of study treatment. Patients who completed the toxicity follow-up period and had PD per irRC during the treatment or retreatment phase then entered the overall survival follow-up phase. Adverse event assessments continued until all related AEs were resolved, returned to baseline, or were deemed irreversible.

Patients continued study treatment until they either experienced intolerable toxicity, confirmed disease progression or the patient requested to stop study treatment.

<div style=\"page-break-after: always\"></div>

## Protocol deviations

Two patients had a significant protocol deviation. One patient in the 10 mg/kg group was diagnosed with Stage 3, M0 metastatic melanoma and underwent surgical excision prior to enrolling in the study, and had no evaluable/measurable lesions at baseline. Despite the resection, her baseline CT scan showed anomalies in the parotid area that were sufficient to indicate that some tumour may have remained, and because the anatomy in the surgical area was distorted, it was impossible to confirm complete surgical excision of the tumour nor perform measurements. Because of this observation and because she was a member of the analysis population, i.e., the treated population, she was, therefore, included in the efficacy, safety and PK analyses. As the anatomy in the surgical area was similarly distorted during subsequent evaluations and the presence of tumour could not be confirmed or ruled out, she was considered to have stable disease through the end of the study.

The second patient was not re-consented in a timely fashion during the follow-up phase.

Four amendments were made to this study (Table 9).

Table 9: Summary of changes to protocol CA184178

Abbreviations: TSH = thyroid stimulating hormone; MRI = magnetic resonance imaging; WOCBP = Women of Child Bearing Potential; imARs = immune-mediated adverse reactions; PK = pharmacokinetics.

| Designation/ Date   | Centers                           | Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 01 28-Feb-2013      | Country Specific (United Kingdom) | Inclusion of exclusionary criteria for participants unwilling tonotify their  general practitioner or referring physician (if applicable) of study participation Provision of further guidance on the length of time participants should be monitored following study treatment infusion Updating of the requirements for review of TSH results.                                                                                                                                                                                          |
| 02 23-Apr-2013      | Country Specific (France)         | Inclusion of recommended management algorithms for suspected GI toxicity, diarrhea/colitis, suspected hepatotoxicity, suspected skin appendix to the protocol                                                                                                                                                                                                                                                                                                                                                                             |
| 03 02-Jul-2013      | Country Specific (Germany)        | Specification of MRI as the standard for tumor assessments Clarification of the use of condoms in combination with spermicides Specification of exclusion criteria for participants with a history of allergic reactions to parental administration of recombinant protein                                                                                                                                                                                                                                                                |
| 04 21-May-2014      | All                               | Change in dose of study medication dose from 10 mg/kg to 3 mg/kg based on the approved adult ipilimumab dose for the advanced melanoma indication Removal of themaintenancephasedue tolackof addedbenefit Addition of one reinduction/retreatment for eligible participants Revision of the definition and guidance for WOCBP Revision of ipilimumab program-specific language for defining imARs Revision of the maximum number of index, non-index and new lesions for follow up Clarification of the pre-dose window time frame for PK |
| 04 21-May-2014      | All                               | Provision for re-enrollment of eligible participants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 04 21-May-2014      | All                               | Provision for additional TSH testing at Week 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 04 21-May-2014      | All                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 04 21-May-2014      | All                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 04 21-May-2014      | All                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 04 21-May-2014      | All                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 04 21-May-2014      | All                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

Source: Appendix 1.1

<div style=\"page-break-after: always\"></div>

## Baseline data

The baseline and disease characteristics are presented below (Table 10). Median overall age was 15.0 years, with a range of 12 to 16 years. Baseline Lansky/Karnofsky scores ranged from 90 to 100 overall. Baseline LDH was normal for 83.3% of patients. Median time from pathological diagnosis to first dose of ipilimumab was 10.45 months, and from diagnosis of advanced melanoma to first dose of ipilimumab was 2.35 months. Consistent with the inclusion criteria, all patients were stage III or IV at study entry.

One patient in the 10 mg/kg group was not evaluable because baseline tumour assessment of the target lesion was made using MRI and the follow-up evaluation was made using PET, and thus, a comparison of the size of the target lesions could not be made. A second patient in the 10 mg/kg group was diagnosed with stage III, M0 metastatic melanoma and underwent surgical excision prior to enrolling in the study, and had no evaluable/measurable lesions at baseline. As the anatomy in the surgical area was similarly distorted during subsequent evaluations and the presence of tumour could not be confirmed or ruled out, she was considered to have stable disease through the end of the study (see also paragraph about protocol deviation).

<div style=\"page-break-after: always\"></div>

Table 10: Baseline demographics and patient characteristics CA184178

Program Source:BMS BMSCA184178\\TRUNK\\TLF\\RT-DC-BSLDCMITT.SAS

|                                                                                                                         | Number of Subjects (%)              | Number of Subjects (%)                 | Number of Subjects (%)                |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------------------------------|---------------------------------------|
|                                                                                                                         | 3 mg/kg Ipilimumab N=4              | 10 mg/kg Ipilimumab N=8                | Total N = 12                          |
| AGE (YEARS)                                                                                                             |                                     |                                        |                                       |
| N MEAN (SD) MEDIAN MIN - MAX                                                                                            | 4 13.3 (1.89) 12.5 12 - 16          | 8 14.9 (0.64) 15.0 14 - 16             | 12 14.3 (1.37) 15.0 12 - 16           |
| GENDER POMALE MALE                                                                                                      | 2 ~ 8:8                             | 3 1 32:3                               | ( 88:3                                |
| RACE WHITE BLACK OR AFRICAN AMERICAN ASIAN AMERICAN INDIAN OR ALASKA NATIVE NATIVEHAWAIIAN OROTHERPACIFICISLANDER OIHER | 310000 (75.0) 25.0)                 | 8 (100.0) 00000                        | 11 91.7) 10:000 8.3)                  |
| REGION EUROPE NORTH AMERICA                                                                                             | 3 ( 75.0) 1 ( 25.0)                 | 21                                     | 6 (50.0) 6(50.0)                      |
| BASELINE HEIGHT (CM)                                                                                                    |                                     |                                        |                                       |
| N MEAN (SD) MEDIAN MIN - MAX                                                                                            | 154.18 ( 8.321) 155.40 143.5 -162.4 | 8 170.48 (12.336) 177.10 154.0 - 182.3 | 12 165.04 (13.422) 160.60 143.5-182.3 |
| BASELINE WEIGHT (KG) N MEAN (SD) MEDIAN MIN - MAX                                                                       | 4 65.55 (19.655) 62.60 45.7-91.3    | 8 64.28 (4.869) 64.85 57.1- 71.6       | 12 64.70(10.993) 64.85 45.7-91.3      |
| BASELINELACTATEDEHYDROGENASE                                                                                            |                                     |                                        |                                       |
| (ELEVATION DEFINEDAS >UPPER NORMAL LIMIT) ELEVATED NORMAL NOT REPORTED                                                  | ( 3号:8  0                           | 1(8:3) 0                               | 10  8:3 (83.3) 0                      |
| BASELINEKARNOFSKY/LANSKYPERFORMANCESTATUS 100 90 NOT REPORTED                                                           | 4  (100.0) 0:0                      |                                        | (75.0) (25.0)                         |
| TIMEFROMINITIALPATHOLOGICALDIAGNOSIS OFMALIGNANT MELANOMA TO 1ST DOSE OF IPILIMUMAB(MONTHS)                             |                                     |                                        |                                       |
| N MEAN (SD) MEDIAN MIN - MAX                                                                                            | 20.35 (18.461) 12.55 8.7 - 47.6     | 8 11.58 ( 7.792) 10.45 2.8 - 27.2      | 12 14.50 (12.258) 10.45 2.8 - 47.6    |
| TIMEFROM DIAGNOSIS OF ADVANCED MDTASTATIC MELANOMA TO1ST DOSE OF IPILIMUMAB(MONTHS)                                     |                                     |                                        |                                       |
| N MEAN (SD) MEDIAN MIN - MAX                                                                                            | 4 :2- 8.3 3.80 ( 3.403)             | 8 21 (1.808) 0.5 -5.3                  | 12 74 (2.419) 6.5 - 8.3 35            |
| DISEASE STAGE AT INITIALDIAGNOSIS OF MALIGNANT MELANOMA II 工 III IV                                                     | 3  (75.0) 0 1 (25.0)                | 0062 (75.0) (25.0)                     | 036 25:83 3 (25.0)                    |
| DISEASESTAGE AT STUDY ENIRY III                                                                                         |                                     | 3 ( 3%:8                               | 16 ~ 8:3                              |
| IV                                                                                                                      | 0 4 (100.0)                         |                                        |                                       |

## Prior anti-cancer therapies

All treated patients had prior surgery, with 58.3% also receiving systemic therapy and 1 (8.3%) receiving radiotherapy (Table 11).

Rum Date:13SEP2016:04:02:51

<div style=\"page-break-after: always\"></div>

## Table 11: Prior anti-cancer therapies CA184178

|                                                                                                          | Number of Subjects (%)           | Number of Subjects (%)                                 | Number of Subjects (%)                    |
|----------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------|-------------------------------------------|
|                                                                                                          | 3 mg/kg Ipilimumab N = 4         | 10 mg/kg Ipilimumab N= 8                               | Total N = 12                              |
| NUMBER OF SUBJECTS WITH ANY PRIOR SYSTEMIC THERAPY NUMBEROFSYSTEMICTHERAPYREGIMENSRECEIVED 123 4         | 3 ( 75.0) 120:00 25.0) 50.0)     | 4 ( 50.0) 12.5) 12 12.5) 0 1 (12.5) 1 (12.5) 1 ( 12.5) | 7 (58.3) 23101 16.7) 25.0) 8.3) 8.3) 8.3) |
| >4                                                                                                       |                                  |                                                        |                                           |
| 1234 >4 NUMBER OF SUBJECTS WITH ANYPRIOR SURGERY RELATED TO CANCER NUMBEROFPRIORSURGERIESRELATEDTOCANCER | 0 0 0:00                         | 0:0 00                                                 | 10:0:0:0                                  |
| NUMBEROFSUBJECTSWITHANYPRIORRADIOTHERAPY NUMBEROFRADIOIHERAPYRDGIMENSRECEIVED                            | 0                                |                                                        | ( 8.3)                                    |
| 1234 >4                                                                                                  | 4 (100.0) 0 (25.0) 0 0 3 ( 75.0) | 8 (100.0) 02123 5) 0 37.5)                             | 12 (100.0) 25.0) 8.3) 16.7) 6 (50.0)      |

## Concomitant therapies

All patients received non-study medications between first dose date and 90 days after last dose of study therapy. These medications were primarily given for the ongoing clinical management of disease symptoms or the treatment of AEs. The classes of concomitant medications used by most patients were analgesics and systemic antihistamines. No patient received anti-cancer therapy during ipilimumab treatment. Two patients received anti-cancer treatment within the reporting period of 90 days. one patient received temozolomide approximately one month after the last ipilimumab 10 mg/kg dose while another received dabrafenib and trametinib almost one month after the last and only dose of ipilimumab 10 mg/kg.

## Subsequent therapies

In study CA184178, subsequent therapy could be initiated for progressive disease, the need for surgical excision, or maintenance therapy after discontinuation due to an AE related to ipilimumab or to maintain response after treatment with another agent subsequent to failing ipilimumab treatment. Collection of information about subsequent therapy for treatment of melanoma was an essential component of patient follow-up, and patients were followed for 90 days or more. All patients in the 3 mg/kg group and 6/8 patients received some type of subsequent therapy. Treatments included chemotherapy (dabrafenib, trametinib, aldesleukin, temozolomide, paclitaxel), immunotherapy (pembrolizumab, nivolumab, MK-3475 [MEKPD]), radiotherapy, surgery, and other (fomustine [chemoembolisation]).

## Numbers analysed

Enrolment in 32 sites across 10 countries was planned (Table 12), and 80% of sites were activated as of December 2013. Because the rarity of adolescent patients with melanoma was greater than anticipated, as well as the availability of competing new emerging therapies (e.g., anti-PD-L1), the majority of sites were unable to enrol a patient over the 3.5-year period, and study closure was recommended by the DMC. At the time of study closure (April 2016), 14 patients were enrolled and 12 were treated in the study:8 patients in the 10 mg/kg and 4 of the 20 planned patients in the 3 mg/kg cohort. All treated patients completed 1-year survival follow-up. No additional patients were enrolled after April 2015. The number of treated patients per country is presented in Table 12.

<div style=\"page-break-after: always\"></div>

The following populations were defined for analysis:

- Enrolled Subjects: All 14 subjects who signed the ICF and who were registered in the IVRS
- Treated subjects: All 12 treated subjects who received at least 1 dose of 3 mg/kg or 10 mg/kg ipilimumab
- Pharmacokinetic  Subjects:  12  treated  subjects  who  had  any  available  serum  time-concentration data
- ADA Subjects: 12 treated subjects who had at least 1 ADA sample collected at screening and onstudy

Table 12: Accrual by country CA184178

| Country       | Number of Sites   |   Number Treated |
|---------------|-------------------|------------------|
| Belgium       | 1                 |                1 |
| Denmark       | 一                 |                1 |
| France        | 2                 |                3 |
| Spain         | 1                 |                1 |
| United States | 5                 |                6 |

## Outcomes and estimation

All 12 treated patients have been followed for survival for more than 1 year. The survival rate at 1 year was 75.0% (95% CI: 12.8, 96.1) in the ipilimumab 3 mg/kg group and 62.5% (95% CI: 22.9, 86.1) in the ipilimumab 10 mg/kg group (Table 13).

Table 13: 1-year overall survival rate CA184178

|                                | 3 mg/kg Ipilimumeb N=4   | 10 mg/kg Ipilimmeb N=   |
|--------------------------------|--------------------------|-------------------------|
| OSRATEAT 1YEAR(）(a) 95CI       | 75.0 (12.8,96.1)         | 62.5 (22.9,86.1)        |
| OS RATE AT 1 YEAR (%)(b) 958CI | 75.0 (19.4,99.4)         | 62.5 （24.5,91.5)        |

(b）Proportionofsubjectsaliveatoneyearfollowingstartoftreatmentdividedbythetotalnumberoftreatedsubjectsand Clopper-Pearsonexacttwo-sided95&amp;confidenceinterval.

All treated patients (having received at least one dose of ipilimumab) were included in the efficacy analysis, see also paragraph about baseline characteristics for more information on two patients with difficulties in tumour evaluation analyses. Efficacy assessments showed stable disease (SD) in 1/4 patients treated with ipilimumab 3 mg/kg, and 1/8 patients treated with ipilimumab 10 mg/kg. None of the patients treated with ipilimumab 3 mg/kg experienced a partial response (PR). Two patients treated with ipilimumab 10 mg/kg experienced a partial response (PR), and the PR for one patient was durable (ongoing for more than 1 year, at time of study closure). BORR was 0% (95% CI: 0, 60.2) in the 3 mg/kg group and 25% (95% CI: 3.2, 65.1) in the 10 mg/kg group. DCR was 25% (95% CI: 0.6, 80.6) in the 3 mg/kg group and 37.5% (95% CI: 8.5, 75.5) in the 10 mg/kg group (Table 14).

<div style=\"page-break-after: always\"></div>

Table 14: BOR and DCR by mWHO criteria CA184178

|                                                                                               | 3 mg/kgIpilimmeb N=4        | 10 mg/kg Ipilimmab N=8        |
|-----------------------------------------------------------------------------------------------|-----------------------------|-------------------------------|
| Best Overall Response (BOR)                                                                   | Number of Subjects ()       | Number of Subjects (%)        |
| COMPLETERESPONSE(CR) STABLE DISEASE (SD) PARTIALRESFONSE(PR) PROGRESSIVE DISEASE (PD) UNKNOWN | 0013  35:8  0               | 0:21 2:83  4 50.0) 12.5)      |
|                                                                                               | Number of Subjects (%) 95CI | Number of Subjects (%) 958 CI |
| BESTOVERALLRESPONSERATE(8)(a)(b)                                                              | 0 (0.0,60.2)                | 2 ( 25.0) (3.2,65.1)          |
| DISEASE CONIROL RATE (%)(C) (b)                                                               | 1 (25.0) (0.6,80.6)         | 3 (37.5) (8.5,75.5)           |

(b)

(c）NumberofsubjectswithCR,PRorSD/Numberoftreatedsubjects.

）2-sided95%exactconfidenceintervals(CI)arecomputedusingthemethodofClopperandPearson.

Responsesarebasedonlyonassessmentstakencuringthetreatmentphaseandfirstprogressionfollow-up\\_phase. RinDate:13SEP2016:04:05:56

Median PFS was 2.6 months (95% CI: 2.3, 8.5) in the 3 mg/kg group and 2.9 months (95% CI:0.7, NA) in the 10 mg/kg group (Table 15).

Table 15: PFS by mWHO criteria CA184178

|                                                                                                                                                               | No.ofEvents/No.of Subjects() Median (Months) (95 CI）(a)                                                                                                       | No.ofEvents/No.of Subjects() Median (Months) (95 CI）(a)                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variable                                                                                                                                                      | 3 mg/kgIpilimumab                                                                                                                                             | 10 mg/kg Ipilimumab                                                                                                                                           |
| PROGRESSION-EREESURVIVAL                                                                                                                                      | 4/4 (100.0) 2.6 (2.3, 8.5)                                                                                                                                    | 5/8 (62.5) 2.9 (0.7,                                                                                                                                          |
| （a)Mecianandassociated2-sided95confidence_intervalscalculatedusing theBrookmeyerandCrowleymethod. （---）indicatesstatisticwasnotreachedorcouldnotbecalculated. | （a)Mecianandassociated2-sided95confidence_intervalscalculatedusing theBrookmeyerandCrowleymethod. （---）indicatesstatisticwasnotreachedorcouldnotbecalculated. | （a)Mecianandassociated2-sided95confidence_intervalscalculatedusing theBrookmeyerandCrowleymethod. （---）indicatesstatisticwasnotreachedorcouldnotbecalculated. |

RunDate:13SEP2016:04:05:50

Median OS was 18.2 months (95% CI:8.9, 18.2) in the 3 mg/kg group and not reached (95% CI: 5.2, NA) in the 10 mg/kg group (Table 16).

Table 16: OS CA184178

|                 | No.ofEvents/No.ofSubjects(%) Median (Months) (958 CI）(a)   | No.ofEvents/No.ofSubjects(%) Median (Months) (958 CI）(a)   |
|-----------------|------------------------------------------------------------|------------------------------------------------------------|
| Variable        | 3mg/kgIpilimmab                                            | 10mg/KgIpilimumab                                          |
| OVERALLSURVIVAL | 2/4 (50.0) 18.2 (8.9, 18.2)                                | 3/8 (37.5) (5.2,                                           |

(a）Mecianandassociated2-sided95confidenceintervalscalculatedusingtheBrookmeyerandCrowleymethod. (---)indicatesstatisticwasnotreachedorcouldnotbecalculated.

ProgramSourOe:EMSEMSCA184178\\TRUNK\\TLF\\RT-EF-OSMITT.SAS

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

RuuDate:13SEP2016:04:05:42

<div style=\"page-break-after: always\"></div>

Table 17: Summary of efficacy for trial CA184178

| Study identifier          | CA184178                                                                                                       | CA184178                                                                                                       | CA184178                                                                                                                                                                                                                                                                  |
|---------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Non-randomised, multicenter, single-arm, open label phase 2 study                                              | Non-randomised, multicenter, single-arm, open label phase 2 study                                              | Non-randomised, multicenter, single-arm, open label phase 2 study                                                                                                                                                                                                         |
| Design                    | Study initiation date: Study completion date:                                                                  | Study initiation date: Study completion date:                                                                  | 23-Apr-2013 22-Jun-2016                                                                                                                                                                                                                                                   |
| Hypothesis                | Exploratory: Primary objectives were to estimate survival rate at 1 year and to assess safety and tolerability | Exploratory: Primary objectives were to estimate survival rate at 1 year and to assess safety and tolerability | Exploratory: Primary objectives were to estimate survival rate at 1 year and to assess safety and tolerability                                                                                                                                                            |
| Treatments groups         | Ipilumumab 3 mg/kg                                                                                             | Ipilumumab 3 mg/kg                                                                                             | n=4                                                                                                                                                                                                                                                                       |
| Treatments groups         | Ipilimumab 10 mg/kg                                                                                            | Ipilimumab 10 mg/kg                                                                                            | n=8                                                                                                                                                                                                                                                                       |
| Endpoints and definitions | Primary: Survival rate at 1 year                                                                               | OSR                                                                                                            | OSR was estimated in 2 ways: 1) Kaplan- Meier estimate at 1 year; 2) proportion of treated patients that were alive for 1-year or longer. The survival rate at one year was defined as the probability that a patient was alive at one year following start of treatment. |
| Endpoints and definitions | Primary: Safety and tolerability                                                                               | NA                                                                                                             | Deaths, AEs, SAEs, AEs leading to discontinuation and dose delay, vital signs, specific laboratory test abnormalities in patients who received at least one dose of study treatment and within 90 days of last dose.                                                      |
| Endpoints and definitions | Secondary: Best overall response rate                                                                          | BORR                                                                                                           | Total number of patients with the best overall response of CR of PR by mWHO criteria, divided by the total number of treated patients.                                                                                                                                    |
| Endpoints and definitions | Secondary: Disease control rate                                                                                | DCR                                                                                                            | Total number of treated patients with a best overall response of CR, PR, or SD by mWHO criteria, divided by the total number of treated patients.                                                                                                                         |
| Endpoints and definitions | Secondary: Progression- free survival                                                                          | PFS                                                                                                            | Time from start of treatment to progression or death, whichever occurred first.                                                                                                                                                                                           |
| Endpoints and definitions | Secondary: Overall survival                                                                                    | OS                                                                                                             | Time from start of study treatment date to death.                                                                                                                                                                                                                         |
| Database lock             | Not reported, data of report 16-Nov-2016                                                                       | Not reported, data of report 16-Nov-2016                                                                       | Not reported, data of report 16-Nov-2016                                                                                                                                                                                                                                  |

## Results and Analysis

| Analysis description                            | Primary Analysis                                   | Primary Analysis                                   | Primary Analysis                                   |
|-------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Analysis population                             | Patients were analyses by posology (3 or 10 mg/kg) | Patients were analyses by posology (3 or 10 mg/kg) | Patients were analyses by posology (3 or 10 mg/kg) |
| Descriptive statistics and estimate variability | Treatment group                                    | 3 mg/kg                                            | 10 mg/kg                                           |
| Descriptive statistics and estimate variability | Number of patient OSR%                             | 4 75.0                                             | 8 62.5                                             |
| Descriptive statistics and estimate variability | (95% CI) BORR% (95% CI)                            | (12.8, 96.1) 0 (0, 60.2)                           | (22.9, 86.1) 25 (3.2, 65.1)                        |
| Descriptive statistics and estimate variability | DCR%                                               | 25 (0.6, 80.6)                                     | 37.5 (8.5, 75.5)                                   |
| Descriptive statistics and estimate variability | (95% CI) PFS                                       | 2.6 8.5)                                           | 2.9 NA)                                            |
| Descriptive statistics and estimate variability | months (95% CI)                                    | (2.3,                                              | (0.7,                                              |
| Descriptive statistics and estimate variability | OS months (95% CI)                                 | 18.2 (8.9, 18.2)                                   | NA (5.2, NA)                                       |

<div style=\"page-break-after: always\"></div>

## Supportive study

## Supportive study: CA184070

Study NCI7458 (or CA184070) was a phase 1, multi-center, open-label, dose-escalation (doses of 1, 3, 5 and 10 mg/kg) study conducted with ipilimumab in children, adolescents, and young adults, ranging in age from 1 to 21 year with untreatable, relapsed or refractory solid malignant tumours (including melanoma) without a curative option with standard therapy. The study was conducted under the supervision of the Pediatric Oncology Branch (POB) of the National Cancer Institute (NCI).

## Study design

The primary objective was to determine the toxicity profile and the maximum tolerated dose of ipilimumab at a range of doses up to, but not exceeding, the highest dose tolerated in adults in patients ≤21 years of age with untreatable, refractory or relapsed solid malignant tumours. The pharmacokinetics (PK) of ipilimumab was also evaluated.

Secondary objectives included evaluation of anti-tumour activity (in terms of ORR) and of the immunomodulatory (pharmacodynamics) activity of ipilimumab.

Ipilimumab was administered intravenously (IV) over 90 minutes on day 1 of each 21-day cycle for 4 cycles in the absence of dose-limiting toxicity (DLT) or disease progression. From cycle 5 onward (with cycle 5 at week 12), ipilimumab was administered approximately every 12 weeks (maintenance dosing). Ipilimumab doses ranging from 1 mg/kg to 10 mg/kg in 4 dose levels (1, 3, 5, or 10 mg/kg) were planned. Three to 6 patients were to be enrolled at each dose level. If none of the first 3 patients who were evaluable for toxicity at a given dose level had a DLT within 6 weeks following the first dose date, dose escalation was performed. No intra-patient dose escalation was allowed. If a DLT related to ipilimumab was observed in 1 patient from a cohort of 3 patients at a given dose level, an additional 3 patients were to be entered at that dose level. If none of these additional patients experienced a DLT(≤1/6 with DLT), the dose of ipilimumab was to be escalated. However, if ≥1 of the additional patients experienced a DLT (≥2/6 with DLT), the highest dose tolerated was determined to be exceeded, and the next lower dose level would be considered the highest tolerated dose for ipilimumab. The cohort of the maximum tolerated dose (MTD) was to be expanded to enrol a total of 12 patients.

A range of doses (1-10 mg/kg) was planned to explore tolerability in the paediatric population. Because of the potential for irreversible or life threatening effects of ipilimumab, a starting dose of 1 mg/kg, the lowest dose at which evidence for biologic activity has been observed, was selected, as no anti-tumour effects have been observed in doses lower than 1 mg/kg. The upper limit of the dose range was 10 mg/kg, the highest tolerated dose tested in adults.

Because there appeared to be a different toxicity profile in patients &lt;12 years old, the expansion cohort of 10 mg/kg was divided into 2 cohorts in 2011. As a result, the 5 mg/kg dose cohort was expanded to a total of 14 patients that included 6 patients &lt;12 years, and the 10 mg/kg dose cohort was expanded to include more patients ≥12 years old.

Re-induction therapy (ipilimumab every 3 weeks for 4 cycles) was allowed: a) in patients experiencing disease progression during the maintenance phase; b) in patients who stopped the maintenance phase due to complete response and subsequently experienced disease progression; c) in patients with an initial partial response (PR), CR, or stable disease (SD) for at least 3 months with subsequent progression.

<div style=\"page-break-after: always\"></div>

All patients who received at least 1 dose of ipilimumab were considered evaluable for safety. The maximum study duration was 2 years total duration of therapy.

Dose-limiting toxicity (DLT) was defined as a drug-related AE according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 until 31-July2010 and Version 4.0 from 1-August-2010, that occurred during induction with ipilimumab:

- -Non-haematologic DLT: Any non-haematologic Grade 3 or 4 toxicity or Grade 2 toxicity requiring immunosuppressive or hormone replacement therapy judged to be at least possibly related to ipilimumab.
- -Haematologic DLT: Grade 4 neutropaenia or thrombocytopaenia, which persisted for 5 days at any time during the treatment cycle or any grade 5 toxicity at least possibly attributable to ipilimumab. Grade 3 haematologic toxicity was not considered dose limiting.

The MTD of ipilimumab was defined as the dose level immediately below the dose level at which ≥2 patients in a cohort (dose level) of two to 6 patients experienced a DLT attributable to ipilimumab.

Immune-related AEs were defined using a predefined list of Medical Dictionary for Regulatory Activities (MedDRA) high-level group terms, high-level terms, and preferred terms (PTs).

The development of immune function was to be evaluated prior to all cycles, based on the following laboratory tests: Rheumatoid factor, anti-nuclear antibody (ANA). If ANA values were positive (&gt;2) subsequent to baseline evaluation, the following tests were also to be performed prior to all cycles of ipilimumab treatment: anticardiolipin antibody (ACA), anti-neutrophil cytoplasmic antibody (ANCA), complement 3 (C3), C4, anti-deoxyribonucleic acid (DNA), anti-Sjögren's syndrome (SS)A, and antiSSB.

Corticosteroids (oral or IV) could be used for treatment of immune-related adverse events (irAEs). In addition, alternative immunosuppressive therapies (e.g., infliximab, mycophenolate mofetil, tacrolimus) could be used to treat irAEs that do not respond to initial steroid therapy.

## Results

## Disposition and baseline/demographic characteristics

A total of 33 patients were enrolled: 13 (39.4%) of the 33 patients in the study were &lt;12 years old and 20 (60.6%) were ≥12 years (Table 18). No patients were ≥1 and &lt;2 years old. All patients were treated at 3 study sites in the United States.

Overall, 57.6% of patients were female and 69.7% Whites. Most (92.9%) of patients in the 5 mg/kg group were female, and in the 10 mg/kg group, most were male (76.9%). Overall, 39.4% were &lt;12 years old and 60.6% were ≥12 years. The minimum age was 2.4 years; one patient in the 3 mg/kg group was 21.8 years old. All patients had baseline Lansky/Karnofsky scores ≥50, as required by the inclusion criteria.

<div style=\"page-break-after: always\"></div>

## Table 18: Demographic and baseline characteristics by dose level NCI7458/CA1840701

NumberofSubjects(%)

|                               | 1 mg/kg Ipilimmab N = 3   | 3 mg/kg Ipilimmab N = 3   | 5 mg/kg Ipilimmab N = 14   | 10 mg/kg Ipilimumab N = 13   | Total N = 33        |
|-------------------------------|---------------------------|---------------------------|----------------------------|------------------------------|---------------------|
| GENDER，n(%)                   |                           |                           |                            |                              |                     |
| FOMALES                       | 2(66.7)                   | 1( 33.3)                  | 13 (92.9)                  | 3(23.1)                      | 19 ( 57.6)          |
| MALES                         | 1 ( 33.3)                 | 2 (66.7)                  | 1 7.1)                     | 10 ( 76.9)                   | 14 ( 42.4)          |
| RACE, n(%)                    |                           |                           |                            |                              |                     |
| WHITE                         | 3 (100.0)                 | 2 (66.7)                  | 10 (71.4)                  | 8 (61.5)                     | 23 3(69.7)          |
| BLACKORAFRICAN AMERICAN       | 0                         | 0                         | 0                          | 2(15.4)                      | 2 (6.1)             |
| ASIAN                         | 0                         | 0                         | 14.3)                      | 3(23.1)                      | (15.2)              |
| AMERICANINDIANOR ALASKANATIVE | 0                         | 1 ( 33.3)                 | 7.1)                       | 0                            | 2 6.1)              |
| UNKNOWN                       | 0                         | 0                         | 1（ 7.1)                    | 0                            | 1 (3.0)             |
| AGE (YEARS)                   |                           |                           |                            |                              |                     |
| N                             | 3                         | 3                         | 14                         | 13                           | 33                  |
| MEAN (STD)                    | 14.57 (10.542) 20.30      | 12.57 (8.832) 11.70       | 12.76 (5.667) 13.50        | 14.18 (3.527) 13.40          | 13.47 (5.490) 13.40 |
| MEDIAN MIN-MAX                | 2.4-21.0                  | 4.2-21.8                  | 3.3 -20.8                  | 7.5 -19.4                    | 2.4-21.8            |
| AGE,n(%)                      |                           |                           |                            |                              |                     |
| <12 YEARS                     | (33.3)                    | 66.7)                     | 6 (42.9)                   | 4(30.8)                      | 13 (39.4)           |
| >= 12 YEARS                   | 2(66.7)                   | (33.3)                    | 8 3(57.1)                  | 9(69.2)                      | 20(60.6)            |

Melanoma was the most common tumour type (12/33 patients), followed by osteosarcoma (n=8), soft tissue sarcoma (n=7), renal cell of the kidney (n=1), clear cell of the kidney (n=1), neuroblastoma (n=1), and solid tumour not otherwise specified (NOS) (n=3), see also Table 19. All patients had received anti-cancer treatment prior to enrolment. All patients had prior surgery. Among patients with prior radiation, 1 had extensive radiation, 4 limited radiation, and 13 radiation (NOS). All 12 melanoma patients were treated with IL-2 or interferon (IFN) alpha prior to enrolment, and most of the patients with other tumour types (63.6%) were treated with standard multi-agent chemotherapy regimens for their particular tumour type. The patient with a neuroblastoma was enrolled and treated following an autologous stem cell rescue.

Table 19: Tumour types by age groups NCI7458/CA1840701

| Age Group      | Tumor Type   |   1 mg/kg |   3 mg/kg | 5 mg/kg   | 10 mg/kg   |   Total |
|----------------|--------------|-----------|-----------|-----------|------------|---------|
| < 12 years old | Melanoma     |         1 |         1 | 4         | 1          |       7 |
|                | Non-melanoma |         0 |         1 | 乙         | 3          |       6 |
| ≥ 12 years old | Melanoma     |         0 |         0 | 3         | 乙          |       5 |
|                | Non-melanoma |         2 |         1 | 5         | 7          |      15 |

Specifically for the 5 melanoma patients older than 12 years, 3 were whites, most were ~13 years, and baseline Lansky/Karnofsky scores ranged from 70 to 90 (Table 20, Table 21). All patients had cancer treatment, including treatment with IL-2 or interferon alpha, as well as surgery prior to enrolment. Two in the 5 mg/kg and one in the 10 m/kg group had prior radiation therapy. The 5 patients were treated with 5 or 10 mg/kg. No patients above 12 years of age and with advanced melanoma was treated with 3 mg/kg.

<div style=\"page-break-after: always\"></div>

Table 20: Demography of advanced melanoma patients ≥12 years NCI7458/CA184070

<!-- image -->

Source:Appendix3.1of theFinalCSRNCI7458/CA184070

Table 21: Disease characteristics of advanced melanoma patients ≥12 years NCI7458/CA184070

<!-- image -->

Source:Appendix3.2 of the FinalCSR NCI7458/CA184070

## Dose escalation NCI7458/CA184070

In the dose escalation study NCI7458/CA184070 (Figure 11) at doses of 1 and 3 mg/kg, 3 patients each were enrolled, regardless of age group. Since no DLTs were observed, the dose was escalated to 5 mg/kg.

At 5 mg/kg, the first cohort of patients to assess DLTs was 4 instead of 3. The second patient enrolled died of progressive disease before 6 weeks on study and was not evaluable. Therefore, the patient was replaced by another patient at this dose level. Since only the 4th patient treated at 5 mg/kg experienced a DLT, an additional 3 patients were enrolled at this dose; however, as none of these experienced a DLT, the dose was escalated to 10 mg/kg.

At 10 mg/kg, one of the first 3 patients enrolled experienced a DLT within 6 weeks of first dose; this patient was &lt;12 year old. Since a DLT was reported for &lt;2 of the 3 patients enrolled and treated at 10 mg/kg, additional patients were enrolled into the 10 mg/kg dose group. A second patient &lt;12 year old experienced a DLT at 10 mg/kg, as enrolment continued into this dose cohort. Therefore, the protocol was amended to limit further treatment of patients &lt;12 year old to the 5 mg/kg dose, thereby limiting expansion of treatment at 10 mg/kg to patients ≥12 years old. Shortly thereafter, the first DLT in a patient ≥12 years old was reported.

<div style=\"page-break-after: always\"></div>

Figure 11: Study scheme NCI7458/CA184070

<!-- image -->

Source:Figure5.1-2oftheFinalCSRNCI7458/CA184070

## Dose expansion phase by age

Since no young children had been enrolled in the 5 mg/kg dose cohort, after escalation to 10 mg/kg, an amendment was put in place to enrol 6 additional patients &lt;12 years at the 5 mg/kg dose. This expansion allowed further exploration of safety and PK at these age group to determine if 5 mg/kg was a tolerated dose for &lt;12-year-old age group. By the time the MTD for patients &lt;12 years old was established, and further treatment had been separated by age groups, and the 10 mg/kg dose level was expanded to enrol additional patients ≥12 years old, besides the initial 3 patients needed to establish the highest tolerated dose tested, 4 patients &lt;12 years old had been treated at 10 mg/kg.

Additional patients ≥12 years old were needed to allow further exploration at this dose, and therefore, 6 additional patients ≥12 years old were enrolled into the 10 mg/kg group for a total of additional 9 patients during the dose expansion phase.

## Dose limiting toxicities

A total of thirteen patients &lt;12 years of age and 20 patients ≥12 years were treated with ipilimumab. In summary, no DLTs were identified in the 1 and 3 mg/kg dose cohorts. For patients ≥1 to &lt;12 years old, the MTD was determined to be 5 mg/kg. Tolerability of the 5 mg/kg dose in this age group was confirmed by expansion of the cohort to a total of 13 patients. DLTs were observed in:

- -1 of a total of 6 patients in this age group treated with 5 mg/kg (anaphylactic reaction)
- -2 of a total of 4 patients in this age group treated with 10 mg/kg cohort (diarrhoea; increased ALT/AST)

The highest tolerated dose tested for patients ≥12 to ≤21 years old was 10 mg/kg. DLTs were observed in:

<div style=\"page-break-after: always\"></div>

- -2 of a total of 8 patients in this age group treated with 5 mg/kg (amylase increased and abdominal pain; autoimmune disorder)
- -2 of a total of 9 patients in this age group treated with 10 mg/kg (pleural effusion; diarrhoea)

For older children (&gt;12 years of age), 10 mg/kg was established in this study as the highest tested tolerated dose.

## Tumour responses

Patients were considered evaluable for tumour response if they completed at least one cycle of therapy, or if they experienced progressive disease prior to that time. None of the patients reached an objective response (PR or CR) per RECIST criteria. Eleven patients had SD as the best overall response (BOR). All patients with SD were treated at doses &gt;1 mg/kg (the minimum dose established to be effective for advanced melanoma in adults). Only 1 of the 13 patients &lt;12 years old achieved SD. Stable disease was achieved in 2 of 12 patients with melanoma, and 9 of the 21 patients with other types of solid tumours. Of 9 patients with SD in patients with non-melanoma solid tumours, 2 were unconfirmed.

Overall, stable disease was of short duration for most patients. Stable disease &gt;6 months duration was observed in 2 patients. One patient with melanoma achieved a duration of SD for nearly 2 years (&gt;22 months). The other patient had an unspecified solid tumour and although SD was achieved, disease progressed within 7 months.

In most cases of non-melanoma patients that achieved SD, SD was maintained for about 3 months or less, and for 3 of the 9 patients the duration of SD was &lt;2 months. For 4 of the 9 non-melanoma patients with SD, all 4 were discontinued due to an AE rather than disease progression and did not continue tumour assessment. Therefore, duration of SD could not be assessed for these patients. Of note, many of the non-melanoma patients enrolled in the study were known with protracted disease course regardless of treatment.

Best overall responses other than SD were:

- -PD: 16 patients; 7 of 13 patients with melanoma, 9 of 21 patients with non-melanoma, with study day of progression between Day 22 and Day 51
- -Assessment not evaluable/performed (patients had only 1 infusion); one melanoma patient died due to disease progression on Day 7 after start of treatment

In summary, for melanoma patients, 2 out of 3 patients developed stable disease in the 5 mg/kg group and none of the patients had PR or CR. For one patient SD was &gt;22 months, the other patient with SD had a duration of response of 104 days. In the 10 mg/kg group, none of the 2 melanoma patients had a response (Table 22).

<div style=\"page-break-after: always\"></div>

Table 22: Best overall response of advanced melanoma patients ≥12 years NCI7458/CA184070

|   Dose Level [mg/kg] |   No. of Ipilimumab Infusions | BOR   | Response Study Day   | Progression Study Day   | Death Study Day   |
|----------------------|-------------------------------|-------|----------------------|-------------------------|-------------------|
|                    5 |                            15 | SD    | 39                   | 732                     | NA                |
|                    5 |                             4 | SD    | 61                   | 104                     | NA                |
|                    5 |                             1 | NE    |                      |                         | 93                |
|                   10 |                             2 | PD    |                      | 41                      |                   |
|                   10 |                             2 | PD    |                      | 41                      |                   |

Abbreviations: BOR = Best Overall Response; SD = stable disease; NA = not available; NE = not evaluable (too early to assess); PD = progressive disease.

Source: Table 7.1 and 7.2 Final CSR NCI7458/CA184070

## 2.4.2. Discussion on clinical efficacy

Ipilimumab for melanoma in the paediatric population was planned to be studied in three clinical studies:

1. NCI7458/CA184070 : multicenter, phase 1, open-label, dose escalation study of ipilimumab 1, 3, 5, and 10 mg/kg in paediatric patients ≥ 1 year to ≤ 21 years of age with measurable/evaluable, untreatable, relapsed or refractory solid malignant tumours without a curative option with standard therapy. The study enrolled 13 patients &lt;12 of age and 20 patients ≥ 12 years of age. Ipilimumab was administered every 3 weeks for 4 doses and then every 12 weeks thereafter in the absence of dose limiting toxicity (DLT) and disease progression.
2. CA184178 : was a non-randomised, multicenter, open-label phase 2 study, in adolescent patients 12 to &lt; 18 years of age with previously treated or untreated, unresectable stage III or Stage IV malignant melanoma. Ipilimumab was administered every 3 weeks for 4 doses.
3. E1609/CA184116 : Phase 3, randomised clinical study of ipilimumab versus high-dose interferon alpha in the adjuvant setting in children with high-risk surgically-resected melanoma

The initial sample size for evaluating ipilimumab in the paediatric clinical trials was 30 melanoma patients. However, due to difficulties in recruitment because of the rarity of melanoma in children and he development of other therapeutic alternatives such as anti-PD-1 antibodies, the PDCO agreed to the MAH request to remove the indication of paediatric patients with melanoma in the adjuvant setting from the PIP and to reduce the number of treated patients in study CA184178 from 30 to 12.Efficacy results were reported for the melanoma patients older than 12 years in the NCI7458/CA184070 and all included patients of the CA184178 study. The E1609/CA184116 study was discontinued and only safety data were reported (see safety section).

<div style=\"page-break-after: always\"></div>

## Design and conduct of clinical studies

Study CA184178 enrolled 14 patients but only 12 patients were treated between the ages of 12-16 years of age: 4 in the 3 mg/kg group and 8 in the 10 mg/kg group. Two patients were not evaluable, both in the 10 mg/kg group. One patient was not evaluable because of different tumour evaluation techniques used at baseline and follow-up. Another patient had no measurable disease at baseline since surgery was performed prior to enrolment. The study excluded patients with active brain metastases and prior therapy with CTLA-4, PD-(L)1, or CD137 targeted agents. The patient population of adolescents treated is considered acceptable. The MAH amended the study protocol to change the proposed dose of 10 mg/kg to the approved adult dose of ipilimumab 3 mg/kg to ensure consistency with the approved dose. This change in dose is acceptable and does not impact on the results of the study as the popPK data has shown that paediatric patients receive a similar exposure for both doses. Patients who tolerated the 10 mg/kg dose stayed at that dose and no dose reduction was allowed. Of the 4 patients in the 3 mg/kg group, 3 received the 4 planned infusions. Of the 8 patients who received 10 mg/kg, 3 patients received the 4 planned infusions demonstrating that the 3 mg/kg dose is more tolerable than the 10 mg/kg. Half of the patients discontinued from study treatment due to toxicity and 33.3% due to disease progression. For 6 patients that discontinued because of toxicity, this was considered to be drug-related. Four patients required interruption of the infusions: one in the 3 mg/kg group and 3 in the 10 mg/kg group. The primary efficacy endpoint was 1-year survival rate. Secondary efficacy endpoints of best overall response rate (BORR), stable disease (SD), disease control rate (DCR), and progression free survival (PFS) were based on mWHO criteria and determined by the investigator's assessment. Overall survival (OS) was also evaluated. Tumour assessment was performed at week 12. All patients were followed for at least 1 year. The primary and secondary endpoints were considered acceptable.  Study NCI7458/CA184070 enrolled 33 patients, 8 of a total of 33 patients across all ages received all 4 of the planned induction (treatment) doses of ipilimumab, and all 8 were ≥12 years old. Two of the 8 patients had melanoma, both in the 5 mg/kg group, and the remaining had other solid malignant tumours. In total of three patients were treated with 5 mg/kg and 2 with 10 mg/kg. Five of the 33 patients had advanced melanoma and were in the age of 13 to 15.7 years. Three of 5 were treated with 5 mg/kg and 2 with 10 mg/kg. Of the 5 patients, 3 were white, most were ~13 years old, and baseline Lansky/Karnofsky scores ranged from 70 to 90. Of patients 12 years of age and older with advanced melanoma, ipilimumab 5 mg/kg was administered to three patients and ipilimumab 10 mg/kg was administered to two patients. The patient population was considered acceptable. The primary objective was to determine the toxicity profile and the maximum tolerated dose of ipilimumab at ranges up to, but not exceeding, the highest dose tolerated in adults in patients ≤21 years. The primary endpoints (measuring DLT) and secondary endpoint (ORR) were considered acceptable.

## Efficacy data and additional analyses

For study CA184070, there were no patients that had objective responses by RECIST criteria. Stable disease was achieved in two patients at the ipilimumab 5mg/kg dose, one with a duration of &gt; 22 months.  Study CA184178 patients were followed for at least 1 year. Stable disease was achieved for 260 days in one patient on ipilimumab 3 mg/kg and approximately 14 months in one patient on ipilimumab 10 mg/kg. Two patients treated with ipilimumab 10 mg/kg experienced a partial response, one of which was a durable response for more than 1 year. For patients receiving 3 mg/kg and 10 mg/kg, PFS was approximately the same at 2.6 months and 2.9 months, respectively, which is comparable to the PFS observed in the adult population. Median OS was 18.2 months in the 3 mg/kg group and was not reached for the 10 mg/kg group (see SmPC section 5.1).

<div style=\"page-break-after: always\"></div>

The available efficacy data in adolescents in the age range of 12 to 18 years with advanced melanoma is limited and efficacy cannot be conclusively established. Anti-tumour activity was observed with an objective response in 2 of 8 patients and best response of SD in 1 additional patient in CA184178 treated with 10 mg/kg, but none of the 2 patients treated with 10 mg/kg in NCI7458/CA184070 showed a response. For the applied posology of 3 mg/kg, only 4 patients in the indicated age range were treated with 1 response of SD (260 days). For 5 mg/kg, 2 of 3 patients showed SD.

Therefore, given the mechanism of action and the PK data showing overlapping ipilimumab exposure in paediatric patients with the ipilimumab exposures in adults, efficacy results can be extrapolated from the adult population. In the adult population, median OS after ipilimumab monotherapy (3 mg/kg) was 10.12 months (CI 95%: 8.02, 13.80) with a 1-year OS rate of 46% (CI 95%: 37.0, 54.1). Median PFS was 2.86 months (CI 95%: 2.76, 3.02). In 137 treated patients, tumour evaluation showed CR in 1.5%, PR in 9.5%, SD in 17.5%, PD in 51.1% of patients respectively, and 20.4% was not evaluable. BORR was 10.9% (CI 95: 6.3, 17.4) [EPAR Ipilimumab; SmPC Ipilimumab].

Regarding posology, a study specifically comparing 3 versus 10 mg/kg ipilimumab in adults was recently published 7 . This randomised, double-blind, multicentre, phase 3 trial was performed in adult patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors. In total 364 patients were treated with 10 mg/kg and 362 with 3 mg/kg. Median follow-up was 14.5 months for the 10 mg/kg group and 11.2 months for the ipilimumab 3 mg/kg group. Median overall survival was 15.7 months (95% CI 11.6-17.8) for 10 mg/kg compared with 11.5 months (95% CI 9.9-13.3) for ipilimumab 3 mg/kg (hazard ratio 0.84, 95% CI 0.70-0.99; p=0.04). 1-year overall survival was 54.3% (95% CI 49.059.3) in the 10 mg/kg group versus 47.6% (42.4-52.7) in the 3 mg/kg group. Median progression-free survival was 2.8 months (95% CI 2.8-3.0) in the 10 mg/kg group and 2.8 months (2.8-2.8) in the 3 mg/kg group. Although direct comparisons cannot be made, these results suggest in adults that the higher dose of 10 mg/kg shows increased efficacy benefit at the cost of increased toxicity (see discussion on safety).

As few patients were enrolled in the studies CA184070 and CA184178, no definitive conclusions can be drawn about the efficacy and appropriate dose in paediatric patients based on the data presented but since the data appears to follow a similar trend as observed in the adults population, the extrapolation of the efficacy and dose from the adult population to paediatric patients ≥ 12 years old seems to be well justified. Only very limited data are available in children younger than 12 years of age. Therefore, ipilimumab should not be used in children younger than 12 years of age.

Before initiating treatment with ipilimumab monotherapy in adolescents of 12 years and older, physicians are advised to carefully evaluate the individual patient, taking into consideration the limited available data, the observed benefits and the toxicity of ipilimumab monotherapy in the paediatric population (see sections 4.8 and 5.1).

7 Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance  A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno  B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D,

Qureshi A, Maio M. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017 May;18(5):611-622

<div style=\"page-break-after: always\"></div>

It is possible that lower immunogenic potential and lower levels of tumour-associated mutations in paediatric tumours might contribute to lower clinical activity observed in paediatric patients. It has been described that high mutational burden in tumours increase neoantigen presentation in adult melanoma8 and subsequent responses9, 10. Paediatric tumours usually harbour fewer mutations and as a result could be less immunogenic. Unfortunately, study CA184070 did not collect tumour tissue samples and hence analysis of the mutational burden could not be correlated to efficacy in adolescents with advanced melanoma.

## 2.4.3. Conclusions on the clinical efficacy

Although limited data is presented on paediatric patients who were treated with ipilimumab, an antitumour activity in terms of BORR, SD and PFS can be observed in the studies of paediatric patients with advanced melanoma. Together with the PK results and efficacy data in the proposed dose in adult patients in the same clinical setting, it is considered acceptable to extrapolate the clinical benefit to the paediatric population with a similar course of disease and prognosis as for the adult population. Given the mechanism of action of ipilimumab and the overlapping PK exposures in paediatric and adult patients, it is very likely that paediatric patients may derived the same beneficial treatment effect as for adults and hence, the CHMP has agreed to a paediatric indication for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age and older.

## 2.5. Clinical safety

## Introduction

The safety results of the paediatric population of advanced melanoma were compared with an Adult Safety Pool. The MAH also reported the safety experiences in two paediatric patients with adjuvant ipilimumab in high risk melanoma.

## Safety analysis of ipilimumab monotherapy in advanced paediatric melanoma

A total of 33 children, adolescents, and young adults (age range 2.4 to 21.8 years) were treated with ipilimumab 1, 3, 5, or 10 mg/kg in NCI7458/CA184070, of which 20 were ≥12 years old. In CA184178 12 children and adolescents (age range 12 to 16 years) were treated with ipilimumab 3 or 10 mg/kg. In total, 45 paediatric patients were treated with ipilimumab across the 4 doses in both studies. In this safety analysis, the focus is on the safety data in the target population, children and adolescents 12 years of age or older with advanced melanoma treated with ipilimumab 3 or 10 mg/kg.

8 Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, Streicher H, Mackall CL. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Mar 15;22(6):1364-70

9 Snyder et al (NEJM 2014)

10 Van Allen et al (Science 2015)

<div style=\"page-break-after: always\"></div>

The paediatric safety data were compared to pooled safety data from four completed phase 2 studies in adults (Table 23), in which ipilimumab 3 or 10 mg/kg administered as monotherapy was evaluated in patients with pretreated and untreated advanced melanoma (CA184004, CA184007, CA184008, and CA184022; n=111 patients treated at 3 mg/kg and 325 at 10 mg/kg). Demographics and baseline characteristics were generally similar and consistent with the paediatric studies, with the exception of age, height and weight. Nearly all patients were white, consistent with the racial distribution of melanoma and the geographical distribution of study patients. Most patients were &lt;65 years: 76/111 in the 3 mg/kg group and 217/325 in the 10 mg/kg group. Most patients were male: 75/111 in the 3 mg/kg group and 185/325 in the 10 mg/kg group. The largest proportion of patients were from Europe (57/111) and North America (46/111) in the 3 mg/kg group and 165/325 and 143/325 in the 10 mg/kg group. Median height of patients in the Adult Safety Pool ranged from 173.0 to 171.0 cm. Approximately one half of the adults weighed ≥80 kg. Prior systemic anti-cancer therapy was given to 100/111 patients in the 3 mg/kg group and 300/325 patients in the 10 mg/kg group. Prior immunotherapy was given to 61/111 patients in the 3 mg/kg group and 180/325 in the 10 mg/kg group.

Pooled analyses of the paediatric studies were not performed. The safety window for study NCI7458/CA184070 and the adults studies was 30 days after last dose, for study CA184178 the safety window was 90 days after the last dose.

Table 23: Completed  phase  2  studies  in  the  adult  safety  pool,  advanced  melanoma, ipilimumab 3 and 10 mg/kg

| Study    | Population                                         | Design                                    | Objectives                                                                                                           | Test Drugs Dose and Duration                                                                                                                                                                                        | Number Treated                                               |
|----------|----------------------------------------------------|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| CA184022 | Previously treated advanced melanoma               | Phase 2, double-blind, randomized (1:1:1) | To assess BORR (primary). Secondary objectives included PFS, OS, safety                                              | IV Ipilimumab Treatment:10, 3,or 0.3 mg/kg, q3 weeks x 4 doses Maintenance: 10, 3, or 0.3 mg/kg, q12 weeks                                                                                                          | 0.3 mg/kg = 72 3 mg/kg = 71 10 mg/kg = 71 Total=214          |
| CA184008 | Previously treated advanced melanoma               | Phase 2, open-label                       | To assess BORR (primary). Secondary objectives included PFS, OS, safety                                              | IV Ipilimumab Treatment: 10 mg/kg, q3 weeks x 4 doses Maintenance:10 mg/kg. q12 weeks                                                                                                                               | 10 mg/kg = 155 Total=155                                     |
| CA184007 | Untreated andpreviously treated advancedmelanoma   | Phase 2, double- blind, randomized (1:1)  | To assess safety (primary). Secondary objectives included BORR,PFS,OS                                                | IV Ipilimumab and oral budesonide or placebo Ipilimumab: Treatment: 10 mg/kg, q3 wks x 4 doses Maintenance: 10 mg/kg, q12 weeks Budesonide: 9 mg qd until Week 12, 6 mg qd until Week 14, and 3 mg qd until Week 16 | 10 mg/kg + placebo = 57 10 mg/kg + budesonide = 58 Total=115 |
| CA184004 | Untreated and previously treated advanced melanoma | Phase 2, double- blind, randomized (1:1)  | To assess potential predictive markers of response or toxicity (primary). Secondary objectives included safety, BORR | IV Ipilimumab Treatment: 3 or 10 mg/kg, q3 weeks x 4 doses Maintenance: 3 or 10 mg/kg. q12 weeks                                                                                                                    | 3 mg/kg = 40 10 mg/kg = 42 Total=82                          |

## Patient exposure

- -NCI7458/CA184070: Overall, 8 of a total of 33 patients in the study with any type of solid tumour in the study across all ages received all 4 of the planned induction (treatment) doses of ipilimumab, and all 8 were ≥12 years old:
- o 1 of 3 patients at 3 mg/kg,

<div style=\"page-break-after: always\"></div>

- o 3 of 8 patients at 5 mg/kg, and
- o 4 of 9 patients at 10 mg/kg.

Two of the 8 patients had melanoma, both in the 5 mg/kg group, and the remaining had other solid malignant tumours. Furthermore, of the 8 patients who completed treatment therapy (4 doses), 3 entered the maintenance treatment portion of the study, according to the protocol: one patient with osteosarcoma metastatic treated with 10 mg/kg received a total of 5 doses, and another with solid tumour NOS received 6 doses. One patient in the 5 mg/kg group with melanoma of the head and neck received 15 doses. This patient was re-induced after the 6th maintenance dose, and following the 4th re-treatment dose, was re-entered into maintenance treatment. Cumulative dose was not analysed in this study.

- -CA184178 : Three patients in each treatment group (75% in the 3 mg/kg group and 37.5% in the 10 mg/kg group) received 4 doses of ipilimumab. All patients received at least one dose. Median number of doses were 4 and 3 in the 3 and 10 mg/kg groups, respectively. Mean doses were 3.5 and 2.8 in the 3 and 10 mg/kg groups, respectively. The cumulative dose (mg) for all 12 patients ranged from 336.6 to 2965.0 mg. The cumulative dose by weight (mg/kg) for all 12 patients ranged from 6.0 to 39.8 mg/kg and the median was 16.0 mg/kg. Median cumulative dose per patient (mg) was 691.25 and 1896.0 in the 3 and 10 mg/kg groups, respectively. Median cumulative dose per patient (mg/kg) was 11.95 and 29.75 mg/kg in the 3 and 10 mg/kg groups, respectively.
- -Adult Safety Pool : Patients in the 3 mg/kg group received a median of 4 doses and a mean of 3.5 doses; 70.3% of the patients received 4 doses. The median cumulative dose (in mg and mg/kg) of ipilimumab for patients in the 3 mg/kg group was 894.0 mg and 12.0 mg/kg. Patients in the pooled 10 mg/kg group received a median of 4 doses and a mean of 3.3 doses during the treatment phase; 58.2% of the patients received 4 doses. The median cumulative dose (in mg and mg/kg) of ipilimumab for patients in this group was 2710.0 mg and 39.9 mg/kg. Comparison of the exposure in the paediatric versus adult patients is shown in Table 24. A higher percentage of patients received all 4 treatment doses in both CA184178 and the Adult Safety Pool, reflective of a higher rate of discontinuation due to study drug toxicity in the 10 vs 3 mg/kg group. Cumulative dose was not evaluated in study NCI7458/CA184070. The lower median number of doses between study NCI7458/CA184070, and study CA184178 and the Adult Safety Pool may be driven by the dose-escalation study design of NCI7458/CA184070, in which dose-limiting toxicities resulted in discontinuation.

<div style=\"page-break-after: always\"></div>

Table 24: Comparison of exposure in paediatric vs adult patients

|                               | NCI7458/CA184070 ≥ 12 to 21 years   | NCI7458/CA184070 ≥ 12 to 21 years   | NCI7458/CA184070 ≥ 12 to 21 years   | CA184178 12 to < 18years   | CA184178 12 to < 18years   | Adult Safety Pool            | Adult Safety Pool                     |
|-------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|----------------------------|----------------------------|------------------------------|---------------------------------------|
|                               | 3 mg/kg N=1                         | 5 mg/kg N=8                         | 10 mg/kg N=9                        | 3 mg/kg N=4                | 10 mg/kg N=8               | CA184004/ 022 3 mg/kg N =111 | CA184004/ 007/008/022 10 mg/kg N =325 |
| Median Doses                  | 4.0                                 | 2.5                                 | 2.0                                 | 4.0                        | 3.0                        | 4.0                          | 4.0                                   |
| Participants with 4 Doses (%) | 1 (33.3)                            | 3 (37.5)                            | 4 (44.4)                            | 3 (75.0)                   | 3 (37.5)                   | 78 ( 70.3)                   | 189 (58.2)                            |
| Median Cumulative (mg)        | NA                                  | NA                                  | NA                                  | 691.25                     | 1896.0                     | 894.0                        | 2710.0                                |
| Median Cumulative (mg/kg)a    | NA                                  | NA                                  | NA                                  | 11.95                      | 29.75                      | 12.0                         | 39.9                                  |

NA = not assessed

Source: Appendix 4.1 of the Final CSR NCI7458/CA184070; Table 6.1-1 and Supplemental Table S.4.2 of the Final CSR CA184178; SCS-A Appendices 1.12A and 1.13A of the 2010 SCS

## Extent of exposure

Overall, 8 patients received 10 mg/kg and 4 patients received 3 mg/kg. Of the 8 patients who received 10 mg/kg, 3 patients received the 4 planned infusions of ipilimumab. Of the 4 patients who received 3 mg/kg, three received the 4 planned infusions (Table 25). In the 3 mg/kg group the median cumulative dose (mg) was 691.25 mg with the min-max 336.6 to 1103.7 mg and in the 10 mg/kg group, the median cumulative dose was 1896.00 mg with the min-max 617 to 2965.0 mg. The cumulative dose median dose (mg/kg) in the 3 mg/kg group was 11.95 mg/kg with a min-max of 6.0 to 12.0 mg/kg and in the 10 mg/kg group the median cumulative dose was 29.75 mg/kg with a minmax of 10.0 to 39.8 mg/kg.

No patients entered the re-treatment phase. At the time of study discontinuation one patient who had PR was eligible for the re-treatment phase.

Table 25: Number of doses of ipilimumab during the study CA184178

<!-- image -->

Program SourCe:BMS BMSCA184178\\TRUNK\\TLF\\RT-EX-NUMDIPI.SAS

<div style=\"page-break-after: always\"></div>

## Adverse events

Adverse events for children and adolescents 12 years of age and older as well as adults are summarised in Table 26.

Table 26: Summary  of  adverse  events  in  paediatric  advanced  (non)melanoma  versus adult advanced melanoma patients

|                                                         | Nunber of Participants (%)                     | Nunber of Participants (%)                     | Nunber of Participants (%)                     | Nunber of Participants (%)   | Nunber of Participants (%)   | Nunber of Participants (%)        | Nunber of Participants (%)                  |
|---------------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------|------------------------------|-----------------------------------|---------------------------------------------|
|                                                         | Age ≥ 12 to 21 year's                          | Age ≥ 12 to 21 year's                          | Age ≥ 12 to 21 year's                          | Age 12 to<18years            | Age 12 to<18years            | Adults                            | Adults                                      |
|                                                         | AdvancedMelanoma and Non-Melanoma Solid Tumors | AdvancedMelanoma and Non-Melanoma Solid Tumors | AdvancedMelanoma and Non-Melanoma Solid Tumors | Advanced Melanoma            | Advanced Melanoma            | Advanced Melanoma                 | Advanced Melanoma                           |
|                                                         | 3 mg/kg n=1                                    | NCI7458/CA184070 5 mg/kg n=8                   | 10 mg/kg n=9                                   | 3 mg/kg n =4                 | CA184178 10 mg/kg n=8        | CA184004/ 022Pooled 3 mg/kg n=111 | CA184004/007 /008/022 Pooled 10 mg/kg n=325 |
| All Deaths,n (%)                                        | 1 (100.0)                                      | 4 (50.0)                                       | 2 (22.2)                                       | 2 (50.0)                     | 3 (37.5)                     | 26 (23.4)                         | 71 (21.8)                                   |
| Treatment-RelatedDeaths,n(%o)                           | 0                                              | 0                                              | 0                                              | 0                            | 0                            | 2 (1.8)                           | 6 (1.8)                                     |
| SAEs, n (%)                                             | 1 (100.0)                                      | 7 (87.5)                                       | 4 ( 44.4)                                      | 1 (25.0)                     | 6 (75.0)                     | 50 (45.0)                         | 168 (51.7)                                  |
| SAEs, drug-related, n (%)                               | 1 (100.0)                                      | 5 (62.5)                                       | 4 ( 44.4)                                      | 1 (25.0)                     | 5 (62.5)                     | 19 (17.1)                         | 95 (29.2)                                   |
| AEs leading to study drug discontinuation,n (%)         | 0                                              | 3 (37.5)                                       | 2 (22.2)                                       | 1 (25.0)                     | 5 (62.5)                     | 12 (10.8)                         | 88 (27.1)                                   |
| Drug-relatedAEsleadingtostudy drug discontinuation,n(%) | 0                                              | 3 (37.5)                                       | 2 (22.2)                                       | 1 (25.0)                     | 5 (62.5)                     | 9 (8.1)                           | 61 (18.8)                                   |
| irAEs, n (%)                                            | 1 (100.0)                                      | 7(87.5)                                        | 7 (77.8)                                       | 2 (50.0)                     | 4 (50.0)                     | 68 (61.3)                         | 234 (72.0)                                  |
| imARs, n (%)                                            | NA                                             | NA                                             | NA                                             | 1 (25.0)                     | 5 (62.5)                     | NA                                | NA                                          |
| AE, n (%)                                               | 1 (100.0)                                      | 8 (100.0)                                      | 9 (100.0)                                      | 4 (100.0)                    | 8 (100.0)                    | 108 (97.3)                        | 315 (96.9)                                  |
| Drug-related AEs, n (%)                                 | 1 (100.0)                                      | 7 (87.5)                                       | 9 (100.0)                                      | 2 (50.0)                     | 7 (87.5)                     | 88 (79.3)                         | 274 (84.3)                                  |

MedDRA v.17.0 for NCI7458/CA184070, v.19.0 for CA184178, and V.12.1 for Adult Safety Pool. NA = not assessed

For adults,deaths reported in this table are within70days ofthelast dose,regardless ofrelationship.Deathsforpediatricparticipants inNC17458/CA184070are thosewith onstudy events within 30 days of the last dose, except for \"All Deaths,\" which were &gt;30 days after the last dose. In CA184178, deaths were reported at least 90 days of the last dose.

Abbreviations:SAEs=serious adverseevents;AEs=adverse events;irAEs=immune-related adverse events;imARs=immune-mediated adversereactions

Source: Table 8.1-1 of the Final CSR NCI7458/CA184070; Table 8.1-1 of the Final CSR CA184178; Tables 2.1.2A, 2.1.3, 2.1.4 and Appendices 2.41A, 2.59A, Table 2.1.1.1 and

Overall, adverse events (AEs) associated with ipilimumab treatment in the paediatric and adult populations were generally reported less frequently at doses of 3 and 5 mg/kg compared with 10 mg/kg. As only 1 patient ≥12 years old with a solid tumour (synovial cell sarcoma) was treated with ipilimumab 3 mg/kg in NCI7458/CA184070, interpretation of safety information in this case is limited.

- -NCI7458/CA184070 : All AEs reported for the single patient in the 3 mg/kg group ≥12 years old in this study were Grade 3 or less in intensity. Adverse events were also reported for all patients in the 5 and 10 mg/kg groups 12 years of age and older. There were 75.0% (6/8 patients) and 55.6% (5/9 patients) ≥12 years old with ≥Grade 3 AEs reported in the 5 and 10 mg/kg groups, respectively. One of the events reported in the 5 mg/kg group was a fatal event due to malignant disease. No individual event ≥Grade 3 was reported in more than 1 patient in the 5 or 10 mg/kg group.
- -CA184178 : Adverse events were reported for all patients in both the 3 and 10 mg/kg groups. In both groups, most events were Grade 1 or 2 in intensity. In the 3 mg/kg group, 1 patient experienced one Grade 3 event. In the 10 mg/kg group, 2 patients experienced Grade 3 events and 3 patients experienced Grade 4 events. No Grade 5 events were reported in any treatment group. The rates Grade 3-5 all-causality AEs were observed more frequently among the ipilimumab 10 mg/kg group (100% Any Grade, 75% Grade 3-5) vs the 3 mg/kg (100% Any Grade, 25% Grade 3-5).

Patients were analysed for multiple occurrences of AEs, i.e., more than 5 occurrences of the same AE in a single patient, and adjusted for exposure (Table 27).

<div style=\"page-break-after: always\"></div>

Table 27: Exposure-adjusted summary of on-study AEs, including multiple occurences of unique events CA184178

|                                                                       | 3 mg/kg Ipilimmeb (N=4) (P-Y =1.5)   | 3 mg/kg Ipilimmeb (N=4) (P-Y =1.5)   | 10 mg/kg Ipilimmab (N=8) (P-Y =2.8)   | 10 mg/kg Ipilimmab (N=8) (P-Y =2.8)   |
|-----------------------------------------------------------------------|--------------------------------------|--------------------------------------|---------------------------------------|---------------------------------------|
| SystemOrganClass PreferredTem                                         | Event Coumt                          | Rate: (IR/100 P-Y)                   | Event Count                           | Rate: (IR/100 P-Y)                    |
| TOTAL EVENIS                                                          | 21                                   | 1400.0                               | 180                                   | 6428.6                                |
| NAUSEA PANCREATITIS VOMITING PYREXIA DECREASEDAPPETITE HYPERGLYCAFMIA | 30:3100                              | 200.0 0 200.0 66.7 0 0               | 10 65                                 | 285.7 35.7 535.7 357.1 214.3 178.6    |

P-Y=Person-yearsofexposure

EventsarecodedaccorcingtoMedDRAv.19.0andgradedaccordingtoNCICTCAE3.0.

On-studyeventisdefinedasanyeventsoccurringon or afterDay1ofstudytreatmentandnolater than90days

followingthelastdayofstudytreatment.

ProgramSourCe:BMSBMSCA184178\\TRUNK\\TLF\\RT-AE-EXPADJMITT.SAS

RumDate:13SEP2016:04:09:38

Patients in the ipilimumab 3 mg/kg group had 1.5 person-years (P-Y) of exposure, and 21 multiple occurrences of on-study unique AEs adjusted for exposure were reported among all patients at an incidence rate per 100 person-years of exposure (IR/100 P-Y) of 1400.0.

Patients in the ipilimumab 10 mg/kg group had 2.8 P-Y of exposure and 180 multiple occurrences of on-study unique AEs adjusted for exposure were reported among all patients at an IR/100 P-Y of 6428.6. The rate of exposure-adjusted, multiple occurrences of unique irAEs was higher in the 10 mg/kg treatment group compared to the 3 mg/kg treatment group.

- -Adult Safety Pool : In the adult pooled 3 mg/kg group, Grade 3-4 AEs were reported in 27.0% of patients, with fatigue (6.3%) being the most common. In the pooled 10 mg/kg group, 37.5% of patients reported at least 1 Grade 3-4 AE, the most common being diarrhoea (10.8%; all Grade 3). Adverse events reported among children and adolescents were consistent with those reported among adults.

## Treatment-related adverse events

- -NCI7458/CA184070 : No investigator-determined drug-related AEs ≥Grade 3 were reported in the 3 mg/kg groups. Drug-related AEs ≥Grade 3 were reported for 42.8% (6/14) and 46.2% (6/13) patients in the 5 and 10 mg/kg groups, respectively. No individual event ≥Grade 3 was reported in more than 1 patient in the 5 or 10 mg/kg group.
- -CA184178 : Drug-related AEs were reported less frequently for ipilimumab 3 mg/kg (50.0% Any Grade, 25.0% Grade 3-5) versus ipilimumab 10 mg/kg (87.5% Any Grade, 62.5% Grade 3-5). No individual event ≥Grade 4 was reported in 3 mg/kg group, and no Grade 5 events were reported in 10 mg/kg group. No individual event ≥Grade 3 was reported in more than 1 patient in the 10 mg/kg group.
- -Adult Safety Pool : Overall, 14.4% of patients in the 3 mg/kg group reported at least 1 Grade 3-4 treatment-related AE, the most common being colitis (2.7%; Grade 3: 1.8%; Grade 4: 0.9%) and diarrhoea (2.7%; Grade 3 in all cases). In the pooled 10 mg/kg group, 30.5% of patients reported at least 1 Grade 3-4 treatment related AE, the most common being diarrhoea (10.2%; all Grade 3).

## Serious adverse event/deaths/other significant events

- -NCI7458/CA184070 : No deaths were attributed to study drug toxicity by the investigator. Overall, death due to malignant disease was recorded for 15 patients in this study as of the database lock (Table 26). Two died within 30 days of the last dose.

<div style=\"page-break-after: always\"></div>

- -CA184178 : Among 12 treated patients, a total of 2/4 (50.0%) and 3/8 (37.5%) deaths were reported in the study with ipilimumab 3 mg/kg and ipilimumab 10 mg/kg, respectively (Table 26). All deaths were due to disease progression. None of the deaths occurred within 90 days of the last dose.
- -Adult Safety Pool : The rate of deaths in Adult Safety Pool during the treatment phase was similar between the 3 and 10 mg/kg groups (Table 28) and 1.8% of deaths were attributed to ipilimumab treatment in both treatment groups.

Table 28: Deaths during treated phase in adult patients

|                    | CA184004/022P00led 3 mg/kg N = 111   | CA184004/007/008/022P00led 10 mg/kg N =325   |
|--------------------|--------------------------------------|----------------------------------------------|
| All Deaths         | 26 (23.4)                            | 71 (21.8)                                    |
| Treatment-relateda | 2 (1.8)                              | 6 (1.8)                                      |

Treatment-related AEs with an outcome of death Source: Table 2.1.2ASCS 2010

## Serious adverse events

SAEs were reported in one patient each in the 3 mg/kg group of studies NCI7458/CA148070 and CA184178. In study NCI7458/CA184070, SAEs were reported less frequently in the 10 mg/kg groups compared with the 5 mg/kg group. SAEs reported in the 10 mg/kg group were reported more frequently in study CA184178 than in the Adult Safety Pool.

- -NCI7458/CA184070 : In the 3 mg/kg group, SAEs were reported for the patient ≥12 years. One had a Grade 3, device-related infection and Grade 1 abdominal pain, nausea, vomiting, pyrexia, chills, and pain and the other had Grade 2 pneumonitis and Grade 1 pyrexia. One Grade 5 (fatal) event of death due to malignant disease was reported for one patient ≥12 years old in the 5 mg/kg dose group. No single event occurred in more than 2 patients in any of the dose groups. The only drug-related SAEs in the 3 mg/kg group were Grade 1 events reported in the single patient ≥12 years (abdominal pain, nausea, and vomiting). In the 5 mg/kg cohort, drug-related SAEs were reported in 5 of the 8 patients ≥12 years old, including 4 patients with Grade 3-4 events. These events included Grade 4 amylase and lipase increased, and Grade 3 autoimmune disorder, abdominal pain, skin infection, musculoskeletal pain, headache, and vision blurred. In the 10 mg/kg cohort, drug-related SAEs were reported in 4 of 9 patients. All were Grade 3-4 events. These events included Grade 4 diarrhoea and blood creatine phosphokinase increased, and Grade 3 diarrhoea, pleural effusion, and upper respiratory tract infection.
- -CA184178 : The rates of all-causality SAEs (Any Grade) were 1/4 (25.0%) in ipilimumab 3 mg/kg and 6/8 (75.0%) in ipilimumab 10 mg/kg. No Grade 5 (fatal) events were reported. The most common SAEs by SOC were Hepatobiliary disorders (25%), Metabolism and Nutrition disorders (25%), Neoplasms Benign Malignant and Unspecified (Incl. Cysts and Polyps) (25%), and Respiratory, Thoracic and Mediastinal disorders (25%) in the 10 mg/kg group (Table 29). All SAEs were considered to be drug-related by the investigator except for 4 events in 2 patients in the 10 mg/kg group. One patient experienced Grade 3 events of hyponatremia, pleural effusion, and a Grade 4 event of progression of metastatic melanoma, and the second patient reported Grade 3 tumour pain.

<div style=\"page-break-after: always\"></div>

Table 29: On-study SAEs CA184178

Treatment Group:3mg/kgIpilimmabN=4

|                                           | Number of Subjects (%)   |   Number of Subjects (%) | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|-------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| System Organ Class (%) Preferred Term (&) |                          |                        2 | 3                        | Worst CTCAE Grade 4      | 5                        | Unkmown                  | Any Grade                |
| TOTALSUBJECTS WITHAN EVENT                | 0                        |                        0 | 1 ( 25.0)                | 0                        | 0                        | 0                        | 1  ( 25.0)               |
| HEPATOBILIARYDISORDERS                    | 0:0                      |                       00 | 1 (25.0) 1 (25.0)        | 0 0                      | 0:0                      | 00                       | 1 ( 25.0) 1 (25.0)       |

Treatment Group: 10 mg/kg Ipilimumab N = 8

|                                                                        | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| System Organ Class (%)                                                 | Worst CTCAE Grade        | Worst CTCAE Grade        | Worst CTCAE Grade        | Worst CTCAE Grade        | Worst CTCAE Grade        | Worst CTCAE Grade        | Worst CTCAE Grade        |
| Preferred Temm ($)                                                     | 1                        | 2                        | 3                        | 4                        | 5                        | Unkmown                  | Any Grade                |
| TOTALSUBJECTSWITHAN EVENT                                              | 1 ( 12.5)                | 0                        | 3 ( 37.5)                | 2 (25.0)                 | 0                        | 0                        | 6 ( 75.0)                |
| HEPATOBILIARYDISORDERS                                                 | 0:0:0                    | 0:0:0                    | 2111 25.0)               | 0:0:0:0                  | 00:0                     | 0                        | 2111                     |
| CHOLECYSTITISACUIE                                                     |                          |                          | 12. .5)                  |                          |                          | 0                        | 5.5                      |
| CHOLESTASIS                                                            |                          |                          | 12.                      |                          |                          | 0                        | 12                       |
| HEPATITIS                                                              | 0                        | 0                        | 12.5)                    |                          | 0                        | 0                        | 12.5)                    |
| METABOLISMANDNUIRITIONDISORDERS                                        | 0                        |                          | (12.5)                   |                          | 0                        | 0                        | 2 25.0)                  |
| HYPOKALAFMTA                                                           | 0:0                      | 0:0:0                    | 101                      | 11 12:5)                 | 0                        |                          | 12.5)                    |
| HYPONATRAFMIA                                                          |                          |                          | (12.5)                   | 0                        | 0                        | 00                       | 1 12.5)                  |
| NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND FOLYPS)    | 0                        | 0                        | 1 (12.5)                 | 1 (12.5)                 | 0                        | 0                        | 2 (25.0)                 |
| METASTATICMALIGNANTMELANOMA TUMOURPAIN                                 | 0 0                      | 0:0                      | (12.5)                   | OT (12.5)                | 00                       | 0                        | 1 ( 12:3                 |
| RESPIRATORY,THORACIC ANDMEDIASTINALDISORDERS PIEURAL EFFUSION          | 0                        | 0 0                      | 2 ~2:8  (25.0)           | 0                        | 0                        | 0                        | 2 ~ 2:8                  |
|                                                                        | 0                        |                          |                          | 0                        | 0                        | 0                        |                          |
| GASIROINIESTINALDISORDERS PANCREATITIS                                 | 12.5)                    | 0 0                      | 0:0                      | 0 o                      | 0 0                      | 0 0                      | 1 (2:3                   |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS INFUSIONRELATEDREACTION | 1 ( 12:3                 | 0                        | 0:0                      | 0:0                      | 0 0                      | 0                        | 1 (2:3                   |
| INVESTIGATIONS                                                         |                          | 0                        |                          |                          |                          | 0                        |                          |
| HEPATICFNZYME INCREASED                                                | 000                      | 0:0                      |                          | 0:0                      | 0:0:                     | 0                        |                          |
| TRANSAMMNASES INCREASED                                                |                          | 0                        | 1 12.5)                  | 0                        | 0                        | 0                        | 12.5)                    |

Events are coded according to MedDRA v.19.0 and graded according to NCI CICAE 3.0. Subjects may haye more than one event.

r o p a s ro i   o    a  se p sr aa s

Program Source: BMS BMSCA184178\\TRUNK\\TLF\\RT-AE-SAECTCMITT.SAS

Rum Date: 13SEP2016:04:07:09

- -Adult Safety Pool : In the pooled 3 mg/kg group, the frequency of all-causality SAEs was 45.0% and 17.1% for treatment-related SAEs overall. Colitis and diarrhoea were each reported as treatment-related in 4.5% of patients, with most individual SAEs reported in no more than 1 patient each. As with the 3 mg/kg dose, the most common (at least 2 patients) treatment-related SAEs in the pooled 10 mg/kg group were diarrhoea (11.4%) and colitis (7.1%). In the pooled 10 mg/kg group, treatment-related SAEs reported under the SOCs of investigations (4.0%) and hepatobiliary disorders (3.1%) were reported most frequently (both were &lt; 1% with the 3 mg/kg dose).

<div style=\"page-break-after: always\"></div>

## Immune-related adverse events

irAEs were reported in similar proportions in the 3 and 10 mg group mg/kg groups in study CA184178 and less frequently in the 3 mg/kg group (61.3%) in the Adult Safety Pool compared with the 10 mg/kg group (72.0%) in the pool. In study NCI7458/CA184070, irAEs were reported less frequently in the 5 (87.5%) and 10 mg/kg (77.8%) groups compared with the single patient in the 3 mg/kg (100%) group. No irAEs in either paediatric study were fatal. Few irAEs in the paediatric studies were Grade 34 in intensity: 25% in the 3 mg/kg group and 11.1% in the 10 mg/kg group in NCI7458/CA184070 and in CA184178, 25.0% in the 3 mg/kg group and 37.5% in the 10 mg/kg group. All were managed according to the protocol-defined treatment guidelines. The frequencies of irAEs in the paediatric and adult populations are difficult to compare due to the small paediatric sample size.

- -NCI7458/CA184070 : No new or unexpected irAEs were observed in this study (Table 30).

Table 30: Summary of irAEs after up to 4 does of 3, 5, and 10 mg/kg in NCI7458/CA184070 vs adults

|              | Number of Participants (%)                      | Number of Participants (%)                      | Number of Participants (%)                      | Number of Participants (%)   | Number of Participants (%)   |
|--------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|------------------------------|------------------------------|
|              | Age ≥ 12 to 21 years                            | Age ≥ 12 to 21 years                            | Age ≥ 12 to 21 years                            | Adult Safety Pool            | Adult Safety Pool            |
|              | Advanced Melanoma and Non-Melanoma Solid Tumors | Advanced Melanoma and Non-Melanoma Solid Tumors | Advanced Melanoma and Non-Melanoma Solid Tumors | AdvancedMelanoma             | AdvancedMelanoma             |
|              | NCI7458/CA184070                                | NCI7458/CA184070                                | NCI7458/CA184070                                | CA184004/ 022Pooled          | CA184004/007 /008/022P00led  |
|              | 3 mg/kg n=1                                     | 5 mg/kg n=8                                     | 10 mg/kg n=9                                    | 3 mg/kg n =111               | 10 mg/kg n=325               |
| irAEs, n (%) | 1 (100.0)                                       | 7 (87.5)                                        | 7(77.8)                                         | 68 (61.3)                    | 234 (72.0)                   |

Source: Table 1

A Grade 1 irAE of autoimmune disorder was reported for one patient ≥12 years old treated with ipilimumab 3 mg/kg. In the 5 mg/kg cohort, irAEs were reported in 87.5% of the 8 patients, of whom 2 (25.0%) had Grade 3-4 irAEs: Grade 4 amylase and lipase increased (in the same patient), Grade 3 ALT increased, AST increased, and autoimmune disorder. In the 10 mg/kg cohort, irAEs was reported in 77.8% of the 9 patients, 1 (11.1%) of whom had a Grade 4 and a Grade 3 diarrhoea. No fatal irAEs were observed. GI perforation, a known albeit rare (&lt;1%) complication of colitis observed in adult patients, occurred in one patient treated in this study. A serious irAE of colonic perforation was reported for one patient &gt; 30 days after the last dose of ipilimumab. The patient, a white female 20.8 years of age in the 5 mg/kg dose group, with a clinical course complicated by events of liver toxicity (Grade 1 event of ALT increased [transaminitis]) on Days 22 and 42 and GI disorder (Grade 1 diarrhoea) on Day 34, was discontinued from the study on Day 49 for an [unspecified] autoimmune disorder. In addition, Grade 3 events of AST increased and ALT increased, as well as Grade 3 elevations in AST and ALT laboratory test values, were reported for this patient on Day 49. An irAE of serious Grade 4 large intestine perforation (verbatim term: colonic perforation) was reported on Day 107, 85 days after last dose of ipilimumab and 58 days after discontinuation from the study. The event of large intestine perforation was reported as resolved. A Grade 2 event of hypophysitis was reported for one patient treated with ipilimumab 5 mg/kg. A drug-related Grade 2 event of diabetes insipidus was also reported for this patient, as well as a Grade 3 SAE of headache prior to the event of hypophysitis on Day 75, which resulted in discontinuation from the study. Autoimmune disorder was reported for 3 patients in the 5 mg/kg group, one of which was Grade 3 in intensity. A Grade 2

<div style=\"page-break-after: always\"></div>

irAE of autoimmune disorder was also reported for 1 patient in the 10 mg/kg group. Low-grade, on-study skin irAEs were reported in 2 patients treated with ipilimumab 5 mg/kg and 3 patients treated with ipilimumab 10 mg/kg.

- -CA184178 : No new or unexpected irAEs were observed in this study. Ipilimumab 3 mg/kg had 2/4 (50.0%) Any Grade and 1/4 (25.0%) Grade 3-5 irAEs compared to 4/8 (50.0%) Any Grade and 3/8 (37.5%) Grade 3-5 in the ipilimumab 10 mg/kg group. No Grade 5 events were reported in either treatment group (Table 31).

Table 31: Summary of irAEs after up to 4 doses of 3, 5, and 10 mg/kg in CA184178 vs adults

|              | Number of Participants (%)   | Number of Participants (%)   | Number of Participants (%)   | Number of Participants (%)   |
|--------------|------------------------------|------------------------------|------------------------------|------------------------------|
|              | Age 12 to < 18years          | Age 12 to < 18years          | AdultSafetyPool              | AdultSafetyPool              |
|              | AdvancedMelanoma             | AdvancedMelanoma             |                              |                              |
|              | CA184178                     | CA184178                     | CA184004/ 022Pooled          | CA184004/007 /008/022P00led  |
|              | 3 mg/kg n=4                  | 10 mg/kg n=8                 | 3 mg/kg n =111               | 10 mg/kg n =325              |
| irAEs, n (%) | 2 (50.0)                     | 4 (50.0)                     | 68 (61.3)                    | 234 (72.0)                   |

Source:Table 1

In the 3 mg/kg group the most common irAEs by SOC were Immune system disorders 2/4 (50%) and Skin and subcutaneous tissue disorders 2/4 (50%). In the 10 mg/kg group the most common irAEs by SOC were Gastrointestinal disorders 3/8 (37.5%) and Investigations 3/8 (37.5%). Onstudy liver irAEs of any grade across all dose levels occurred in 4 patients who experienced hepatitis, cholestasis, ALT increased, AST increased, hepatic enzyme increased and transaminases increased. On-study skin irAEs of any grade across all dose levels occurred in 2 patients in the 3 mg/kg treatment group and 2 patients in the 10 mg/kg group who experienced Grade 1 rash and pruritus (Table 32). Two patients in the 10 mg/kg group who experienced a Grade 1 and Grade 3 on study endocrine irAE of hyperglycaemia. No on-study neurological irAEs were reported in any treatment group. Two patients ≥12 years in the 10 mg/kg group experienced Grade 2 diarrhoea and Grade 2 haematochezia on-study gastrointestinal irAEs. On-study other irAEs of any grade occurred in 2 patients in the 3 mg/kg group who experienced Grade 2 drug hypersensitivity and Grade 1 hypersensitivity. In the 10 mg/kg group 1 patient experienced Grade 1 pancreatitis, Grade 2 amylase increased, and Grade 4 lipase increased.

<div style=\"page-break-after: always\"></div>

Table 32: On-study irAEs CA184178

Treatment Group: 3 mg/kg Ipilimumab N = 4

|                                                                | Number of Subjects (*)   | Number of Subjects (*)   | Number of Subjects (*)   | Number of Subjects (*)   | Number of Subjects (*)   | Number of Subjects (*)   | Number of Subjects (*)   |
|----------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| System Organ Class (%)                                         | Worst CICAE Grade        | Worst CICAE Grade        | Worst CICAE Grade        | Worst CICAE Grade        | Worst CICAE Grade        | Worst CICAE Grade        | Worst CICAE Grade        |
| Preferred Term (*)                                             | 1                        | 2                        | 3                        | 4                        | 5                        | Unkmowm                  | Any Grade                |
| TOTAL SUBJECTS WITH AN EVENT                                   | 1 ( 25.0)                | 0                        | 1 ( 25.0)                | 0                        | 0                        | 0                        | 2 ( 50.0)                |
| IMMUNE SYSTDM DISORDERS DRUG HYPERSENSITIVITY HYPERSENSITIVITY | 101 (25.0) (25.0)        | 110 25.0) 25.0)          | 0 0:0                    | 0 0:0                    | 0:0:0                    | 0:0:0                    | 1 :8 (50.0)              |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS PRURITUS RASH           | 211 50.0)                | 0:0:0                    | 0 0 0                    | 0:0                      | 0:0:0                    | 0:0: 0                   | 128                      |
| HEPATOBILIARYDISORDERS HEPATITIS                               |                          |                          | 1 ( 2号:8)                | 0                        |                          |                          | 2 ( 50.0)                |
|                                                                | 0:0                      | 0:0                      |                          | 0:0                      |                          | 0:0                      | 1 ( 25:8)                |
|                                                                |                          |                          |                          |                          | 0:0                      |                          |                          |

Treatment Group: 10 mg/kg Ipilimmab N = 8

|                                                                                                                                                                     | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)           | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|----------------------------------|--------------------------|--------------------------|--------------------------------|
| System Organ Class (%) Preferred Tenm (%)                                                                                                                           | 1                        | 2                        | 3                        | Worst CICAE Grade 4              | 5                        | Unkmown                  | Any Grade                      |
| TOTALSUBJECTSWITHANEVENT                                                                                                                                            | 0                        | 1 ( 12.5)                | 1 ( 12.5)                | 2 ( 25.0)                        | 0                        | 0                        | 4 ( 50.0)                      |
| GASIROINIESTINALDISORDERS DIARRHOEA HAFMATOCHEZIA PANCREATITIS                                                                                                      | 1 (12.5) 100 1 12.5)     | 2110 25.0) 12.5) 12.5)   | 0:0:00                   | 0:0:00                           | 0 0:0:0                  | 0 0 0 0                  | 3111 222 .5)                   |
| INVESTIGATIONS ALANINEAMINOIRANSFERASEINCREASED ASPARTATEAMINOIRANSFERASEINCREASED AMYLASEINCREASED HEPATIC ENZYMEINCREASED LIPASE INCREASED TRANSAMINASESINCREASED | 0:0 1 (12.5) 0:00 0      | (12:53} 0 0 0 0          | TOTTOOO 12:5)  12.5)     | 2110010 25.0) 12.5) 12.5) (12.5) | 000000: 0                | 0 0 0 0 0 0 0            | 3221111 3551222 500555 12. .5) |
| HEPATOBILIARYDISORDERS CHOLESTASIS HEPATITIS                                                                                                                        | 0 0:0                    | 0 0 0                    | 21 1 (12.5)              | 0:0:0                            | 0 0 0                    | 0 0 0                    | 21 25.0) 12.5) 1 (12.5)        |
| METABOLISM ANDNUTRITION DISORDDRS HYPERGLYCAEMIA                                                                                                                    | 1 ( 12:3)                | 0:0                      | 1 ( 12:3)                | o:0                              | 0 0                      | 0 0                      | 2 ~ 2:83                       |
| RASH                                                                                                                                                                | 221 8: 25.0              | 0:0:0                    | 0:00                     | 0:0:0                            | 0:00                     | 0                        | 221 ( 25.0)                    |
| PRURITUS                                                                                                                                                            |                          |                          |                          |                                  |                          | 0:0                      |                                |

Events are coded according to MedDRA v.19.0 and graded according to NCI CICAE 3.0. Subjects mayhave more than one event.

On-study events are events reported between first dose date of study therapy and 90 days after last dose of study therapy. Unkmown intensities are included in \"Any Grade\" columm.

ProgramSourCe:BMSBMSCA184178\\TRUNK\\TLF\\RT-AE-IRAESI.SAS

Run Date:13SEP2016:04:07:58

- -Adult Safety Pool : In the pooled 3 mg/kg group, the proportion of patients with irAEs of any grade was 61.3% and 6.3% for Grade 3-4 irAEs. The most common irAEs in this group were skin (42.3%) and GI (30.6%) irAEs. As with the 3 mg/kg dose, the most common irAEs were GI and skin irAEs, with a frequency of 36.3% and 51.4% in the pooled 10 mg/kg group, respectively. Grade 3-4 irAEs were reported in 24.3% of patients in the pooled 10 mg/kg group, most of which were Grade 3 in intensity (Grade 3, 20.6%; Grade 4, 3.7%). The rates of Grade 3-4 GI and Grade 3-4 hepatic irAEs were 11.7% and 6.8%, respectively. In the pooled 3 mg/kg group, 1 (0.9%) patient died due to large intestine perforation. One patient (0.3%) in the pooled 10 mg/kg group died of large intestine perforation more than 70 days after last dose. In addition, 1 (0.3%) patient in the pooled 10 mg/kg group underwent a colectomy to treat GI bleed.

The frequency of unique irAEs was analysed in the paediatric studies:

- -NCI7458/CA184070 : 3 patients ≥12 years old experienced a unique irAE more than once. Multiple occurrences of irAEs were reported for events of increased ALT, increased AST, and diarrhoea. All 3 events are well-known irAEs associated with ipilimumab treatment:
- Two to 3 occurrences of events of increased ALT were reported for 1 patient ≥12 years in the 5 mg/kg group.

<div style=\"page-break-after: always\"></div>

- Two to 3 occurrences of events of increased AST were reported for 1 patient ≥12 years each in he 5 and 10 mg/kg groups.
- At least 4 occurrences of events of diarrhoea were reported for each of 2 patients ≥12 years in the 5 mg/kg group.
- -CA184178 : 4 of 12 patients experienced a unique irAE more than once. One patient in the ipilimumab 3 mg/kg group experienced 2 to 3 occurrences of rash. In the 10 mg/kg group, multiple occurrences of irAEs were reported for events of increased ALT (2-3x), increased AST (23x), hyperglycaemia (≥4x), and rash (2-3x). All of these events are well-known irAEs associated with ipilimumab treatment.
- -Adult Safety Pool : The frequency of unique irAEs was not determined in the pooled analyses of adult safety.

Multiple occurences of irAEs were analysed for the paediatric population:

- -NCI7458/CA184070 : Multiple occurrences of irAEs adjusted for exposure were analysed in study NCI7458/CA184070 for all patients regardless of age or dose. Patients in the study had 7.00 person-years (P-Y) of exposure to ipilimumab among the total of 33 patients in the study ranging in age from 2.4 to 21.8 years who were treated at doses of 1, 3, 5 and 10 mg/kg. Among these, a total of 69 multiple occurrences of on-study unique irAEs adjusted for exposure were reported, at an incidence rate per 100 person-years of exposure (IR/100 P-Y) of 985.2. The overall rates of multiple events of irAEs with increased P-Y of exposure was slightly higher at doses of 5 and 10 mg/kg compared to the lower doses of 1 and 3 mg/kg. The most common irAEs were increased AST (a total of 11 events with an IR/100 P-Y of 157.1), increased ALT (a total of 10 events with an IR/100 P-Y of 142.8), and diarrhoea (a total of 23 events with an IR/100 P-Y of 328.4).
- -CA184178 : In study CA184178, multiple occurrences of overall AEs adjusted for exposure were analysed in study (SCS-A Appendix 14). Patients in the ipilimumab 3 mg/kg group had 1.5 personyears (P-Y) of exposure and those in the in the ipilimumab 10 mg/kg group had 2.8 P-Y of exposure. Multiple occurrences of events typical of irAEs by SOC:
- Gastrointestinal Disorders
- No endocrine AEs were reported in either treatment group.

-  3 mg/kg: 7 events, 466.7 IR/100 P-Y

-  10 mg/kg: 37 events, 1321.4 IR/100 P-Y

- Hepatobiliary Disorders

-  3 mg/kg: 1 events, 66.7 IR/100 P-Y

-  10 mg/kg: 3 events, 107.1 IR/100 P-Y

- Immune System Disorders

-  3 mg/kg: 2 events, 133.3 IR/100 P-Y

-  10 mg/kg: 0 events, 0 IR/100 P-Y

- Investigations

-  3 mg/kg: 0 events, 0 IR/100 P-Y



10 mg/kg: 34events, 1214.3 IR/100 P-Y

- Nervous Systems

-  3 mg/kg: 3 events, 200.0 IR/100 P-Y

-  10 mg/kg: 9 events, 321.4 IR/100 P-Y

- Metabolism and Nutrition Disorders

-  3 mg/kg: 0 events, 0 IR/100 P-Y

-  10 mg/kg: 26 events, 928.6 IR/100 P-Y

- Skin and Subcutaneous Tissue Disorders

-  3 mg/kg: 3 events, 200.0 IR/100 P-Y

-  10 mg/kg: 12 events, 428.6 IR/100 P-Y

<div style=\"page-break-after: always\"></div>

## Immune-mediated adverse reactions

ImARs were not collected or analysed for NCI7458/CA184070 or the studies in the adult safety pool, as these studies were initiated prior to the development of the definition of imARs. For CA184178, the frequency of severe (Grade 3-5) imARs of ipilimumab was the primary safety objective. The proportion of patients treated with ipilimumab 3 mg/kg who experienced Grade 3-5 imARs was 1/4 (25.0%; 95% CI: 0.6, 80.6), compared to the ipilimumab 10 mg/kg group where 5/8 (62.5%; 95% CI: 24.5, 91.5) patients experienced Grade 3-5 imARs (Table 33). No Grade 5 events were reported in either treatment group.

No patients in the 3 mg/ kg treatment group experienced a Grade 2 imAR, while in the 10 mg/kg group 2/8 (25.0%; 1 with diarrhoea and 1 with haematochezia) patients experienced Grade 2 events. There was 1 Grade 3-4 imAR of hepatitis in the 3 mg/kg group. The most common Grade 3-4 imARs in the 10 mg/kg group were hepatitis (2/8, 25.0%) and pyrexia (2/8, 25.0%).

Table 33: Severe (Grade 3-5) imARs CA184178

ProgramSoUrCe:BMSBMSCA184178\\TRUNK\\TLF\\RT-AE-RATESEVIMAR.SAS

<!-- image -->

## Laboratory findings

In study NCI7458/CA184070, blood samples were collected during Cycles 1 and 3, Days 1 (predose and at completion of drug infusion), and Days 2, 3, 8, and 15. Samples were collected predose and weekly during Cycles 2 and 4, and pre-dose and biweekly for Cycles 5 through 8. Posttherapy evaluations were to be performed within 30 days after the last dose or at the time of discontinuation from the study. Results for all ages (2.4 to 21.8 years) across all solid tumour types are reported due to the limited number of participants. In study CA184178, laboratory testing was performed within 14 days of the first dose, within 3 days prior to each treatment, and at the end of treatment visit. In the Adult Safety Pool, laboratory tests conducted on or after Day 2 and no later than the earliest of the day before the start date of re-treatment/maintenance dosing or 70 days after the last day of treatment dosing were considered for tabulation for the treatment period analyses. Laboratory grading for intensity was based on CTC version 3.0 and 4.0 in study NCI7458/CA184070, version 3.0 for study CA184178 and the Adult Safety Pool.

## Haematology

- -NCI7458/CA184070 : Decreases in haematological parameters during treatment were ≤Grade 2 for most patients ≥12 years treated with ipilimumab 5 or 10 mg/kg with available data. Worsening shifts from baseline CTC Grade to Grade 3 or 4 in patients ≥12 years were observed for white blood cells (1/8 in the 10 mg/kg group), haemoglobin (2/9 in the 10 mg/kg group), and absolute lymphocyte counts (1/8 in the 5 mg/kg group, 1/8 in the 10 mg/kg group).

<div style=\"page-break-after: always\"></div>

- -CA184178 : Decreases in haematological parameters during treatment were ≤Grade 2 for most patients. One patient in the 10 mg/kg group experienced a Grade 4 decreased platelet count and Grade 4 decreased white blood cell count from Grade 0 at baseline.
- -Adult Safety Pool : In the pooled 3 mg/kg group, ≥90% of patients had normal on-study WBC, ANC, and platelet counts; Grade 3-4 abnormalities in WBC, ANC, and platelets were each reported in ~2% of patients. On-study haemoglobin abnormalities were reported for 61.0% of patients and Grade 3-4 in 4.8% of patients; all but 1 of these participants had an abnormal baseline haemoglobin value. Most patients in the pooled 10 mg/kg group had normal on-study WBC, ANC, and platelet levels (92.2%, 94.2%, and 86.4% of patients, respectively). On-study abnormalities in WBC, ANC, and platelets were primarily Grade 1-2 in intensity; Grade 3-4 abnormalities in WBC, ANC, and platelets were each reported in ≤1% of participants in the pooled 10 mg/kg group.

## Liver function tests

- -NCI7458/CA184070 : Grade 3 or 4 increases in LFT values occurred in few patients ≥12 years treated with ipilimumab 5 or 10 mg/kg with available data. There were no apparent dose- or age-related changes in LFT values. Increases from baseline CTC Grade to Grade 3 were observed for alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) values; no Grade 4 values were observed for these LFTs. No Grade 3 or 4 increases in total bilirubin (TBL) values were observed. No patients experienced LFT values suggestive of drug-induced liver injury (DILI; ALT or AST &gt;3× upper limit of normal (ULN) and TBL &gt;2× ULN within 14 days on or after elevation).
- -CA184178 : Grade 3 or 4 increases in LFT values occurred in few patients treated with ipilimumab 10 mg/kg. Increases from baseline CTC Grade to Grade 4 were observed for ALT, AST, and TBL values. There were no abnormal elevations (≥Grade 1) in ALP values for all patients. An AE of hepatitis was reported for one patient in the 3 mg/kg group with a Grade 3 shift in ALT and AST. AEs of increased ALT and AST, cholestasis, and transaminases increased were reported for one patent in the 10 mg/kg group with Grade 3-4 shifts in ALT, AST, and TBL, and an AE of hepatitis was reported for another patient in the 10 mg/kg group with Grade 3 shifts in ALT and TBL. No patients experienced LFT values suggestive of drug-induced liver injury (DILI; ALT or AST &gt;3× upper limit of normal (ULN) and TBL &gt;2× ULN within 14 days on or after elevation).
- -Adult Safety Pool : On-study abnormalities in ALT, AST, TBL, and ALP were primarily Grade 1-2 in intensity. In the pooled 3 mg/kg group, Grade 3-4 abnormalities in ALT and AST were each reported in ~2% of patients. Grade 3 abnormalities in ALP were reported in 6.7% (7/111) of patients in the pooled 3 mg/kg group; all 7 of the patients in the pooled 3 mg/kg group who had Grade 3 on-study abnormalities had abnormalities at baseline. No patients in the pooled 3 mg/kg group met the criteria for drug-induced liver injury. As with the 3 mg/kg dose, on-study LFT abnormalities were primarily Grade 1-2 in intensity. In the pooled 10 mg/kg group, Grade 3-4 abnormalities in ALT, AST, and TBL were reported in 7.5%, 7.2%, and 2.0% of patients, respectively. These rates are higher than with the 3 mg/kg dose, and consistent with the higher rate of hepatic irAEs in the pooled 10 mg/kg group (1.2%, 4/325) compared with the pooled 3 mg/kg group (0). Two participants in the pooled 10 mg/kg group met the criteria for drug-induced liver injury, with no confounding factors.

<div style=\"page-break-after: always\"></div>

## Renal function tests

- -NCI7458/CA184070 : No Grade 3 or 4 increases in creatinine values were reported for any patient during treatment.
- -CA184178 : No Grade 3 or 4 increases in creatinine values were reported for any patient during treatment.
- -Adult Safety Pool : A Grade 3 abnormality in creatinine values was reported in 1/111 patients (1.0%) in the pooled 3 mg/kg group. In the pooled 10 mg/kg group, on-study abnormalities in creatinine levels were primarily Grade 1 in intensity. Grade 2 abnormalities were reported in 3.6% (11/325) of patients; 1/325 (0.3%) patients, who had a normal value at baseline, had a Grade 4 on-study abnormality.

## Pancreatic enzymes

- -NCI7458/CA184070 : Grade 3 or 4 increases in serum lipase and amylase laboratory values occurred in 2 patients during treatment. One of 8 (12.5%) patients ≥12 years in the 5 mg/kg dose group experienced an increase from Grade 0 at baseline to Grade 4 for both serum lipase and serum amylase, consistent with a clinical diagnosis of pancreatitis.
- -CA184178 : Grade 3 or 4 increases in serum chemistry values occurred in 2 of 8 (25%) patients in the 10 mg/kg treatment group during treatment. An AE of pancreatitis was reported for one of these patients.
- -Adult Safety Pool : In the pooled 3 mg/kg group, lipase abnormalities were reported in 20.8% (22/111) of patients; Grade 3-4 abnormalities were reported in 8.5% (9/111) of patients. In the pooled 3 mg/kg group, amylase abnormalities were primarily Grade 1-2; Grade 3-4 abnormalities were reported in 2.8% (3/111) of patients. No cases of pancreatitis were reported in the pooled 3 mg/kg group. In the pooled 10 mg/kg group, on-study lipase abnormalities were reported in 22.7% (70/325) of patients; Grade 3-4 lipase abnormalities were reported in 6.5% (20/325) of patients. On-study abnormalities in amylase were primarily Grade 1-2 in intensity. Grade 3-4 amylase abnormalities were reported in 1.6% (5/325) of patients. Pancreatitis was reported in 2/325 (0.6%) patients in the pooled 10 mg/kg group.

## Vital signs and other observations related to safety

No clinically relevant changes from baseline in vital signs were observed in either paediatric study nor in the Adult Safety Pool.

No pregnancies were reported in either paediatric studies.

## Autoimmune and endocrine function tests

- -NCI7458/CA184070 : Samples for autoimmune testing were collected at baseline and prior to each cycle. In all treated patients (n=33) 3 experienced ANA values &gt;2. Two patients had elevated levels at baseline, the other patient experienced elevated ANA values on Day 63 (day before 4 th  and last induction dose) and Day 93. Two patients reported elevated rheumatoid factor, one at baseline and one on Day 43 Abnormal endocrine laboratory values diagnostic for an endocrine disorder were reported in 3 patients (2 autoimmune thyroiditis, 1 hypophysitis).
- -CA184178 : The majority of patients had normal TSH, free T3, free T4, and adrenocorticotropic hormone (ACTH) levels at baseline and throughout the treatment period. Two patients in the 3 mg/kg group and 2 patients in the 10 mg/kg group had elevated free T3 at baseline, which remained elevated throughout treatment.

<div style=\"page-break-after: always\"></div>

The MAH did not compare endocrine functions tests to the Adult Safety Pool.

## Paediatric safety report for study CA184116

The MAH provided the interim safety data from 2 adolescent patients treated with ipilimumab in the prematurely stopped phase 3 randomised study of adjuvant ipilimumab versus high dose interferon α -2b for resected high risk melanoma as of 09-Nov-2016. Both patients are off study and are considered to have completed the study.

1. Patient treated with ipilimumab 3mg/kg, start date 03-Nov-2014, end date treatment 28-Dec2015, reason treatment ended was treatment completed per protocol criteria, status alive, no recurrence
2. -Baseline toxicity: gastroesophageal reflux disease G2, sinusitis G2, nervous system disordersother G2, skin and subcutaneous tissue- other G1
3. -Toxicities on study:
- Fatigue G2, attribution definite
- Flu like symptoms G2, attribution unrelated
- Gastroesophageal reflux disease G2, attribution unrelated
- Sinusitis G2, attribution unrelated
- Nervous system disorder- other G2, attribution unrelated
- Pruritus G1, attribution probable
- Endocrine disorders- other G1, attribution possible
- Skin and subcutaneous tissue- other G1, attribution unrelated
- Adrenal insufficiency G1, attribution unrelated
- Diarrhoea G1, attribution unrelated
- Nausea G1, attribution unrelated
- Vomiting G1, attribution unrelated
- ALT increased G1, attribution unrelated
- CPK increased G1, attribution unrelated
- Myalgia G1, attribution unrelated
2. Patient,treated with ipilimumab 10mg/kg, start date 06-Feb-2015, end date treatment 20-Mar2015, reason treatment ended was adverse events, status alive, no recurrence
20. -Baseline toxicity: fatigue G1, abdominal pain G1, dizziness G1, psychiatric disorders- other G1
21. -Toxicities on study:
- Abdominal pain G2, attribution possible
- Diarrhoea G2, attribution possible
- Nasal congestion G1, attribution unrelated

## Discontinuation due to adverse events

Disease progression was the most common reason for premature discontinuation of study drug, followed by study drug toxicity/adverse events. The reasons for discontinuation prior to completing treatment with 4 doses are presented in Table 34; eligible patients in study NCI7458/CA184070 could have received more than 4 doses. More patients treated with ipilimumab at 10 mg/kg did not complete the treatment phase compared to 3 mg/kg in study CA184178 and the Adult Safety Pool. Patients may have received 4 doses but were not considered to have completed the treatment phase if they experienced progressive disease or study drug toxicity. Study drug toxicity was defined as AEs considered to be related by the investigator.

<div style=\"page-break-after: always\"></div>

Table 34: Most common reasons for discontinuation in paediatric vs adult patients

|                                             | Number of Participants (%)        | Number of Participants (%)        | Number of Participants (%)        | Number of Participants (%)   | Number of Participants (%)   | Number of Participants (%)   | Number of Participants (%)     |
|---------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|------------------------------|------------------------------|------------------------------|--------------------------------|
|                                             | NCI7458/CA184070 ≥ 12 to 21 years | NCI7458/CA184070 ≥ 12 to 21 years | NCI7458/CA184070 ≥ 12 to 21 years | CA184178 12 to < 18years     | CA184178 12 to < 18years     | Adult Safety Pool            | Adult Safety Pool              |
|                                             | 3 mg/kg                           | 5 mg/kg                           | 10 mg/kg                          | 3 mg/kg                      | 10 mg/kg                     | CA184004 /022 3 mg/kg        | CA184004 /007/008/022 10 mg/kg |
| Participants Treated                        | 1                                 | 8                                 | 9                                 | 4                            | 8                            | 111                          | 325                            |
| Completed treatment phase                   |                                   | 1(33.3)a  3 (37.5)b               | 4 (44.4)c                         | 1 (25.0)                     | 1 (12.5)                     | 78 (70.3)                    | 189 (58.2)                     |
| Did not complete treatment                  | 0                                 | 0                                 | 0                                 | 3 (75.0)                     | 7 (87.5)                     | 33 (29.7)                    | 136 (41.8)                     |
| Reason for Discontinuation Prior to 4 Doses |                                   |                                   |                                   |                              |                              |                              |                                |
| Progressive Disease                         | 0                                 | 3 (37.5)                          | 4 (44.4)                          | 2 (50.0)                     | 2 (25.0)                     | 69 (62.2)                    | 170 (52.3)                     |
| Study Drug Toxicity/ Adverse Event          | 0                                 | 2 (22.2)                          | 1 (11.1%)                         | 1 (25.0)                     | 5 (62.5)                     | 8 (7.2)                      | 54 (16.6)                      |

Treatment phase defined as having received 4 doses. Eligible participants in study NCI7458/CA184070 could have received more than 4 doses.

a Discontinued due to progressive disease after 4 doses.

b Two discontinued due to progressive disease and one discontinued due to an AE after 4 doses.

- Two discontinued due to progressive disease after 4 doses. Source: Appendix 4.1 and 4.3 of the Final CSR NCI7458/CA184070; Table 6.2-1 of the Final CSR CA184178;

Table 1.2.1 and 1.2.2.1 of the 2010 SCS; SCS-A Appendix 1.13A of the 2010 SCS

## Adverse events leading to discontinuation

AEs leading to discontinuation of study therapy were reported less frequently in the 3 mg/kg group in study CA184178 and the Adult Safety Pool compared with the 10 mg/kg group in study CA184178.

- -NCI7458/CA184070 : No AEs leading to discontinuation were reported for the single patient ≥12 years treated with ipilimumab 3 mg/kg. Adverse events leading to discontinuation for patients ≥12 years were reported in 37.5% in the 5 mg/kg group and 22.2% of the 10 mg/kg group. All AEs leading to discontinuation were considered related by the investigator. All but one were severe (Grade 3-4), one event, occurred in a patient that had both a Grade 3 event of diarrhoea and a Grade 2 event of vomiting in the 10 mg/kg group. The PTs for events leading to discontinuation in the 5 mg/kg group were autoimmune disorder, abdominal pain, amylase increased, lipase increased, and headache, and in the 10 mg/kg group, diarrhoea, and pleural effusion.
- -CA184178 : The rates of all-causality AEs leading to discontinuation were less frequent in ipilimumab 3 mg/kg (1/4 [25.0%]) compared to ipilimumab 10 mg/kg (5/8 [62.5%]). Grade 3-4 AEs leading to discontinuation were 1/4 (25.0%) in the ipilimumab 3 mg/kg group compared to 4/8 (50.0%) in ipilimumab 10 mg/kg group. No Grade 5 AEs were reported. All AEs leading to discontinuation were considered to be related to study drug by the investigator (Table 35).

<div style=\"page-break-after: always\"></div>

Table 35: On-study AEs leading to discontinuation of study drug CA184178

Treatment Group: 3 mg/kg Ipilimumeb N = 4

|                                           | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|-------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| System Organ Class (%) Preferred Tenm (*) | 1                        | 2                        | 3                        | Worst CICAE Grade 4      | 5                        | Unkmown                  | Any Grade                |
| TOTALSUBJECTSWITHANEVENT                  | 0                        | 0                        | 1 ( 25.0)                | 0                        | 0                        | 0                        | 1 ( 25.0)                |
| HEPATOBILIARYDISORDERS HEPATITIS          | 0 0                      | 0 0                      | 25.0) 25.0)              | 0                        | 0 0                      | 0 0                      | 25.0) 25.0)              |

Treatment Group: 10 mg/kg Ipilimumab N = 8

|                                                                                                            | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)     | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| System Organ Class (8)                                                                                     | Worst CTCAE Grade        | Worst CTCAE Grade        | Worst CTCAE Grade          | Worst CTCAE Grade        | Worst CTCAE Grade        | Worst CTCAE Grade        | Worst CTCAE Grade        |
| Preferred Tenm (%)                                                                                         | 1                        | 2                        | 3                          | 4                        | 5                        | Unkmown                  | Any Grace                |
| TOTALSUBJECTS WITHAN EVENT                                                                                 | 1 ( 12.5)                | 0                        | 3 ( 37.5)                  | 1 ( 12.5)                | 0                        | 0                        | 5 ( 62.5)                |
| INVESTIGATIONS ALANINEAMINOIRANSFERASEINCREASED ASPARTATEAMMNOTRANSFERASEINCREASED BLOODPOTASSIUMDECREASED | 0:00:0                   | OTO:0 (12.5)             | 21 (25.0) 12.5) 0 1 (12.5) | 0:0 0:0                  | 0:0: 0 0                 | 0:00:0                   | 21 25.0) 1 (12.5)        |
| GASTROINIESTINALDISORDERS PANCREATITIS                                                                     | 1 ( 12:3)                | 00                       | 00                         | 00                       | 0 0                      | 0                        |                          |
| GENERALDISORDERSANDADMINISIRATIONSITE CONDITIONS                                                           | 0                        |                          | 0                          | 0                        |                          | 0                        | 1 ( 12:3)                |
| PYREXIA                                                                                                    | 0                        | 1 (12.5)                 | 0                          | 0                        | 0                        | 0 0                      | 1 ( 12.5) 1 (12.5)       |
| HEPATOBILIARYDISORDERS                                                                                     |                          | 1 (12.5)                 | 1(:3)                      |                          | 0                        | 0                        |                          |
| HEPATITIS                                                                                                  | 0:0                      | 00                       |                            | 00                       | 00                       | 0                        | 1 ( 12:3)                |
| METABOLISMANDNUIRITIONDISORDERS HYPOKALAFMIA                                                               | 0:0                      | 0 0                      | 0:0                        | 1 ( 12:5)                | 0:0                      | 0:0                      | 1 ( 12:3)                |
|                                                                                                            | 0                        | 0                        | 1 (2:3                     |                          | 0                        | 0                        | 1 (2:3                   |
| RESPIRATORY，THORACIC AND MEDIASTINAL DISORDERS                                                             |                          | 0                        |                            |                          |                          |                          |                          |
| PLEURALEFTUSION                                                                                            | 0                        |                          |                            | 0:0                      | 0                        | 0                        |                          |

Subjectsmayhavemore thanone event.

90 days following the last day of study therapy.

Oon-study event is defined as any event with onset on or after Day 1 of study therapy and no later than

AEs leading to discontinuation are events with an action indicating discontinuation of study medication.

Rum Date:13SEP2016:04:07:34

- -Adult Safety Pool : In the pooled 3 mg/kg group, similar overall rates of discontinuations due to AEs (10.8%) and treatment-related AEs (8.1%) were reported. In this group, the most common treatment-related AE leading to discontinuation was hypopituitarism, which led to discontinuation in 2.7% of patients. Treatment-related AEs of colitis and diarrhoea led to discontinuation in 2 (1.8%) and 1 (1.9%) patients, respectively. Discontinuation due to treatment-related AEs occurred in 18.8% of patients in the pooled 10 mg/kg group. The most common treatment-related AEs leading to discontinuation in the pooled 10 mg/kg group were diarrhoea (6.5%) and colitis (4.3%). In the pooled 10 mg/kg group, 3.1% of patients discontinued due to treatment-related events reported under the SOC of investigations and 3.1% of patients discontinued due to treatment-related events reported under the SOC of hepatobiliary disorders.

## Discontinuation of study therapy

Most patients (50%) in the study were discontinued from treatment due to study drug toxicity. Four patients (33.3%) were discontinued due to disease progression (Table 36). Six patients were discontinued due to study drug toxicity which was considered to be drug-related by the investigator (see safety part for more information on discontinuation due to toxicity). Of these 6 patients, 2 were discontinued after 1 dose, 2 after 2 doses, and 2 after 3 doses.

<div style=\"page-break-after: always\"></div>

Table 36: Discontinuation of study therapy CA184178

Number of Subjects (%)

|                                                                        | 3 mg/kg Ipilimumab N=4                 | 10 mg/kg Ipilimumab N'=8               | Total N = 12           |
|------------------------------------------------------------------------|----------------------------------------|----------------------------------------|------------------------|
| SUBJECTS TREATED                                                       |                                        |                                        |                        |
| IN THE TREATMENT PHASE COMPLETED PHASE DIDNOT COMPLETEPHASE            | ４１ 25.0) 3 75.0)                       | ８１７ 12.5) ( 87.5)                      | 12 2( 16.7) 10 ( 83.3) |
| REASON FOR NON-COMPLETION (a) : STUDY DRUG TOXICITY DISEASEPROGRESSION | 1 25.0) 2 50.0)                        | 5 62.5) 2 ( 25.0)                      | 6 50.0) 4 33.3)        |
| s    as       d  () 13SEP2016:04:05:07                                 | s    as       d  () 13SEP2016:04:05:07 | s    as       d  () 13SEP2016:04:05:07 | Run Date:              |

## Interruption or delay of study therapy

Four patients required interruption of study drug due to AEs; one in the 3 mg/kg group and 3 patients in the 10 mg/kg group:

- -Treatment was interrupted for a patients in the 3 mg/kg group due to a hypersensitivity reaction (drug fever to 38.3 degrees) on day 22. Ipilimumab was then given at half the infusion rate without complication.
- -Treatment was interrupted for a patient in the 10 mg/kg group due to hypersensitivity reaction (chills) on day 1. The patient continued with treatment cycles 2 and 3 without reoccurrence of the event.
- -Treatment was interrupted for a patient in the 10 mg/kg group due to complaints of burning sensation beside the new infusion port on day 1. The rate of the infusion was decreased and the burning sensation did not return.
- -Treatment was interrupted for a patient in the 10 mg/kg group due to hypersensitivity reaction of mild nausea and a strange feeling inside on day 1. The rate of the infusion was decreased for the duration of the day 1 treatment.

## 2.5.1. Discussion on clinical safety

In the paediatric safety database 5 patients were treated with 3 mg/kg, 8 with 5 mg/kg and 17 with 10 mg/kg, with in total 30 adolescents ≥12 years old divided over two clinical studies. Pooling the patients treated in NCI7458/CA1847070 and CA184178 with the same doses of ipilumumab, the number of deaths was 60%, 50%, and 29% in the 3, 5, and 10 mg/kg group due to disease progression. None of the deaths were reported to be drug-related. In the Adult Safety Pool 111 patients were treated with 3 mg/kg and 325 with 10 mg/kg, and in both 1.8% of deaths were reported to be treatment-related. The percentage of drug-related SAEs were 40, 63, 52% in the paediatric population in the increasing dose groups and for the adults 17% (3 mg/kg) and 29% (10 mg/kg). Also the number of drug-related AEs leading to study drug discontinuation was higher in the paediatric versus the adult safety population. In adolescents these numbers were 20% in 3 mg/kg, 38% in 5 mg/kg, and 41% in 10 mg/kg. In adults 3 mg/kg led to study drug discontinuation due to drug-related AEs in 8% in the 3 and 19% in the 10 mg/kg. The incidence of irAEs was similar in adolescents and adults. For adolescents 60% in 3 mg/kg, 88% in 5 mg/kg, and 64% in 10 mg/kg. For adults these percentages were 61% in 3 mg/kg, and 72% in 10 mg/kg.

<div style=\"page-break-after: always\"></div>

In study CA184070, no immune related adverse reactions (irAR) ≥Grade 3 were reported for the single patient 12 years of age and older who was treated with ipilimumab 3 mg/kg. Two (25.0%) of 8 patients treated with 5 mg/kg and 1 (11.1%) of 9 patients treated with 10 mg/kg reported Grade 3-4 events. None of the events were fatal. The types of irARs were consistent with the adult experience, with the most commonly reported irARs across all groups in the categories of gastrointestinal (0 [3 mg/kg], 62.5% [5 mg/kg], and 44.4% [10 mg/kg]), hepatic function (0 [3 mg/kg], 75.0% [5 mg/kg], 33.3% [10 mg/kg]), and skin (0 [3 mg/kg], 25.0% [5 mg/kg], 33.3% [10 mg/kg]) events. No new or unexpected irARs were observed in this study. No differences in the spectrum of irARs reported in adults and the paediatric population were evident.

In study CA184178, no new or unexpected irARs were observed, and the observed irARs were similar in frequency, intensity and organ site to what has been reported in adult studies. Two patients in the 10 mg/kg group experienced a Grade 1 and Grade 3 on-study endocrine irAR of hyperglycemia. No other endocrine abnormalities were reported.

Although no new safety signals were identified in the paediatric population, the number of (drugrelated) AEs leading to discontinuation and the number of drug-related SAEs were numerically higher in the paediatric versus the adult population for both 3 and 10 mg/kg (see also Table 26). In adolescents 3 mg/kg was better tolerated than 10 mg/kg with lower numbers of (drug-related) SAEs, (drug-related) AEs leading to discontinuation, and drug-related AEs. The numbers of irAEs and AEs in general did not differ between 3 and 10 mg/kg. When analysed for multiple occurrences of unique events and irAEs, the rate of exposure adjusted, multiple occurrences of unique irAEs was higher in the 10 mg/kg treatment group compared to the 3 mg/kg treatment group. No treatment-related deaths occurred in the studied paediatric population.

In the aforementioned study comparing 3 versus 10 mg/kg ipilimumab in adults, the most common grade 3-4 treatment-related adverse events were diarrhoea (10% 10 mg/kg group vs 6% 3 mg/kg), colitis (5% vs 2%), increased alanine aminotransferase (3% vs 1%), and hypophysitis (3% vs 2%). Treatment-related serious adverse events were reported in 37% in the 10 mg/kg group and 18% in the 3 mg/kg group; 1% versus &lt;1% died from treatment-related adverse events. In adults, the 10 mg/kg dosing led to increased treatment-related adverse events.

The available safety data in the proposed posology of 3 mg/kg in adolescents is limited due to the small number of patients and short follow-up. The limited available data show that adolescent patients treated with ipilimumab suffer a high burden of morbidity based on the severity of the ADRs and the rates of discontinuation of therapy During the 1 year follow-up described in study CA184178 75% and 62.5% of the adolescents are alive in the 3 and 10 mg/kg group, respectively. The treated adolescents experienced a high number of drug-related SAEs and drug-related AEs leading to discontinuation (25% for 3 mg/kg and 62.5% for 10 mg/kg for both drug-related SAEs/AEs leading to discontinuation). The very limited safety data in adolescents could be accepted provided that additional safety data will be collected prospectively and to this end, a clear plan for post-marketing collection should be provided, including the implementation of a registry, preferably by joining an existing melanoma registry. Therefore, the CHMP has proposed to prospectively collect safety data in a registry to get further insight into the differences of AEs compared to adults and how these AEs can be best managed in adolescents as well as to evaluate the known immune-related endocrine adverse events in children where hormonal disturbances may have important developmental consequences during growth and puberty. The MAH has committed to extend the Dutch Melanoma Treatment Registry (DMTR) to include paediatric patients to supplement the safety database with long term safety from a larger pool of treated paediatric patients..

<div style=\"page-break-after: always\"></div>

## 2.5.2. Conclusions on clinical safety

No new safety concerns and no new adverse drug reactions were reported in adolescents 12 years of age and older, however, ipilimumab seems to be less well tolerated in adolescents compared to adults. Toxicity is substantial with severe and life threatening adverse events, which is already known for adults. To further characterise the safety profile in children and mitigate the uncertainties surrounding a negative effect of ipilimumab on endocrine-related ADRs which may affect hormonal and sexual development in adolescents, the MAH has committed to implement a post-marketing collection of paediatric safety data through joining the existing DMTR registry as additional pharmacovigilance activities (see RMP).

The CHMP considers the following measures necessary to address issues related to safety:

- Extension of the Dutch Melanoma Treatment Registry (DMTR) to include paediatric patients as additional pharmacovigilance activities in the RMP.

An updated RMP with a synopsis on timelines, enrollment, methodology for analysis and of the proposed safety data collection should be provided within 90 days of Opinion.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 18.6 is acceptable.

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | - GI irARs (eg, diarrhea, colitis, GI perforation) - Hepatic irARs (eg, hepatitis) - Skin irARs (eg, rash, pruritus, TEN, and DRESS) - Neurologic irARs (eg, neuropathy) - Endocrine irARs (eg, hypopituitarism, hypothyroidism, adrenal insufficiency) - Other irARs (eg, pneumonitis, nephritis, non- infective myocarditis, and pancreatitis) - Severe infusion reactions |
| Important potential risks    | - Immunogenicity - Severe skin drug reactions from concurrent or sequential (in any order) use of ipilimumab and vemurafenib or PD-1/PD-L1 inhibitors                                                                                                                                                                                                                        |
| Missing information          | - Reproductive and lactation data                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                           |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | - Long-term safety in children and adolescent patients > 12 years of age - Data in ethnic groups - Potential PD interaction with systemic immunosuppressants - Patients with severe hepatic impairment - Patients with severe renal impairment - Patients with autoimmune disease - Long-term safety |

## Pharmacovigilance plan

| Activity/Study title                                                                                                                                                                                               | Objectives                                                                   | Safety concerns addressed                                | Status                        | Date for submission of final reports                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------|---------------------------------------------------------------------------------------------------|
| CA184143 - Post- marketing epidemiologic prospective cohort study (category 3)                                                                                                                                     | To estimate incidence of irARs and assess their management                   | Post-marketing safety                                    | Ongoing                       | Final study report: 4Q 2018                                                                       |
| CA184332 - A Multi site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY) as First line Therapy in a Community Practice Setting (category 3) | To assess outcomes in subjects prescribed 3 mg/kg in the first- line setting | AE frequency                                             | Concluded; CSR in preparation | Final study report: 4Q 2017                                                                       |
| CA184338 - A Multi site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY) as First line Therapy (category 3)                                 | To assess outcomes in subjects prescribed 3 mg/kg in the first- line setting | AE frequency                                             | Concluded; CSR in preparation | Final study report: 4Q 2017                                                                       |
| MAH to sponsor extension of the DMTR to include paediatric subjects and to their collect safety data (3)                                                                                                           | To obtain additional safety information in paediatric patients               | Long-term safety in adolescent patients >12 years of age | Planned                       | -Synopsis of the DMTR: 1Q 2018 -Registration of paediatric patients in the DMTR register: 4Q 2018 |

<div style=\"page-break-after: always\"></div>

| Activity/Study title   | Objectives   | Safety concerns addressed   | Status   | Date for submission of final reports                         |
|------------------------|--------------|-----------------------------|----------|--------------------------------------------------------------|
|                        |              |                             |          | -Interim safety reporting: PSUR -Final study report: 4Q 2028 |

## Risk minimisation measures

| Safety concern                                                                                                                                                           | Routine risk minimisation measures        | Additional risk minimisation measures                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Identified risks                                                                                                                                                         |                                           |                                                                                                                                                           |
| Immune-related Adverse Reactions (GI irARs, hepatic irARs, skin irARs, neurological irARs, endocrine irARs, and other irARs)                                             | Sections 4.2, 4.4 and 4.8 of the SmPC     | Additional risk minimization plan to ensure HCPs are informed of the key irARs safety and management messages and provide patient education tools to HCPs |
| Severe infusion reactions                                                                                                                                                | Section 4.3, 4.4 and 4.8 of the SmPC      | N/A                                                                                                                                                       |
| Potential risks                                                                                                                                                          |                                           |                                                                                                                                                           |
| Immunogenicity                                                                                                                                                           | Section 5.1 of the SmPC                   | N/A                                                                                                                                                       |
| Hypersensitivity skin drug reactions following switch from ipilimumab to vemurafenib or PD-1 / PDL-1 inhibitors, or when ipilimumab and any of these agents are combined | Section 4.4 of the SmPC                   | N/A                                                                                                                                                       |
| Missing information                                                                                                                                                      |                                           |                                                                                                                                                           |
| Reproductive and lactation data                                                                                                                                          | Section 4.6 and 5.3 of the SmPC           | N/A                                                                                                                                                       |
| - Long-term safety in children and adolescent patients > 12 years of age                                                                                                 | Section 4.2, 4.4, 4.8 and 5.2 of the SmPC | N/A                                                                                                                                                       |
| Data in ethnic groups                                                                                                                                                    | Section 5.2 of the SmPC                   | N/A                                                                                                                                                       |
| Potential PD interaction with systemic immunosuppressants                                                                                                                | Section 4.5 of the SmPC                   | N/A                                                                                                                                                       |
| Patients with severe renal impairment                                                                                                                                    | Section 4.2 and 5.2 of the SmPC           | N/A                                                                                                                                                       |
| Patients with severe hepatic impairment                                                                                                                                  | Section 4.2 and 5.1 of the SmPC           | N/A                                                                                                                                                       |
| Patients with autoimmune disease                                                                                                                                         | Section 4.4 of the SmPC                   | N/A                                                                                                                                                       |
| Long term safety                                                                                                                                                         | N/A                                       | N/A                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated. Particularly, a new warning with regard to the benefit risk balance in patient below the age of 12 that has been added to the product information. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons: The modifications now proposed in the PL (i.e., those relevant to the new indication) do not represent major changes to the general design, layout and readability of the proposed PL.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

Ipilimumab is a fully human monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It potentiates T-cell activation by blocking the binding to its ligands B7-1 and B7-2. Ipilimumab is approved as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults at a dose of 3 mg/kg administered IV once every 3 weeks for a total of 4 doses.

## 3.1.1. Disease or condition

Melanoma is predominantly diagnosed in the adult population, but the incidence in children is rising. Melanoma in preadolescent patients behaves different than melanoma in the adult population, but in adolescents behaviour of melanomas is similar to adults. Current treatment regimens in children are based on the treatments in adults. For paediatric patients, 5-year disease-specific survival is 57% in the case of distant disease.

## 3.1.2. Available therapies and unmet medical need

In clinical practice, ipilimumab is no longer used in the first-line setting for melanoma in the adult population in most countries. In this setting, nivolumab and pembrolizumab also show efficacy in melanoma and have improved tolerability compared to ipilimumab. Moreover, in BRAF-mutated patients, BRAF and MEK inhibitor combinations can be used. Furthermore, ipilimumab at 3 mg/kg shows increased benefit when used in combination with nivolumab compared with ipilimumab monotherapy. Nevertheless, there are no approved therapies for paediatric patients with advanced or metastatic melanoma. The MAH initially applied to extend the indication of ipilumumab to children and adolescents 12 years of age and older.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The application is supported by data from two clinical studies. Study NCI7458/CA184070 is a phase 1, open-label, dose-escalation clinical study in children and adolescents of 1 to 21 years old with advanced and/or refractory solid malignant tumours (3 melanoma patients treated with 5 mg/kg, 2 with 10 mg/kg). Study CA184178 is a phase 2, open-label, single-arm efficacy and safety clinical study in adolescents 12 to &lt;18 years with untreated or previously treated advanced/metastatic melanoma (4 patients treated with 3 mg/kg, 8 with 10 mg/kg). Prior therapy with a CTLA-4, PD-1, PD-L1, or CD137 targeted agent was an exclusion criterium.

## 3.2. Favourable effects

The PK results from paediatric studies CA184070 and CA184178 indicated that ipilimumab exposure in pediatric patients is similar and overlaps with the ipilimumab exposures in adults when dosed by mg/kg. The popPK showed that CL was not dependent on age and therefore it is considered reasonable to extrapolate the dose-response relationship from the adults to paediatric patients.

In study CA184178, anti-tumour activity with an objective response was shown in 2 out of 8 adolescents in the age range of 12 to 18 years with advanced melanoma and best response of SD in 1 additional patient treated with 10 mg/kg. Overall survival rate at 1 year was 75.0% (95% CI: 12.8, 96.1) in the ipilimumab 3 mg/kg group and 62.5% (95% CI: 22.9, 86.1) in the ipilimumab 10 mg/kg group. Median OS was 18.2 months (95% CI: 8.9, 18.2) in the 3 mg/kg group and not reached (95% CI: 5.2, NA) in the 10 mg/kg group. Median PFS was 2.6 months (95% CI: 2.3, 8.5) in the 3 mg/kg group and 2.9 months (95% CI: 0.7, NA) in the 10 mg/kg group. This is very similar to the adult population where median OS after ipilimumab monotherapy (3 mg/kg) was 10.12 months (CI 95%: 8.02, 13.80) with a 1-year OS rate of 46% (CI 95%: 37.0, 54.1). Median PFS was 2.86 months (CI 95%: 2.76, 3.02). In 137 treated patients, tumour evaluation showed CR in 1.5%, PR in 9.5%, SD in 17.5%, PD in 51.1% of patients respectively, and 20.4% was not evaluable. BORR was 10.9% (CI 95: 6.3, 17.4) [EPAR Ipilimumab; SmPC Ipilimumab].

In study NCI7458/CA184070, none of the 2 patients treated with 10 mg/kg showed a response. Only 4 patients in the indicated age range were treated with the posology of 3 mg/kg. One patient had a response of SD(260 days). For 5 mg/kg 2 of 3 patients showed SD.

## 3.3. Uncertainties and limitations about favourable effects

The safety and efficacy of ipilimumab in children younger than 12 years of age has not been established since there is very limited data that are available. YERVOY should not be used in children younger than 12 years of age (SmPC section 4.2).

Patients with ocular melanoma, active brain metastases and prior therapy with ipilimumab were not included in the paediatric trial CA184070 (see SmPC section 5.1). Patients with ocular melanoma, active brain metastases and prior therapy with CTLA-4, PD-1, PD-L1, or CD137 targeted agents were not included in the paediatric trial CA184178 (see SmPC section 5.1). Therefore, there are no efficacy data in these patient populations and a warning has been included in section 4.4 of the SmPC.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

Toxicity in adolescents is significant, in particular in the 10 mg/kg group. In the paediatric safety database 5 patients were treated with 3 mg/kg, 8 with 5 mg/kg and 17 with 10 mg/kg, with in total 30 adolescents ≥12 years old. Pooling the patients treated in NCI7458/CA1847070 and CA184178 with the same doses of ipilumumab, the number of deaths was 60%, 50%, and 29% in the 3, 5, and 10 mg/kg group. None of the deaths were reported to be drug-related.

The percentage of drug-related SAEs were 40, 63, 52% in the paediatric population in the increasing dose groups and for the adults 17% (3 mg/kg) and 29% (10 mg/kg). Also the number of drug-related AEs leading to study drug discontinuation was higher in the paediatric versus the adult safety population. In adolescents these numbers were 20% in 3 mg/kg, 38% in 5 mg/kg, and 41% in 10 mg/kg. In adults 3 mg/kg led to study drug discontinuation due to drug-related AEs in 8% in the 3 and 19% in the 10 mg/kg.

The incidence of irAEs was similar occurring in adolescents and adults. For adolescents 60% in 3 mg/kg, 88% in 5 mg/kg, and 64% in 10 mg/kg. For adults these percentages were 61% in 3 mg/kg, and 72% in 10 mg/kg.

## 3.5. Uncertainties and limitations about unfavourable effects

Based on the safety data from the paediatric studies, the overall safety profile of ipilimumab in adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma seems to be less well tolerated in adolescents compared to adults. Paediatric patients appear to experience substantial toxicity with severe and life threatening adverse events, which is already known for adults. The safety experience of treating adolescents &gt;12 years is very limited with a sample size of only 30 patients and restricted to the 1L treatment setting and no long-term safety data in the paediatric population are available. Therefore, missing information in the RMP has been updated with long-term safety in children and adolescent patients &gt; 12 years of age.

There are also uncertainties as to whether the general safety profile (AEs, SAEs, discontinuations), is similar in adults and adolescents. Therefore, the CHMP has proposed to prospectively collect safety data in a registry to get further insight into the differences of AEs compared to adults and how these how best to manage the ADRs  in adolescents. As the immune system of adolescent is undergoing maturation, the registry would also help in evaluating the known immune-related adverse events in children in relation to their developing immune system but also where hormonal disturbances could have important developmental consequences during growth and puberty. The MAH has committed to sponsor an extension of the Dutch Melanoma Treatment Registry (DMTR) to include paediatric patients as additional pharmacovigilance activities in the RMP.  Safety data would be collected in this registry. A synopsis is proposed to be provided within 90 days of Opinion.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 37: Effects  table  for  ipilimumab  in  the  treatment  of  advanced  melanoma  in  children  and adolescents &gt;12 years NCI7458/CA184070

| Effect                                      | Short Description                           | Unit                  | 3 mg/kg               | 5 mg/kg               | 10 mg/kg              | Uncertainties/ Strength of evidence                                                                                                     | Refere es             |
|---------------------------------------------|---------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Favourable Effects                          | Favourable Effects                          | Favourable Effects    | Favourable Effects    | Favourable Effects    | Favourable Effects    | Favourable Effects                                                                                                                      | Favourable Effects    |
| SD                                          | Stable disease                              | N                     | NA                    | 2/3                   | 0/2                   | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| OR                                          | Objective response                          | N                     | NA                    | 0/3                   | 0/2                   | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| Unfavourable Effects*                       | Unfavourable Effects*                       | Unfavourable Effects* | Unfavourable Effects* | Unfavourable Effects* | Unfavourable Effects* | Unfavourable Effects*                                                                                                                   | Unfavourable Effects* |
| All deaths                                  | All deaths                                  | N (%)                 | 1 (100)               | 4 (50)                | 2 (22)                | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| Treatment-related deaths                    | Treatment-related deaths                    | N (%)                 | 0                     | 0                     | 0                     | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| SAEs                                        | SAEs                                        | N (%)                 | 1 (100)               | 7 (88)                | 4 (44)                | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| SAEs drug-related                           | SAEs drug-related                           | N (%)                 | 1 (100)               | 5 (63)                | 4 (44)                | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| AEs leading to discontinuation              | AEs leading to discontinuation              | N (%)                 | 0                     | 3 (37.5)              | 2 (22)                | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| Drug-related AEs leading to discontinuation | Drug-related AEs leading to discontinuation | N (%)                 | 0                     | 3 (37.5)              | 2 (22)                | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| irAEs                                       | irAEs                                       | N (%)                 | 1 (100)               | 7 (87.5)              | 7 (78)                | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| AEs                                         | AEs                                         | N (%)                 | 1 (100)               | 8 (100)               | 9 (100)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |
| Drug-related AEs                            | Drug-related AEs                            | N (%)                 | 1 (100)               | 7 (87.5)              | 9 (100)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                   |

<div style=\"page-break-after: always\"></div>

Table 38: Effects  table  for  ipilimumab  in  the  treatment  of  advanced  melanoma  in children and adolescents &gt;12 years CA184178

| Effect                                      | Short Description                           | Unit                 | 3 mg/kg              | 10 mg/kg             | Uncertainties/ Strength of evidence                                                                                                     | References           |
|---------------------------------------------|---------------------------------------------|----------------------|----------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects                          | Favourable Effects                          | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                                                                      | Favourable Effects   |
| 1 yr OS                                     | 1-year survival rate                        | % (CI95)             | 75.0 (12.8- 96.1)    | 62.5 (22.9- 86.1)    | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| SD                                          | Stable disease                              | N                    | 1/4                  | 1/8                  |                                                                                                                                         | CSR                  |
| OR                                          | Objective response                          | N                    | 0/4                  | 2/8                  |                                                                                                                                         | CSR                  |
| BORR                                        | Best overall response                       | % (CI95)             | 0 (0-60.2)           | 25 (3.2-65.1)        |                                                                                                                                         | CSR                  |
| DCR                                         | Disease control rate                        | % (CI95)             | 25 (0.6- 80.6)       | 37.5 (8.5-75.5)      |                                                                                                                                         | CSR                  |
| PFS                                         | Progression- free survival (months)         | Median (CI95)        | 2.6 (2.3-8.5)        | 2.9 (0.7-NA)         |                                                                                                                                         | CSR                  |
| OS                                          | Overall survival (months)                   | Median (CI95)        | 18.2 (8.9- 18.2)     | NA (5.2-NA)          |                                                                                                                                         | CSR                  |
| Unfavourable Effects                        | Unfavourable Effects                        | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                                                    | Unfavourable Effects |
| All deaths                                  | All deaths                                  | N (%)                | 2 (50)               | 3 (38)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| Treatment-related deaths                    | Treatment-related deaths                    | N (%)                | 0                    | 0                    | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| SAEs                                        | SAEs                                        | N (%)                | 1 (25)               | 6 (75)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| Drug-related SAEs                           | Drug-related SAEs                           | N (%)                | 1 (25)               | 5 (63)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| AEs leading to                              | AEs leading to                              | N (%)                | 1 (25)               | 5 (63)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| Drug-related AEs leading to discontinuation | Drug-related AEs leading to discontinuation | N (%)                | 1 (25)               | 5 (63)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| irAEs                                       | irAEs                                       | N (%)                | 2 (50)               | 4 (50)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| imARs                                       | imARs                                       | N (%)                | 1 (25)               | 5 (63)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| AEs                                         | AEs                                         | N (%)                | 4 (100)              | 8 (100)              | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |
| Drug-related AEs                            | Drug-related AEs                            | N (%)                | 2 (50)               | 7 (88)               | Limited sample size, no comparative data. Results were obtained in the 1 st line setting; no data available from the 2 nd line setting. | CSR                  |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Pharmacokinetics and Efficacy - Melanoma is a rare disease in children, but the incidence is rising with a 5-year disease-specific survival rate for advanced disease of only 57%.  Melanoma in adolescents behaves similarly to melanoma in adults, as also described in the PIP for melanoma (EMA000117-PIP02-10), and therefore based on the PK exposure data, extrapolation of the data from adult

<div style=\"page-break-after: always\"></div>

to children above 12 years of age is acceptable (see also reflection paper on extrapolation of efficacy and safety in paediatric medicine development; EMA/199678/2016). Although in clinical practice ipilimumab is no longer used in the first-line setting for melanoma in most countries, there is still a need in children with melanoma as no therapies have been yet approved for this patient population.

It is reassuring that the available results indicate anti-tumour activity of ipilimumab in the paediatric population of 12 years and older. Although the number of treated patients between the age of 12 and 18 years is small, it is reasonable to extrapolate the efficacy results and the clinical benefit from adults as the disease course is similar between adolescents and adults and the ipilimumab exposure in paediatric patients is overlapping with the ipilimumab exposure in adults when dosed by mg/kg (see also pharmacokinetics section).

SafetySafety data of adolescents treated with ipilimumab is scarce and for the 2L or more treatment setting data are lacking. Reliable comparisons with adults are not possible due the limited sample size, but tolerability in the paediatric population of 12 years and older seem to be worse with higher numbers of drug-related AEs and (drug-related) AEs leading to discontinuation, for which no explanation is provided. As in adults safety seems worse in the higher 10 mg/kg dosing. It is therefore unclear whether the safety in adolescents is similar to that in adults. Therefore, the uncertainty on the limited of safety database will be addressed in the long-term by additional safety data collected prospectively in post-authorisation in a registry.

## 3.7.2. Balance of benefits and risks

Advanced melanoma in adolescents is challenging to treat with limited licensed therapeutic options and hence, there is a need for new therapies in this population with a dismal prognosis. This application is based on descriptive data of a limited number of adolescents treated at different doses of ipilimumab. The data presented are supported by PK data that allows assessing the B/R by extrapolating the efficacy and safety data from the adult melanoma patient population. Extrapolation of efficacy results from the adults is acceptable given a similar course of the disease and an overlapping PK exposure of ipilimumab in children compared to adults. It is reasonable to expect that paediatric patients will derive similar clinical benefits as for what has been observed in the adults. Only very limited data are available in children younger than 12 years of age. Therefore, the indication has been restricted to patients ≥12 years of age  and ipilimumab should not be used in children younger than 12 years of age.  Exposure in paediatric patients seems overlapping with the ipilimumab exposures in adults when dosed by mg/kg. As there is limited safety follow-up, there is uncertainty in terms of the robustness of the safety data concerning the ADRs observed so far in this paediatric population which seems to indicate a worse safety profile and tolerability of ipilimumab in the paediatric population compared to adults. During the 1 year follow-up described in study CA184178 75% and 62.5% of the adolescents are alive in the 3 and 10 mg/kg group, respectively. The treated adolescents experienced a high number of drug-related SAEs and drug-related AEs leading to discontinuation (25% for 3 mg/kg and 62.5% for 10 mg/kg for both drug-related SAEs/AEs leading to discontinuation). This would imply that the treatment of adolescents with ipilimumab involves higher morbidity and possible complications in the long term. As a result, it is of utmost importance to prospectively collect safety data and further evaluate how best to manage the ADRs and assess any impact on growth and sexual maturation on adolescents. The MAH has committed to collect this data as additional pharmacovigilance activities as part of a registry.

<div style=\"page-break-after: always\"></div>

## 3.7.3. Additional considerations on the benefit-risk balance

Ipilimumab monotherapy is no longer considered the primary choice for first line treatment of patients with advanced melanoma. In the 2L or more treatment setting, where ipilimumab monotherapy may provide a relevant treatment option, no results were provided. Whether it is possible to extrapolate efficacy data from the 1L treatment setting to the 2L setting following another immunotherapy drug, is unclear at this time. After failure of anti-PD1 therapy, there is still a need for ipilimumab and activity has been shown in second line 11 , although evidence is limited. The uncertainty in which line ipilimumab should be used and the limited evidence about efficacy of ipilimumab after first line with anti-PD1 therapy also exists in adults. Since it is challenging to treat advanced melanoma in adolescents with currently very limited licensed therapeutic options, a clear unmet medical need exists in any line of therapy. Therefore, the indication has not been restricted to a line of therapy.  Before initiating treatment with ipilimumab monotherapy in adolescents of 12 years and older, physicians are advised to carefully evaluate the individual patient, taking into consideration the limited available data, the observed benefits and the toxicity of ipilimumab monotherapy in the paediatric population (see sections 4.4, 4.8 and 5.1).

## 3.8. Conclusions

The overall B/R of Yervoy is positive.

The CHMP considers the following measures necessary to address issues related to safety:

- Extension of the Dutch Melanoma Treatment Registry (DMTR) to include paediatric patients as additional pharmacovigilance activities in the RMP.

An updated RMP with a synopsis on timelines, enrolment, methodology for analysis and of the proposed safety data collection should be provided within 90 days of Opinion.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older for Yervoy. As a consequence sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and the RMP (version 15) are updated in accordance.

<div style=\"page-break-after: always\"></div>

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0003/2017 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, in the Package Leaflet.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" Steps after the authorisation \" will be updated as follows:

## Scope

Extension of indication to include the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older for Yervoy. As a consequence sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and the RMP (version 15) are updated in accordance.

## Summary

Please refer to the published assessment report Yervoy-II-44: EPAR - Assessment Report - Variation

## Attachments

1. SmPC, Package Leaflet (changes highlighted) of Yervoy, as adopted by the CHMP on 14 December 2017.

## Appendix

N/A

11 Zimmer et al, 2017